UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------------------------------------------------------------------
FORM 10-KSB
[x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the Fiscal Year Ended September 30, 2005
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the Transition Period From _____ to _____
--------------------------------------------------------------------------------
Commission File Number 002-90539
APPLIED DNA SCIENCES, INC.
(Exact name of small business issuer as specified in its charter)
Nevada 59-2262718
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
25 Health Sciences Drive, Suite 113
Stony Brook, New York 11790 (631) 444-6862
(Address of principal executive office) (Postal Code) (Issuer's telephone
number)
Securities registered under Section 12(b) of the Exchange Act: None
Securities registered under Section 12(g) of the Exchange Act: None
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [ ] No [ X ]
Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B contained in this form, and no disclosure will be contained, to
the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB. [ ]
State issuer's revenues for its most recent fiscal year. None
State the aggregate market value of the voting stock held by non-affiliates
computed by reference to the price at which the stock was sold, or the average
bid and asked prices of such stock, as of a specified date within the past 60
days. $29,662,093.50 as of December 5, 2005.
Number of outstanding shares of the registrant's par value $0.001 common stock
as of December 5, 2005: 112,380,392
--------------------------------------------------------------------------------
APPLIED DNA SCIENCES, INC.
FORM 10-KSB
For the Fiscal Year Ended September 30, 2005
Part I Page
Item 1. Description of Business. 3
Item 2. Description of Property. 14
Item 3. Legal Proceedings. 14
Item 4. Submission of Matters to a Vote of Security Holders. 15
Part ll Page
Item 5. Market for Common Equity and Related Stockholder Matters. 16
Item 6. Management's Discussion and Analysis or Plan of Operation. 17
Item 7. Financial Statements F-1
Item 8. Changes In and Disagreements With Accountants on Accounting
and Financial Disclosure. 36
Item 8A. Controls and Procedures. 36
Item 8B. Other Information. 36
Part lll Page
Item 9. Directors, Executive Officers, Promoters and Control Persons;
Compliance with Section 16(a) of the Exchange Act. 37
Item 10. Executive Compensation. 39
Item 11. Security Ownership of Certain Beneficial Owners and Management
and Related Stockholder Matters 41
Item 12. Certain Relationships and Related Transactions. 44
Item 13. Exhibits. 45
Item 14. Principal Accountant Fees and Services. 48
Signatures. 49
PART I
FORWARD-LOOKING INFORMATION
This Annual Report on Form 10-KSB (including the section regarding
Management's Discussion and Analysis of Financial Condition and Results of
Operations) contains forward-looking statements regarding our business,
financial condition, results of operations and prospects. Words such as
"expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates"
and similar expressions or variations of such words are intended to identify
forward-looking statements, but are not deemed to represent an all-inclusive
means of identifying forward-looking statements as denoted in this Annual Report
on Form 10-KSB. Additionally, statements concerning future matters are
forward-looking statements.
Although forward-looking statements in this Annual Report on Form 10-KSB
reflect the good faith judgment of our management, such statements can only be
based on facts and factors currently known by us. Consequently, forward-looking
statements are inherently subject to risks and uncertainties and actual results
and outcomes may differ materially from the results and outcomes discussed in or
anticipated by the forward-looking statements. Factors that could cause or
contribute to such differences in results and outcomes include, without
limitation, those specifically addressed under the heading "Risks Related to Our
Business" below, as well as those discussed elsewhere in this Annual Report on
Form 10-KSB. Readers are urged not to place undue reliance on these
forward-looking statements, which speak only as of the date of this Annual
Report on Form 10-KSB. We file reports with the Securities and Exchange
Commission ("SEC"). We make available on our website under "Investor
Relations/SEC Filings," free of charge, our annual reports on Form 10-KSB,
quarterly reports on Form 10-QSB, current reports on Form 8-K and amendments to
those reports as soon as reasonably practicable after we electronically file
such materials with or furnish them to the SEC. Our website address is
www.adnas.com. You can also read and copy any materials we file with the SEC at
the SEC's Public Reference Room at 100 F Street, N.E., Washington, DC 20549. You
can obtain additional information about the operation of the Public Reference
Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an
Internet site (www.sec.gov) that contains reports, proxy and information
statements, and other information regarding issuers that file electronically
with the SEC, including us.
We undertake no obligation to revise or update any forward-looking
statements in order to reflect any event or circumstance that may arise after
the date of this Annual Report on Form 10-KSB. Readers are urged to carefully
review and consider the various disclosures made throughout the entirety of this
Annual Report, which attempt to advise interested parties of the risks and
factors that may affect our business, financial condition, results of operations
and prospects.
ITEM 1. DESCRIPTION OF BUSINESS.
CORPORATE HISTORY
We are a Nevada corporation, which was initially formed under the laws of
the state of Florida as Datalink Systems, Inc. in 1983. We changed names and
then redomesticated to Nevada in 1998, and in 1999, became ProHealth Medical
Technologies, Inc. In November of 2002, we changed our corporation name to
Applied DNA Sciences, Inc. in connection with a reverse merger. As a result of
the reverse merger, we changed our business to that of our acquirer, which
involves researching, developing and selling security and anti-counterfeiting
products that utilize plant DNA for verification purposes. During this time,
most of our efforts were focused on research and development and the execution
of an exclusive license, as described further herein.
3
OVERVIEW
Every living organism has a unique genetic composition (DNA code or DNA
sequence) that determines the character and composition of its cells. Genetic
specificity is determined by the sequence of nucleotides in the organism's DNA.
Our technical platform involves isolation of botanical genes that are fragmented
and then reconstituted to form unique "chimers" whose sequences are known only
to us. These chimers are stabilized for use for hundreds of years by a unique
encapsulation system that is compatible with a broad universe of chemistries.
This adaptability allows us to embed our unique DNA primers in petroleum and
petroleum derivatives, inks, dyes, laminates, glues, threads, textiles and other
materials. Once embedded in a product, we offer proprietary methods to free the
unique chimers from encapsulation and embedment, whereupon the chimers are
detected by our complimentary primers using methods well established in
molecular biology. Detection of the chimeric sequence unique to a particular
item allows us to authenticate its origination
We provide a platform of proprietary, embedded DNA products that protect
consumers, corporations and governments from counterfeiting, fraud, piracy,
product diversion and unauthorized intrusion. Our technologies are protected by
a broad array of intellectual property. We offer a cost effective method to
detect, deter, interdict and prosecute counterfeiting enterprises.. This
technology can also be used to authenticate microchips and circuit boards that
contain them. The DNA AC (anti-counterfeit) biochip is a product in which DNA is
embedded into a microchip. When biochips are embedded into circuitry, the
biological data can be read electronically and the component can be
authenticated. The biochip acts like a gatekeeper to guard the access to the
device; only once an authorized user is verified, can the device be accessed.
Without authentication, the device will not operate.
Sectors of commerce that could benefit from our products include:
corporations, federal government agencies, information technology, security and
surveillance, entertainment media, the arts, cosmetics, pharmaceutical and
biometrics, as well as vertical retail markets. Our applications can also
enhance capabilities of product origination, identification verification, and
validation of the source of components for critical manufacturing, defense,
medical and other highly-integrity or secure products.
Our mission is to become the recognized standard in providing total
security solutions to protect consumers, corporate and intellectual property
from counterfeiting and fraud. We intend to deliver our products to a global
market by selling directly to manufacturers, and via strategic business
development agreements with recognized leaders in the security industry and
through collaborations with leading security consultancy companies.
We believe that we have a very seasoned and experienced management team.
Our combined executive team has extensive professional experience in the areas
of anti-counterfeiting technology, microchip development, printing, marketing,
IP development and exploitation, and cross-corporate -license development. Dr.
Hayward is a molecular biologist and has spent 20 years commercializing
biotechnologies and has successfully developed several companies. Dr. Sheu is
trained as a molecular biologist and has more than 10 years of experience in
developing and commercializing DNA related applications, including DNA security
and DNA vaccines. He has been a consultant for many well-known biotechnology
companies and he is the founder of Biowell Technology Inc. Dr. Liang is the
chief scientist involved in developing DNA security-related applications. He was
also a founding member of Biowell.
AGREEMENT WITH HOLOGRAMMAS S.A. DE C.V. (HOLOMEX)
On November 10, 2004, we entered into a joint product development and
marketing agreement with Holomex, pursuant to which we agreed to work together
to jointly develop products utilizing Holomex's holographic packaging and label
products and our DNA security products. All products developed will be jointly
owned by the companies. All costs, expenses and revenues will be divided between
the parties as established on a product-by-product basis. The agreement remains
in full force and effect until such time as patents for jointly developed
products and their extensions expire and/or as long as both parties continue to
produce and market the products, whichever is longer. Either party may terminate
the agreement upon 120 days written notice, during which time the
non-terminating party has the right to purchase from the terminating part all
rights to the products and intellectual property jointly owned.
4
COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA) WITH THE DEPARTMENT OF
ENERGY
On September 2, 2004, we entered into a CRADA with Bechtel BWXT Idaho, LLC,
a national laboratory contractor with the Department of Energy. As allowed
pursuant to the CRADA, we received notice from the DOE that they have decided to
terminate the CRADA, effective January 23, 2006. The DOE laboratories have
provided third party detection and authentication of items which had been tagged
with embedded DNA sequences by us.
SUB-LICENSING AGREEMENT
In July of 2003, we, Biowell and G. A. Corporate Finance Ltd. entered into
a Sub-License Agreement for the United Kingdom in exchange for $3,000,000. G. A.
Corporate Finance Ltd. paid $25,000 upon its execution of the Agreement, and the
remaining $2,975,000 is subject to an interest bearing promissory note, payable
in twenty (20) consecutive quarterly installments of Principal and Interest in
the amount equal to the lower of $185,937.50 or 35% of gross revenues for that
quarter due on the final day of the quarter.
The minimum guarantees that G. A. Corporate Finance, LLC must meet each
year of the license agreement to retain the exclusive license for the
technologies are as follows:
Year Minimum Guarantee
---- -----------------
1st year $50,000 gross purchase orders
2nd year $150,000 gross purchase orders
3rd year $300,000 gross purchase orders
4th year $360,000 gross purchase orders
5th year $432,000 gross purchase orders
Due to the lack of marketable products since execution of this agreement,
we suspended the payment under the note and the minimum guarantees owed to us.
We are currently in negotiations with this sub-licensee to either amend or
terminate this agreement.
As with our Exclusive License Agreement with Biowell, our UK Sub-Licensee
will have the opportunity to apply for new product licenses, which can remain
exclusive in its territory for the first eighteen months.
RECENT DEVELOPMENTS
On July 15, 2005, we closed upon the stock purchase agreement with Biowell
Technology Inc., a Taiwan corporation, that was executed on January 28, 2005.
Pursuant to the agreement, through our wholly-owned subsidiary, APDN (B.V.I.)
Inc., a British Virgin Islands company, we acquired all of the issued and
outstanding shares of Rixflex Holdings Limited, a British Virgin Islands
company. Pursuant to an asset purchase agreement, Biowell Technology, Inc.
transferred all of its intellectual property to Rixflex prior to our acquisition
of Rixflex. In exchange for all of the issued and outstanding shares of Rixflex,
we issued to the shareholders of Rixflex 36 million shares of our common stock.
5
The intellectual property governs the use of plant-derived, but
biosynthetically modified DNA sequences to identify original commercial and
consumer products, private and government documents, artwork and other items.
The intellectual property uses synthetically created DNA fragments that have
unique characteristics and one-of-a-kind sequences. Our proprietary DNA-embedded
biotechnology solutions protect these items from counterfeiting, fraud, piracy,
product diversion and unauthorized intrusions. Our technologies are applicable
to a large percentage of global trade.The technologies offer a cost effective
method to detect, deter, interdict and prosecute global counterfeiting
organizations. Our platform may be integrated with pre-existing alternative
anti-counterfeit technologies, such as inks, thread, labels, microchips, glues,
paints and holograms. The intellectual property defines methods that tag and
authenticate the DNA fragments to ensure that the product has not been tampered
with or counterfeited.
In connection with the closing with Biowell, we terminated the license
agreement that we had previously entered into with Biowell in October 2002,
under which we had the exclusive right to sell, market, and sub-license
Biowell's technology within the United States, the European Union, Canada,
Mexico, Colombia, Saudi Arabia and the United Arab Emirates.
In connection with the closing with Biowell, we entered into a license
agreement with Biowell, whereby we granted Biowell an exclusive license to sell,
market, and sub-license our products in selected Asian countries. The exclusive
license for such selected territories is for an initial period of until December
31, 2010, and if Biowell meets its performance goals, the license agreement will
extend for an additional five year term. The license agreement gives Biowell the
initial rights to future anti-fraud biotechnologies we develop and also new
applications for the existing technology that may be developed for the
marketplace as long as the license agreement remains in effect. In the event
that Biowell shall sub-license the products within its territories, Biowell
shall pay us 50% of all fees, payments or consideration or any kind received in
connection with the grant of the sublicense. Biowell is required to pay a
royalty of 10% on all net sales made and is required to meet certain minimum
annual net sales in its various territories. The territories and minimum net
sales are as follows:
6
-------------------------- ----------------------------------------------------------------------------
COUNTRY MINIMUM ANNUAL NET SALES
(US DOLLARS)
-------------------------- -------------- --------------- -------------- -------------- ---------------
YEAR 1 YEAR 2 YEAR 3 YEAR 4 YEAR 5
-------------------------- -------------- --------------- -------------- -------------- ---------------
AUSTRALIA 200,000 250,000 500,000 750,000 1,000,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
AFGHANISTAN ZERO 25,000 50,000 100,000 100,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
BANGLADESH ZERO 25,000 50,000 100,000 100,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
BHUTAN ZERO 25,000 50,000 100,000 100,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
BRUNEI ZERO 100,000 250,000 400,000 500,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
CAMBODIA ZERO 100,000 250,000 400,000 500,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
CHINA 1,000,000 2,000,000 4,000,000 6,000,000 8,000,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
INDIA 500,000 1,000,000 2,000,000 3,000,000 4,000,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
INDONESIA 500,000 1,000,000 2,000,000 3,000,000 4,000,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
JAPAN 500,000 1,000,000 2,000,000 3,000,000 4,000,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
SOUTH KOREA 250,000 500,000 1,000,000 2,000,000 4,000,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
LAOS ZERO 100,000 250,000 400,000 500,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
MALAYSIA ZERO 250,000 500,000 1,000,000 2,000,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
MYANMAR ZERO 25,000 50,000 100,000 100,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
PAKISTAN ZERO 100,000 250,000 400,000 500,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
PHILIPPINES 100,000 250,000 500,000 750,000 1,000,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
SINGAPORE ZERO 100,000 250,000 400,000 500,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
SRI LANKA ZERO 25,000 50,000 100,000 100,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
TAIWAN 250,000 500,000 1,000,000 2,000,000 4,000,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
THAILAND 250,000 500,000 1,000,000 2,000,000 4,000,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
VIETNAM 250,000 500,000 1,000,000 2,000,000 4,000,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
UAE ZERO 25,000 50,000 100,000 100,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
BAHRAIN ZERO 25,000 50,000 100,000 100,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
CYPRUS ZERO 25,000 50,000 100,000 100,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
IRAN ZERO 25,000 50,000 100,000 100,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
IRAQ ZERO 25,000 50,000 100,000 100,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
JORDAN ZERO 100,000 250,000 500,000 750,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
KUWAIT ZERO 100,000 250,000 500,000 750,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
LEBANON ZERO 25,000 50,000 100,000 100,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
OMAN ZERO 100,000 250,000 500,000 750,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
QATAR ZERO 100,000 250,000 500,000 750,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
SAUDI ARABIA ZERO 500,000 1,000,000 2,000,000 4,000,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
SYRIA ZERO 100,000 250,000 500,000 750,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
YEMEN ZERO 100,000 250,000 500,000 750,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
TOTAL 3,800,000 9,625,000 19,800,000 33,600,000 52,100,000
-------------------------- -------------- --------------- -------------- -------------- ---------------
7
We have subsequently amended the license agreement to state that any
country that has been identified by the U.S. State Department as state sponsors
of terrorism or are subject to economic sanctions administered by the U.S.
Treasury Department's Office of Foreign Assets Control will not be a territory
under the license agreement until such time as that country has been removed
from such list of state sponsors of terrorism and are not subject to economic
sanctions by the U.S. Treasury Department's Office of Foreign Assets Control. As
Syria and Iran are currently recognized by the U.S. State Department as state
sponsors of terrorism and are subject to economic sanctions administered by the
U.S. Treasury Department's Office of Foreign Assets Control, the sections of the
license agreement concerning those countries shall be suspended until such time
as those countries have been removed from the list of the U.S. State Department
as state sponsors of terrorism and are no longer subject to economic sanctions
administered by the U.S. Treasury Department's Office of Foreign Assets Control.
In addition, we entered into a consulting agreement with Timpix
International Limited for the consulting services of three former Biowell
employees, Drs. Jun-Jei Sheu, Ben Liang and Johnson Chen. The consulting
agreement is for the shorter of two years, or until all of the consultants have
obtained a visa to work in the United States and execute employment agreements
with us. Such consulting agreement shall automatically renew for one year
periods until terminated. Pursuant to the consulting agreement, we shall pay
$47,000 per month, which is apportioned at $20,000 per month for Mr. Sheu,
$15,000 per month for Mr. Liang and $12,000 per month for Mr. Chen. In the event
that either of Messrs. Sheu, Liang or Chen becomes employed by us, the monthly
consulting fee shall be reduced accordingly. We have negotiated an agreement in
principle to restructure the Consulting Agreement, whereby, fees owed to Timplex
from July 2005 through December 2005 will be waived, and salaries for each of
the three consultants will be reduced starting January 1, 2006.
OUR PRODUCTS
With our acquired proprietary DNA technologies from Biowell, we will be
working to provide complete DNA anti-counterfeit and fraud prevention solutions.
We will offer comprehensive and price-competitive products and solutions. The
key characteristics of the DNA biotechnology are as follows:
Unique and Impossible to Replicate DNA Codes -- specially processed DNA
fragments, with unique characteristics and one-of-a-kind sequences, are used.
The embedded DNA concentration is extremely small (3-5 ppm) and cannot be
analyzed unless proprietary primers and reagents are used.
Easy to Customize -- We can tailor the DNA marker to meet the customer's
product marking requirements to mark a product, a specific country or factory of
origin and all associated Quality Assurance and shipping documents. The DNA
codes can be generated based on one or more DNA sources and one or more
anti-counterfeit technologies.
Easy and Quick to Use -- With the advanced DNA testing kits and detection
devices, a fast read-out can be obtained for on-site verification. The
authentication process can be performed quickly. Quantitative, or Real-time PCR
methods can produce authentication in less than 15 minutes using portable
devices. We are working to condense this time course.
Low Cost and High Accuracy - Only a minimal amount of DNA is needed to
provide forensic accuracy and proof of authenticity. It is a cost effective and
secure method for authentication and t prevention of counterfeiting.
Our technologies enable integration with other technologies that permit
line-of-sight instant verification (via DNA holograms) and forensic verification
in inks, threads, etc. We believe that these combined products will provide an
effective and timesaving deterrent against counterfeiters and smugglers.
Broad Applications -- DNA anti-counterfeiting technology can be applied to
almost any product on the market. The edible DNA ink is safe to consume and can
be used on tablets or capsules ensuring against counterfeiting pharmaceuticals.
DNA MARKERS
Our first products available for sales directly by us are
anti-counterfeiting products that have already been sold by Biowell to Asian
customers and have been tested in the marketplace prior to our acquisition of
Biowell. These products have included DNA-embedded teabag labels, liquor labels,
food product labels and other DNA-ink-dependent products.
8
Our second product is a DNA-encrypted hologram. The product is embedded
together with additional security features and has been sold by Biowell for
application to over 600 million CD's and DVD's as an anti-counterfeiting
technology deployed by the Government of the People's Republic of China. As of
June 2005, this product has been established by the Government of China as the
new national standard for DNA-based encryption and authentication. Applied DNA
Sciences has also developed a DNA-encrypted hologram together with Holomex.
Our third anti-counterfeiting product is a DNA Marker, embedded in a
bonding agent for thread that can be used to authenticate textile products. The
DNA Marker can be applied to the finished garment, bag, purse, shoe or domestic
household product (linens, etc). As the DNA Marker can be applied to any fabric
from cotton to wool, this will help textile vendors and governments determine
the origin of thread, yarn and fabric through to the high-end garment and luxury
fashion accessory manufacturers who suffer lost sales and product diversion at
the hands of counterfeiters. DNA Marker protection will also help preserve jobs
at the legitimate textile and clothing manufacturers as well as ensuring that
the proper taxes are collected on textiles and garments from authorities. The
DNA Marker will remain effective into the 22nd century and will be detectable
throughout the different manufacturing stages without degrading. It can be
detected in a variety of manners from inspection under UV light to laboratory
forensic analysis that authenticates it to a certainty of 99.9999 percent. The
efficacy of the DNA Marker was tested and verified by US Federal Government
Laboratories in late 2005. We will continuously assess the anti-counterfeit
needs of markets, companies and governmental organizations and will develop
proprietary technologies, solutions and products for these opportunities
INKS
DNA anti-counterfeit ink has been developed as two major applications. The
first ink is Biowell's unique anti-counterfeit ink (covert ink), which can be
authenticated at a forensic-science level of certainty with detailed DNA
analysis performed in a laboratory or on site using PCR methods.
The second application is an enhanced version of the first, integrating
into the original anti-counterfeit ink an additional instant detection function
for on-site authentication (overt ink).
This instant verification process has been designed to allow sampling at
any point in the product supply chain. By swabbing a "Q-tip" embedded with a
fluid containing a special activation buffer across the authentic DNA ink
surface, a biochemical reaction occurs between the coating of the DNA molecules
in the ink and the buffer fluid. This reaction manifests as a reversible color
change, with the ink changing color from blue to pink, and back to blue within
seconds. Testing can be repeated at various checkpoints throughout the product
supply chain. This ink can be embedded into special tamper-proof labels or
directly into packaging, lottery tickets, etc to enable simple on-the-spot
verification. The DNA-labels represent a "first" in its ability to enable
consumers to validate a product before purchase, ingestion, etc. The
implications for the food, beverage, pharmaceutical and other industries are
significant.
DNA ink can be applied to:
o General Company Use: trade marks, patents, company logos, important
documents
o Financial industry: currency, stocks, checks, bills, bonds, checks
o Retail: event tickets, VIP tickets, clothing labels
o Medicines: capsule and pill surface printing
o Inner package: foil blister packs
o Outer package: boxes, bottles
o Fine Art and Collectibles: paintings, artifacts, antiques, stamps,
coins, documents, collectibles and memorabilia
o Others: lottery tickets, inspection stamps, custom seals, passports,
visas, etc.
9
Virtually any item that can be duplicated now can be protected with any of
these DNA ink applications. The applications are cost-effective and can be
adapted to any company's current branding, product tracking, or other
anti-counterfeiting program.
DNA LABELS
DNA anti-counterfeit ink can be applied to paper or woven garment labels.
It can also be printed onto logos or on any other surface. Labels are printed
with the proprietary ink containing the specific authentication DNA code for a
manufacturer. The labels can then be easily tested for authenticity.
Knowledge that the labels are DNA-imprinted and can be quickly and easily
verified serves as a deterrent to counterfeiters. We believe this in itself will
create a demand for the proprietary DNA ink-impregnated label technology.
DNA MICROCHIPS
Computer and electronic signals constitute the basis for most corporate
security systems. These systems are of similar function and design, and are
susceptible to duplication, penetration and counterfeit. The polymorphism of DNA
is significantly more complex than electronic signals, and better suited for
security systems.
The DNA chip card is intended for both authentication of the card and
identification of an individual. For that purpose, a specific DNA (group ID) is
assigned to a set of DNA chip cards, along with an individual's identification
information, which is recorded in the chip's memory. A reader module is
configured to recognize (and therefore verify) only the chip carrying the
correct group ID. Any DNA chip card with different group ID, or indeed any other
chip card, will be rejected by the DNA chip card reader.
The DNA chip uses botanical DNA, which is artificially re-constructed. Each
user group has the same DNA code. Individuals are differentiated in the system
by identification codes stored in the chip's memory. In addition, the DNA chip
can be configured for the customer to have a particular person's own DNA as the
source DNA for that user group. The DNA chip generates unique signals and will
not function properly once removed from the casing. The empty chip is not
available anywhere else on the market, thus making it impossible to counterfeit.
Once the imbedded DNA chip is sabotaged or removed the chip, it will cease
functioning, thus preventing data on the chip from being duplicated.
The signal of a DNA chip is generated through an interaction between DNA
and a specially devised mechanism known as a DNA chip reader. A real DNA chip
will generate an analog signal upon receiving a signal from a card reader and
send back an encoded signal to the reader after the chip is stimulated. An LCD
display screen provides immediate authentication by reading the unique DNA
signals embedded in the chip.
The DNA chip function is versatile, which allows it to be integrated into
the form of slot reader, slide through reader, or contact point reader for
instant authentication. Biowell has also developed a portable, lightweight,
hand-held scanner that can be used to authenticate the DNA chips. The cost of
the DNA chip, card, and reader system is comparable to existing smart card
systems. Above all, the reader can be linked externally with existing card
readers to save replacement costs.
10
The DNA encrypted microchip won the prize for Best New Technology for
Security Access at the Conference of the Security Industry Association held in
Washington DC in late 2004, in competition against some of the world's largest
corporations. Shortly thereafter, we were inducted into the InteGuard Alliance,
a consortium of 29 major companies providing security services and security
technology to the US Government. We believe that the DNA chip system is more
secure than all other systems; since it cannot be copied or hacked, and works
with specially configured readers.
The DNA biochip can be applied to many products. For example:
o Security ID cards
o Passports
o Licenses
o Credit and ATM cards
o Debit cards
o Consumer merchandise (CDs, VCDs, DVDs, notebook computers,
PDAs, handbags, etc.)
o Other applications where authentication is required
(antiques, paintings, security access, ignitions, etc.)
INTELLECTUAL PROPERTY
Key to our success is ongoing research and development. We have over 12
patents pending. While patents are an important asset, they are not the only
instruments used to sequester a competitive position for us. We are developing
numerous tools to maintain technical superiority, which includes licensing other
component and complementary technologies that will keep pace with our speed to
market efforts.
We regard our trade secrets and other intellectual property as an integral
component of our success. We rely on patent law, trademark law, trade secret
protection and confidentiality and/or license agreements with employees,
customers, partners and others to protect our intellectual property. Effective
patent, trademark and trade secret protection may not be available in every
country in which our products are available. We cannot be certain that we have
taken adequate steps to protect our intellectual property, especially in
countries where the laws may not protect our rights as fully as in the United
States. In addition, if our third-party confidentiality agreements are breached
there may not be an adequate remedy available to us. If our trade secrets become
publicly known, we may lose our competitive position.
Additionally, litigation regarding patents and other intellectual property
rights is extensive in the biotechnology industry. In the event of an
intellectual property dispute, we may be forced to litigate. This litigation
could involve proceedings instituted by the U.S. Patent and Trademark Office or
the International Trade Commission, as well as proceedings brought directly by
affected third parties. Intellectual property litigation can be extremely
expensive, and these expenses, as well as the consequences should we not
prevail, could seriously harm our business.
If a third party claims an intellectual property right to technology we
use, we might need to discontinue an important product or product line, alter
our products and processes, pay license fees or cease our affected business
activities. Although we might under these circumstances attempt to obtain a
license to this intellectual property, we may not be able to do so on favorable
terms, or at all.
11
Patents Pending
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
Patent Name Application No. Filed by Date Filed Jurisdiction
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
A Method of Utilizing 089108443 Biowell (1) March 17, 2000 Taiwan
Nucleic Acids as
Markers for Product 00107580.2 May 18, 2000 China
Anti-Counterfeit Labeling
and Verification 09/832,048; April 9, 2001 United States
published 20020187263-A1
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
EppenLocker (A 089204158 Biowell (1) March 10, 2000 Taiwan
Leakage-Prevention Apparatus
of Microcentrifuge)
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
Multiple Tube Structure for 089210575 Biowell (1) June 20, 2000 Taiwan
Multiple in a Closed
Container
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
Method for Processing 89111477 Biowell (1) June 12, 2000 Taiwan
Multi-PCR in Closed Vessel
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
Method for Mixing Nucleic 2002-294229 Biowell (1) August 31, 2002 Japan
Acid in
Water Insoluble Media and 03007023.9 March 27, 2003 European
Application Thereof Patent Office
92121973 August 11, 2003 Taiwan
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
Method for Hiding Secret 92121490 Biowell (1) August 6, 2003 Taiwan
Message Carrying a DNA
Molecule and a Method for pending August 6, 2003 China
Decoding the Secret Message
Hiding by thereof
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
Method for Transferring 92119302 Biowell (1) July 15, 2003 Taiwan
Giveback Funds by
Recognizing Plurality of 03150071.4 July 31, 2003 China
Objects
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
Anti-Counterfeit Chip None Biowell (1) To be filed Taiwan
Recognizing Device
China
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
A System and Method for 60/463215 Biowell (1) April 16, 2003 United States
Marking Textiles Using DNA
Applied DNA Sciences
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
A System and Method for 2004/012031 Applied DNA Sciences April 15, 2004 United States
Marking Textiles Using
Nucleic Acids
------------------------------ --------------------------- --------------------------- --------------------------- -----------------
System and Method for 10/825968 Applied DNA Sciences January 21, 2004 United States
Authenticating Clients on a
Local Area Network Using
Nucleic Acids
(1) All patent applications filed by Biowell have either been assigned to us or
are in the process of being assigned to us.
12
CUSTOMERS
We do not currently have any revenue-generating customers at this point.
Our targeted client base includes major corporations, government entities and
educational institutions. We will provide DNA chip technology, DNA ink
technology as well as DNA profiling/tagging technology through various types of
resale agreements. We will apply these technologies to labels and security ink,
to a chip and reader as well as textile markers and agriculture profiling.
COMPETITION
The anti-counterfeit and fraud prevention market is highly competitive and
diverse. Since we believe that other forms of anti-counterfeiting and security
measures can be easily defeated, we expect that utilizing DNA, which cannot be
replicated, will garner great demand from the market. Some examples of
biotechnology and other security technologies include:
FINGERPRINT- a systems scans fingerprints before granting access to
computer files.
VOICE- Off-the-shelf software authenticates users based on individual vocal
patterns.
CORNEA- Scanners that scan the iris of a user's eye to match compared to a
computer database.
FACIAL SCAN- Computers can use complex algorithms to distinguish one face
from another.
IC CHIP & MAGNETIC STRIP- Integrated circuit chip that runs an electric
current through a circuit and is verified by a IC card. Is used in many parts of
Europe and Asia.
HOLOGRAPH- Optical security elements ('holograms') constitute a family of
optically variable microstructures, which are difficult to copy. Most of them
are difficult to reproduce using advanced color photocopiers and printing
techniques. This is why they are so widely used as anti-counterfeit devices.
Holograms are only one member of a family of optically variable devices which
all have several features in common. These are:
o Highly visible to the naked eye under good or reasonable
conditions of illumination.
o Colorful and change their colors with viewing angle.
o They derive their colorful effects from microstructures
within the devices, which cause interference or diffraction
of the light falling upon them.
FLUORESCENCE- X-ray Fluorescence (XRF) and elemental taggant technologies
were developed as a unique method for assaying uranium ore. Later on was used as
a handheld alloy grade identification and spectral analysis instrument. Its use
is limited to label/printing applications.
RADIOACTIVITY& RARE MOLECULES- a method of Radiation detection is very
effective but limited to use on crude oil.
Some of the bigger competitors in the field of anti-counterfeiting and
fraud protection include:
o DNA Technologies, Inc.
o Art Guard International
o Theft Protection Systems
o Cypher Science (United Kingdom) Mt. Sinai Hospital
o ChemTAG (Norway)
o NTT DATA Labs (Japan)
o November AG.
13
EMPLOYEES
As of January 1, 2006, we employ 5 full-time employees, of which two are in
management and three are sales & marketing executives. We expect to add
approximately 10 scientists and technical staff in R&D and product development
in the first half of 2006. Our recent restructuring of management and staff has
resulted in terminations and relocations of certain employees. We are
negotiating the final elements of our restructuring in early 2006. These actions
may cause short-term acrimony with our employees, but we believe that our
relations with our current employees is good.
ITEM 2. DESCRIPTION OF PROPERTY.
Presently, we maintain our principal office at 25 Health Sciences Drive,
Suite 113, Stony Brook, New York 11790. We signed a lease for our office and
laboratory space located in the Long Island High Technology Incubator facility
located within the campus of the State University of New York in Stony Brook in
November 2005. The laboratory and office space is provided to us for $50,000 per
year. We believe that our current office space and facilities are sufficient to
meet our present needs and do not anticipate any difficulty securing alternative
or additional space, as needed, on terms acceptable to us. We maintain a website
at www.adnas.com.
ITEM 3. LEGAL PROCEEDINGS.
From time to time, we may become involved in various lawsuits and legal
proceedings, which arise in the ordinary course of business. However, litigation
is subject to inherent uncertainties, and an adverse result in these or other
matters may arise from time to time that may harm our business. Except as
disclosed below, we are currently not aware of any such legal proceedings or
claims that we believe will have, individually or in the aggregate, a material
adverse affect on our business, financial condition or operating results.
STERN & CO. V. APPLIED DNA SCIENCES, INC., CASE NO.: 05 CV 00202
Plaintiff Stern & Co. commenced this action against us in the United States
District Court for the Southern District of New York on or about January 10,
2005. In this action, Stern & Co. alleges that it entered into a contract with
us to perform media and investor relations for a monthly fee of $5,000 and stock
options. Stern & Co. claims that we failed to make certain payments pursuant to
the contract and seeks damages in the amount of $96,042.00. We answered the
complaint on May 12, 2005, denying Stern & Co.'s allegations and we asserted a
number of defenses. This action is in the early stages of discovery and we
intend to vigorously defend this matter.
OCEANIC CONSULTING, S.A. V. APPLIED DNA SCIENCES, INC., INDEX NO.: 603974/04
Plaintiff Oceanic Consulting, S.A. commenced this action against us in the
Supreme Court of the State of New York, County of New York. Oceanic Consulting,
S.A. asserts a cause of action for breach of contract based upon the allegation
that we failed to make payments pursuant to a consulting agreement. Oceanic
Consulting, S.A.also asserts a causes of action in which it seeks reimbursement
of its expenses and attorneys' fees. Oceanic Consulting, S.A. seeks damages in
the amount of $137,500.00. Oceanic Consulting, S.A. moved for a default
judgment, which we have opposed based upon Oceanic Consulting, S.A.'s failure to
properly serve the complaint as well as our meritorious defenses. Thereafter,
Oceanic Consulting, S.A. agreed to withdraw its motion for a default judgment
and accepted service of our answer on May 23, 2005. We dispute the allegations
of the complaint. This action is in the early stages of discovery and we intend
to vigorously defend this matter.
14
CRYSTAL RESEARCH ASSOCIATES, LLC V. APPLIED DNA SCIENCES, INC., DOCKET NO.:
L-7947-04
On April 29, 2005, Crystal Research Associates, LLC obtained a default
judgment against us for $13,000 in the Superior Court of New Jersey, Middlesex
County. We intend to move to vacate the default judgment on various grounds. We
dispute the allegations of the complaint and we intend to vigorously defend this
matter.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
None.
15
PART II
ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.
MARKET INFORMATION
Our Common Stock is traded over-the-counter on the Over the Counter
Bulletin Board maintained by the National Association of Securities Dealers
under the symbol "APDN". There is no certainty assurance that the Common Stock
will continue to be quoted or that any liquidity exists for our shareholders.
The following table sets forth the quarterly quotes of high and low prices
for our Common Stock on the OTC Bulletin Board during the fiscal years September
30, 2004 and September 30, 2005. In February of 2003, we changed our year end to
September 30. We changed our fiscal year end in connection with a reverse merger
we entered into in December 2002, in which the acquirer for accounting purposes
had a fiscal year end of September 30. For ease of fiscal reporting, we adopted
the same fiscal year end.
Fiscal 2005 Fiscal 2004
----------- -----------
High Low High Low
---- --- ---- ---
First Quarter $2.39 $0.42 $3.54 $2.45
Second Quarter $1.83 $0.78 $3.55 $1.51
Third Quarter $1.01 $0.58 $2.55 $0.71
Fourth Quarter $0.74 $0.48 $0.96 $0.43
HOLDERS
As of December 5, 2005, we had approximately 1,285 holders of our common
stock. The number of record holders was determined from the records of our
transfer agent and does not include beneficial owners of common stock whose
shares are held in the names of various security brokers, dealers, and
registered clearing agencies. The transfer agent of our common stock is American
Stock Transfer & Trust Company, 6201 15th Avenue, Brooklyn, New York 11219.
DIVIDENDS
We have never declared or paid any cash dividends on our common stock. We
do not anticipate paying any cash dividends to stockholders in the foreseeable
future. In addition, any future determination to pay cash dividends will be at
the discretion of the Board of Directors and will be dependent upon our
financial condition, results of operations, capital requirements, and such other
factors as the Board of Directors deem relevant.
RECENT SALE OF UNREGISTERED SECURITIES
None.
16
ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.
The following information should be read in conjunction with the
consolidated financial statements and the notes thereto contained elsewhere in
this report. The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements. Information in this Item 6,
"Management's Discussion and Analysis or Plan of Operation," and elsewhere in
this 10-KSB that does not consist of historical facts, are "forward-looking
statements." Statements accompanied or qualified by, or containing words such as
"may," "will," "should," "believes," "expects," "intends," "plans," "projects,"
"estimates," "predicts," "potential," "outlook," "forecast," "anticipates,"
"presume," and "assume" constitute forward-looking statements, and as such, are
not a guarantee of future performance. The statements involve factors, risks and
uncertainties including those discussed in the "Risk Factors" section contained
elsewhere in this report, the impact or occurrence of which can cause actual
results to differ materially from the expected results described in such
statements. Risks and uncertainties can include, among others, fluctuations in
general business cycles and changing economic conditions; changing product
demand and industry capacity; increased competition and pricing pressures;
advances in technology that can reduce the demand for the Company's products, as
well as other factors, many or all of which may be beyond the Company's control.
Consequently, investors should not place undue reliance on forward-looking
statements as predictive of future results. The Company disclaims any obligation
to update the forward-looking statements in this report.
PLAN OF OPERATIONS
SALES AND MARKETING
Our revenues will come from three sources:
1) direct sales to manufacturer,
2) sales through our OEM relationships, and,
3) authentication (laboratory) services.
We employ a multi-tier sales and marketing strategy involving our marketing
and sales staff working together with high-level contacts in target industries
and our OEM base. We are attempting to develop strategic alliances and marketing
partners by setting up alliances with Biowell's technology partners, granting
licenses to existing anti-counterfeit suppliers and partner with industry
leaders for intellectual property development.
We are cognizant that no technology exists today to enable someone in the
street to ascertain, at the point of purchase, whether an expensive product, or
a child's foodstuff, or pharmaceutical product is genuine, worth the money being
paid and safe to use or ingest. No brand owner is able to rapidly determine
whether a product is real of fake. Many multi-billion dollar brands have no
technology to protect against counterfeiting, to detect its occurrence and to
interdict or prosecute the counterfeiter. No company has the capability to
determine with forensic certainty that it is subject to attack. Such companies
remain seriously exposed to product liability, loss of consumer confidence and
loss of revenues. Governments have no rapid detection system to determine at the
point of entry, inspection or seizure whether products are real or fake. A major
thrust of our marketing efforts is to work with consumer groups, media,
corporate officers, government departments, Customs, insurers and others to
bring home the message that, in a world of criminality and terrorism, no-one is
safe.
BUSINESS STRATEGY AND APPROACH
We have established integrated business operations addressing and servicing
the needs of the global security marketplace on the part of corporations and
governments for; anti-counterfeiting, fraud prevention, product authentication,
brand protection, supply chain management and protection.
17
INTELLECTUAL PROPERTY DEVELOPMENT, PRODUCT OPERATIONS & PARTNERSHIPS
We have proprietary DNA security technology, and develop security solutions
that protect corporate and intellectual property from counterfeiting, fraud,
piracy and product diversion using botanical DNA as an encrypted/code molecule
that can be embedded in inks, paper, substrates, liquids, textiles, thread,
plastics, holograms and microchips.
We produce security solutions customized to our customer's needs. We market
and sell DNA anti-counterfeit and fraud prevention solutions that integrate
into, and layer with, existing security solutions. These DNA security features
are integrated at the original equipment manufacturer level with ink, paper,
liquids, thread and hologram producers, who in turn sell/supply finished
security products such as primary and secondary product packaging for
pharmaceuticals, beauty products, textiles, currency, passports, ID cards, etc.
We have strict protocols for specifying, integrating, testing, shipping and
confirming the presence of DNA in any given product.
We plan to develop new product lines that will address specific new
challenges in the security marketplace, and bring these advances to target
industries, customers and countries.
Additionally, we will identify strategic partnerships and co-marketing
ventures, and licensees to work with us to develop, market and sell our
biotechnological security products. This will include sub-licensing the
technology to key partners in specific sectors with an established base of
customers. These partners will be able to enhance their product lines and client
services by adding our technology to the existing security matrix in their
products, providing an enhanced solution to deter fraud and counterfeiting.
MANAGEMENT STRATEGY
We anticipate a period of rapid change as we begin commercialization of the
products now available subsequent to: a) the signing of our licenses with
Biowell, b) the establishment of our prototyping labs at Stony Brook, and c) the
availability of products that have recently been commercialized in Asia by
Biowell.
We have organized our resources to manage our commercialization
effectively, optimizing the delivery of new prototypes for customers, and
managing outsourcing especially through our OEMs. Our Chief Executive Officer is
responsible for the strategic direction, coordinating with our overseas
technology partner Biowell and scientific development as well as corporate
governance and operations. Our President is responsible for business
development, including relations with US and foreign government agencies,
developing business relationships with target corporations and OEM's, and
securing revenues. Our Chief Financial Officer covers overall financial
management, financial reporting, corporate administration, investors relations.
Our marketing department develops strategic awareness of our technologies across
target industry sectors, their associated media and lobbying companies and
liaises with regulatory bodies (EPA, FDA, etc) and industry Associations (CTFA,
PHARMA, etc). Our sales department covers specific industries, such as the
pharmaceutical, packaging, ink, cosmetic and comestible sectors and acts as our
media spokesperson, clarifying for the pharmaceutical and nutraceutical
industries, allied health professionals and consumers the advantages of our
anti-counterfeit, diversion and piracy applications and products. Our Chairman
oversees the Biowell and Stony Brook DNA production Laboratories and the
development of core DNA sciences for current and future applications. Our
Strategic Technology Development Officer is principally engaged in the
productization of DNA markers for specific industry applications, and for
liaison with corresponding scientists from our principal OEM partners, e.g.,
petroleum markers, chemical markers, markers for precious stones, DNA-encrypted
inks, DNA markers for the pharmaceutical industry, etc.
18
CONSULTANT & ENFORCEMENT OPERATIONS
As nations are threatened by terrorism and corporations try to prevent
corporate fraud, counterfeiting, product diversion and industrial espionage, the
need for secure anti-counterfeiting and identification systems increases. Our
technology can provide important and cost-effective support for local, state,
and federal governments as well as corporations doing business with highly
sensitive information or products susceptible to counterfeit. Our
anti-counterfeiting technology can be used for the following types of
identification and important government documents:
o Passports
o Green cards
o Visas
o Driver's licenses
o Social Security cards
o Student visas
o Military ID's
o Other important Identity cards and official documents
We intend to work in collaboration with Biowell and other security
organizations in order to continue to research and develop new product lines
derived from, but not limited to, DNA technology. Research and development of
new product lines is an ongoing commitment and is currently underway in the
Biowell labs and will continue in the U.S. at our new facilities being
established at the Long Island High Technology Incubator (LIHTI) at Stony Brook
University in New York. Research and development objectives include the
development of a new line of detection technologies that will provide faster and
more convenient ways to authenticate DNA, continuous effort to incorporate our
DNA markers with various products for new applications, and establishment of a
leading DNA authentication service lab. We believe that we will obtain
commercial revenues for these efforts within 12-24 months, although no
assurances can be given that we will ever generate revenues. Our prototyping
laboratory will customize "off-the-shelf" products for new customers on a
case-by-case basis. These new products are typically newly configured labels,
inks or packing elements. We have identified several options for remote
detection and faster detection methodologies.
We will consult with our clients on a total security service offering; how
to protect their brands, intellectual property, products and physical security
access and how to reduce risk exposure, product liability exposure and product
recall liabilities. We plan to offer worldwide DNA analysis services supporting
the authentication of products and the detection, interdiction, deterrence and
prosecution of counterfeiters and related crimes, through our subcontractors,
sub-licensees and security industry collaborative partners.
INTERNATIONAL SUB-LICENSE OPERATIONS
Developing Technology - We have an in-depth understanding of DNA microchip
design and applications. We will jointly develop DNA-holograms and
DNA-Hologram-RFID devices, DNA-inks, DNA-dyes and DNA-security labels with
leading original equipment manufacturers in these specialist fields.
We will utilize our existing relationships and develop new ones to
introduce our anti-counterfeiting technology to generate business. Each industry
has unique requirements and needs for their anti-counterfeit solutions, and we
believe our DNA technology will provide maximum security technologies. For
example, our smart packaging solutions with DNA security markers in ink, paper
and holograms has widespread application in packaging for pharmaceuticals,
cosmetics, automotive markets, passports, ID's and currency. Our proprietary
technology offers immediate and affordable detection and security for their
brands and products.
19
Strong Technology Alliances - Our technology can also provide advanced
security dimensions to:
o Electronics security: access and physical/plant security (biometric
security cards enhanced with DNA)
o Security Holograms (DNA enhanced)
o Radio Frequency Identification systems (DNA + RFID)
o Security papers and printing
o Holograms (DNA holograms)
o Other security-related products and systems
Law Enforcement Expertise - The resources of our collaborative partners in
the security industry include former federal law enforcement, security, and
intelligence officers who provide the company with extensive contacts and
hands-on experience in:
o Intellectual property investigation
o Counter-intelligence
o Personal security services
o Anti-counterfeit technologies
o Secure communications and data management
CRITICAL ACCOUNTING POLICIES
The preparation of our consolidated financial statements in conformity with
accounting principles generally accepted in the United States requires us to
make estimates and judgments that affect our reported assets, liabilities,
revenues, and expenses, and the disclosure of contingent assets and liabilities.
We base our estimates and judgments on historical experience and on various
other assumptions we believe to be reasonable under the circumstances. Future
events, however, may differ markedly from our current expectations and
assumptions. While there are a number of significant accounting policies
affecting our consolidated financial statements; we believe the following
critical accounting policies involve the most complex, difficult and subjective
estimates and judgments:
o stock-based compensation
o fair value of intangible assets
STOCK-BASED COMPENSATION
In December 2002, the FASB issued SFAS No. 148 - Accounting for Stock-Based
Compensation - Transition and Disclosure. This statement amends SFAS No. 123 -
Accounting for Stock-Based Compensation, providing alternative methods of
voluntarily transitioning to the fair market value based method of accounting
for stock based employee compensation. FAS 148 also requires disclosure of the
method used to account for stock-based employee compensation and the effect of
the method in both the annual and interim financial statements. The provisions
of this statement related to transition methods are effective for fiscal years
ending after December 15, 2002, while provisions related to disclosure
requirements are effective in financial reports for interim periods beginning
after December 31, 2003.
We elected to continue to account for stock-based compensation plans using
the intrinsic value-based method of accounting prescribed by APB No. 25,
"Accounting for Stock Issued to Employees," and related interpretations. Under
the provisions of APB No. 25, compensation expense is measured at the grant date
for the difference between the fair value of the stock and the exercise price.
20
From its inception, the Company has incurred significant costs in
connection with the issuance of equity- based compensation, which is comprised
primarily of our common stock and warrants to acquire our common stock, to
non-employees. The Company anticipates continuing to incur such costs in order
to conserve its limited financial resources. The determination of the
volatility, expected term and other assumptions used to determine the fair value
of equity based compensation issued to non-employees under SFAS 123 involves
subjective judgment and the consideration of a variety of factors, including our
historical stock price, option exercise activity to date and the review of
assumptions used by comparable enterprises.
We account for equity based compensation, issued to non-employees in
exchange for goods or services , in accordance with the provisions of SFAS No.
123 and EITF No. 96-18, "Accounting for Equity Instruments That are Issued to
Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or
Services".
FAIR VALUE OF INTANGIBLE ASSETS
We have adopted SFAS No. 142, Goodwill and Other Intangible Assets, whereby
we periodically test our intangible assets for impairment. On an annual basis,
and when there is reason to suspect that their values have been diminished or
impaired, these assets are tested for impairment, and write-downs will be
included in results from operations.
On July 12, 2005, we acquired certain intellectual properties from Biowell
through an Asset Purchase Agreement in exchange for 36 million shares of our
restricted common stock having an aggregate fair value at the date of issuance
of $ 24,120,000. The value of the acquired intangible assets was $ 9,430,900,
with the balance of the purchase price, or $14,689,100, charged to operations as
a cost of the transaction.
The identifiable intangible assets acquired and their carrying value at
September 30, 2005 are:
Weighted
Average
Gross Amortization
Carrying Accumulated Residual Period
Amount Amortization Net Value (Years)
------------- --------------- ------------ ---------- ----------
Amortizable
Intangible
Assets:
Intellectual
Property $9,430,900 $336,818 $9,094,082 - 7
Patents 34,237 11,764 22,493 - 5
Total
Amortized
Identifiable
Intangible $9,465,137 $348,582 $9,116,575 - 6.99
---------- ======== ---------- -
Assets
Total amortization expense charged to operations for the year ended
September 30, 2005 and 2004 were $346,825 and $1,756.
21
Estimated amortization expense as of September 30, 2005 is as follows:
2006 $ 1,357,279
2007 1,357,279
2008 1,349,748
2009 1,347,271
2010 and after 3,704,998
Total $ 9,116,575
RECENT ACCOUNTING PRONOUNCEMENTS
In April 2003, the FASB issued Statement of Financial Accounting Standards
(SFAS) No. 149, Amendment of Statement No. 133 on Derivative Instruments and
Hedging Activities. SFAS 149 amends SFAS No. 133 to provide clarification on the
financial accounting and reporting of derivative instruments and hedging
activities and requires that contracts with similar characteristics be accounted
for on a comparable basis. The provisions of SFAS 149 are effective for
contracts entered into or modified after June 30, 2003, and for hedging
relationships designated after June 30, 2003. The adoption of SFAS 149 did not
have a material impact on the Company's results of operations or financial
position.
In May 2003, the FASB issued SFAS No. 150, Accounting for Certain Financial
Instruments with Characteristics of Both Liabilities and Equity. SFAS 150
establishes standards on the classification and measurement of certain financial
instruments with characteristics of both liabilities and equity. The provisions
of SFAS 150 are effective for financial instruments entered into or modified
after May 31, 2003 and to all other instruments that exist as of the beginning
of the first interim financial reporting period beginning after June 15, 2003.
The adoption of SFAS 150 did not have a material impact on the Company's results
of operations or financial position.
In December 2003, the FASB issued a revision of SFAS No. 132, "Employers'
Disclosures About Pensions And Other Postretirement Benefits." This
pronouncement, SFAS No. 132-R, expands employers' disclosures about pension
plans and other post-retirement benefits, but does not change the measurement or
recognition of such plans required by SFAS No. 87, No. 88, and No. 106. SFAS No.
132-R retains the existing disclosure requirements of SFAS No. 132, and requires
certain additional disclosures about defined benefit post-retirement plans.
Except as described in the following sentence, SFAS No. 132-R is effective for
foreign plans for fiscal years ending after June 15, 2004; after the effective
date, restatement for some of the new disclosures is required for earlier annual
periods. Some of the interim-period disclosures mandated by SFAS No. 132-R (such
as the components of net periodic benefit cost, and certain key assumptions) are
effective for foreign plans for quarters beginning after December 15, 2003;
other interim-period disclosures will not be required for the Company until the
first quarter of 2005. Since the Company does not have any defined benefit
post-retirement plans, the adoption of this pronouncement did not have any
impact on the Company's results of operations or financial condition.
In November 2004, the Financial Accounting Standards Board (FASB) issued
SFAS 151, Inventory Costs-- an amendment of ARB No. 43, Chapter 4. This
Statement amends the guidance in ARB No. 43, Chapter 4, "Inventory Pricing," to
clarify the accounting for abnormal amounts of idle facility expense, freight,
handling costs, and wasted material (spoilage). Paragraph 5 of ARB 43, Chapter
4, previously stated that ". . . under some circumstances, items such as idle
facility expense, excessive spoilage, double freight, and rehandling costs may
be so abnormal as to require treatment as current period charges. . . ." This
Statement requires that those items be recognized as current-period charges
regardless of whether they meet the criterion of "so abnormal." In addition,
this Statement requires that allocation of fixed production overheads to the
costs of conversion be based on the normal capacity of the production
facilities. This Statement is effective for inventory costs incurred during
fiscal years beginning after June 15, 2005. Management does not believe the
adoption of this Statement will have any immediate material impact on the
Company.
22
In December 2004, the FASB issued SFAS No.152, "Accounting for Real Estate
Time-Sharing Transactions--an amendment of FASB Statements No. 66 and 67" ("SFAS
152) The amendments made by Statement 152 This Statement amends FASB Statement
No. 66, Accounting for Sales of Real Estate, to reference the financial
accounting and reporting guidance for real estate time-sharing transactions that
is provided in AICPA Statement of Position (SOP) 04-2, Accounting for Real
Estate Time-Sharing Transactions. This Statement also amends FASB Statement No.
67, Accounting for Costs and Initial Rental Operations of Real Estate Projects,
to state that the guidance for (a) incidental operations and (b) costs incurred
to sell real estate projects does not apply to real estate time-sharing
transactions. The accounting for those operations and costs is subject to the
guidance in SOP 04-2. This Statement is effective for financial statements for
fiscal years beginning after June 15, 2005. with earlier application encouraged.
The Company does not anticipate that the implementation of this standard will
have a material impact on its financial position, results of operations or cash
flows.
On December 16, 2004, the Financial Accounting Standards Board ("FASB")
published Statement of Financial Accounting Standards No. 123 (Revised 2004),
Share-Based Payment ("SFAS 123R"). SFAS 123R requires that compensation cost
related to share-based payment transactions be recognized in the financial
statements. Share-based payment transactions within the scope of SFAS 123R
include stock options, restricted stock plans, performance-based awards, stock
appreciation rights, and employee share purchase plans. The provisions of SFAS
123R are effective as of the first interim period that begins after June 15,
2005. Accordingly, the Company will implement the revised standard in the third
quarter of fiscal year 2005. Currently, the Company accounts for its share-based
payment transactions under the provisions of APB 25, which does not necessarily
require the recognition of compensation cost in the financial statements.
Management is assessing the implications of this revised standard, which may
materially impact the Company's results of operations in the third quarter of
fiscal year 2005 and thereafter.
On December 16, 2004, FASB issued Statement of Financial Accounting
Standards No. 153, Exchanges of Nonmonetary Assets, an amendment of APB Opinion
No. 29, Accounting for Non-monetary Transactions (" SFAS 153"). This statement
amends APB Opinion 29 to eliminate the exception for non-monetary exchanges of
similar productive assets and replaces it with a general exception for exchanges
of non-monetary assets that do not have commercial substance. Under SFAS 153, if
a non-monetary exchange of similar productive assets meets a
commercial-substance criterion and fair value is determinable, the transaction
must be accounted for at fair value resulting in recognition of any gain or
loss. SFAS 153 is effective for non-monetary transactions in fiscal periods that
begin after June 15, 2005. The Company does not anticipate that the
implementation of this standard will have a material impact on its financial
position, results of operations or cash flows.
REVENUES
From our inception on September 16, 2002, we have not generated revenues
from operations. We believe we will begin generating revenues from operations in
the fiscal year as we transition from a development stage enterprise to that of
an active growth stage company, although no assurances can be given that we will
generate any revenues from operations.
COSTS AND EXPENSES
Selling, general and administrative expenses for the twelve months ended
September 30, 2005 compared to 2004 increased 146% to $42.662 million from
$17.342 million in the prior period. See a discussion of non cash items below in
the Liquidity & Capital Resources section. Included within the $25.320 million
increase compared to the twelve months ended September 30, 2005 is $14.689
million in expensed intellectual property acquisition costs occurring during the
quarter ended September 30, 2005, $4.714 million in fund raising and consultant
costs, $3.960 million in ESOP compensation to employees, $1.232 million in
increased salaries and wages due to higher headcount, $777,000 in penalty shares
related to the pending SB-2 registration, $550,000 in higher royalty expense,
$255,000 in higher facility rent as well as offsets of $857,000 in lower warrant
expense and other.
Research and development expenses increased $400,000 for the twelve months
ended September 30, 2005 compared to 2004 from $239,000 to $639,000 primarily
due to increased independent testing costs.
23
In the twelve months ended September 30, 2005, depreciation and
amortization increased $353,000 for the period compared to 2004 from $3,000 to
$356,000. In the quarter ended September 30, 2005, we capitalized $9.431 million
related to an intellectual property asset acquisition. As a result, we recorded
amortization expense totaling $336,000 for the quarter ended September 30, 2005.
We estimate a seven-year useful life that commenced during the fourth fiscal
quarter of 2005.
Total operating expenses increased to $43.657 million from $17.583 million,
or an increase of $26.074 million as a result of the combination of factors
listed above.
Other income, for the twelve months ended September 30, 2005 increased to
$5,000 from $1,000 in the same period of 2004, due primarily to the $3,000 of
licensing fees received from Biowell during the quarter ended September 30,
2005.
Interest expense, for the twelve months ended September 30, 2005 increased
to $8.958 million from $1.776 million in the same period of 2004, an increase of
$7.182 million due to $5.116 million due to increased beneficial conversion
feature related to the sale of convertible debt and attached warrants in the
year ended September 30, 2005. In 2005, we recorded beneficial conversion
feature for debt totaling $5.116 million and $3.720 million for warrants. We
charged $121,000 to interest expense related to other debt during the year ended
September 30, 2005.
Net loss for the twelve months ended September 30, 2005 increased to a loss
of $52.610 million from a loss of $19.358 million in the prior period as a
result of the combination of factors described above.
In the quarter ended September 30, 2005, we issued 36 million shares of
stock with a fair market value of $24.120 million to acquire intellectual
property. We capitalized $9.431 million as an intangible asset and charged
$336,000 to amortization expense for the year ended September 30, 2005. The
remaining $14.689 million was charged to operating expense.
Liquidity and Capital Resources
Our liquidity needs will come from working capital requirements,
indebtedness payments and research and development expenditure funding.
Historically, we have financed our operations through the sale of equity and
convertible debt as well as borrowings from various credit sources.
In 2005, we completed two sales of convertible debt. The first sale for
$1.465 million was for $0.50 per share plus attached warrants for $0.75, while
the second sale for $7.371 million was also for $0.50 per share plus attached
warrants for $0.75. Additional private sales raised $243,000. Of the $9.079
million in total proceeds from the equity sales, we used the proceeds to fund
financing fees, consultants and public reporting costs, salaries and wages,
royalties, research and development, facility costs as well as and general
working capital needs. Proceeds of $70,750 resulting from the exercise of
207,500 warrants occurred during the current period.
Substantially all of the real property used in our business is leased under
operating lease agreements.
As of September 30, 2005, we had a working capital deficit of $2,552,278.
For the year ended September 30, 2005, we generated a net cash flow deficit from
operating activities of $9,116,000 consisting primarily of year to date losses
of $52,610,000. Non cash equity adjustments included $8,836,000 for beneficial
conversion amortization, $14,805,000 in net stock issued for consulting
services, $14,689,000 in stock issued for intellectual property, $3,960,000 in
stock issued for ESOP shares, $777,000 in penalty stock issued pursuant to the
pending SB-2 registration, $956,000 for warrants issued to consultants and
$(1,078,000) in cancelled shares for services previously rendered. Finally, non
cash depreciation and amortizations totaled $350,000 and net liabilities and
other increased by $199,000. Cash used in investing activities totaled $4,000,
which was utilized for patent expenses. Cash provided by financing activities
for the year ended September 30, 2005 totaled $9,150,000 consisting of
$9,079,000 in proceeds from subscribed stock and 71,000 in exercised options
proceeds.
We expect capital expenditures to be less than $500,000 fiscal 2006. Our
primary investments will be in laboratory equipment to support prototyping and
our authentication services.
Exploitation of potential revenue sources will be financed primarily
through the sale of securities and convertible debt, exercise of outstanding
warrants, issuance of notes payable and other debt or a combination thereof,
depending upon the transaction size, market conditions and other factors.
While we have raised capital to meet our working capital and financing
needs in the past, additional financing is required within the next 12 months in
order to meet our current and projected cash flow deficits from operations and
development. We have sufficient funds to conduct our operations for several
months, but not for 12 months or more. There can be no assurance that financing
will be available in amounts or on terms acceptable to us, if at all.
24
By adjusting our operations and development to the level of capitalization,
we believe we have sufficient capital resources to meet projected cash flow
deficits. However, if during that period or thereafter, we are not successful in
generating sufficient liquidity from operations or in raising sufficient capital
resources, on terms acceptable to us, this could have a material adverse effect
on our business, results of operations liquidity and financial condition.
Our registered independent certified public accountants have stated in
their report dated October 21, 2005, that we have incurred operating losses in
the last two years, and that we are dependent upon management's ability to
develop profitable operations. These factors among others may raise substantial
doubt about our ability to continue as a going concern.
To obtain funding for our ongoing operations, we sold $1,465,000 in
convertible promissory notes to 13 investors in December 2004. Each promissory
note was automatically convertible into shares of our common stock, at a price
of $0.50 per share, upon the closing of a private placement for $1 million or
more. On January 28, 2005, we closed upon a private placement transaction in
excess of $1 million, and on February 2, 2005, the promissory notes were
converted into an aggregate of 2,930,000 shares of common stock. In connection
with the sale of the convertible promissory notes, we issued 2,930,000 warrants
to purchase shares of common stock. The warrants are exercisable until three
years from the date of issuance at a purchase price of $0.75 per share.
To obtain funding for our ongoing operations, we conducted a private
placement offering in January and February 2005, in which we sold $7,371,000 of
10% Secured Convertible Promissory Notes to 61 investors. The 10% Secured
Convertible Promissory Notes automatically convert into shares of our common
stock, at a price of $0.50 per share, upon the filing of this registration
statement. In connection with the private placement offering, we have issued
15,242,000 warrants. The warrants are exercisable until five years from the date
of issuance at a purchase price of $0.75 per share.
Since the conversion price was less than the market price of the common
stock at the time the secured convertible notes were issued, we recognized a
charge relating to the beneficial conversion feature of the secured convertible
notes during the quarter in which they are issued, including the first quarter
of fiscal 2005 when $1,465,000 of secured convertible notes were issued and the
second quarter of fiscal 2005 when $7,371,000 of secured convertible notes were
issued
In connection with the private placement, we granted the investors
registration rights. Pursuant to the registration rights agreement, if we did
not file the registration statement by February 15, 2005, or if we did not have
the registration statement declared effective on or before July 15, 2005, we are
obligated to pay liquidated damages in the amount of 3.5% per month of the face
amount of the notes, which equals $257,985, until the registration statement is
declared effective. At our option, these liquidated damages can be paid in cash
or restricted shares of our common stock. We have currently decided to pay the
liquidated damages due at this point in common stock, although any future
payments of liquidated damages could be made in cash. If we decide to pay the
liquidated damages in cash, we would be required to use our limited working
capital and potentially raise additional funds. If we decide to pay the
liquidated damages in shares of common stock, the number of shares issued would
depend on our stock price at the time that payment is due. Based on closing
market prices of $0.66, $0.58, $0.70, $0.49, $0.32 and $0.20 for our common
stock on July 15, 2005, August 15, 2005, September 15, 2005, October 17, 2005,
November 15, 2005 and December 15, 2005, respectively, we issued approximately
390,887, 444,802, 368,550, 526,500, 806,204 and 1,289,927 shares of common stock
per month, respectively, in liquidated damages.
We presently do not have any available credit, bank financing or other
external sources of liquidity. Due to our brief history and historical operating
losses, our operations have not been a source of liquidity. We will need to
obtain additional capital in order to expand operations and become profitable.
We intend to pursue the building of a re-seller network outside the United
States, and if successful, the re-seller agreements would constitute a source of
liquidity and capital over time. In order to obtain capital, we may need to sell
additional shares of our common stock or borrow funds from private lenders.
There can be no assurance that we will be successful in obtaining additional
funding and execution of re-seller agreements outside the Unites States.
25
We will still need additional investments in order to continue operations
to cash flow break even. Additional investments are being sought, but we cannot
guarantee that we will be able to obtain such investments. Financing
transactions may include the issuance of equity or debt securities, obtaining
credit facilities, or other financing mechanisms. However, the trading price of
our common stock and the downturn in the U.S. stock and debt markets could make
it more difficult to obtain financing through the issuance of equity or debt
securities. Even if we are able to raise the funds required, it is possible that
we could incur unexpected costs and expenses, fail to collect significant
amounts owed to us, or experience unexpected cash requirements that would force
us to seek alternative financing. Further, if we issue additional equity or debt
securities, stockholders may experience additional dilution or the new equity
securities may have rights, preferences or privileges senior to those of
existing holders of our common stock. If additional financing is not available
or is not available on acceptable terms, we will have to curtail our operations.
FACTORS THAT COULD AFFECT FUTURE RESULTS
Because of the following factors, as wells as other variables affecting our
operating results and financial condition, past financial performance may not be
a reliable indicator of future performance, and historical trends should not be
used to anticipate results or trends in future periods.
Risks Relating to Our Business:
------------------------------
WE HAVE A HISTORY OF LOSSES WHICH MAY CONTINUE, WHICH MAY NEGATIVELY IMPACT OUR
ABILITY TO ACHIEVE OUR BUSINESS OBJECTIVES.
We incurred net losses of $52,610,380 for the year ended September 30, 2005
and $19,358,259 for the year ended September 30, 2004. We cannot assure you that
we can achieve or sustain profitability on a quarterly or annual basis in the
future. Our operations are subject to the risks and competition inherent in the
establishment of a business enterprise. There can be no assurance that future
operations will be profitable. Revenues and profits, if any, will depend upon
various factors, including whether we will be able to generate revenue. As a
result of continuing losses, we may exhaust all of our resources prior to
completing the development of our products. Additionally, as we continue to
incur losses, our accumulated deficit will continue to increase, which might
make it harder for us to obtain financing in the future. We may not achieve our
business objectives and the failure to achieve such goals would have an adverse
impact on us, which could result in reducing or terminating our operations.
IF WE ARE UNABLE TO OBTAIN ADDITIONAL FUNDING OUR BUSINESS OPERATIONS WILL BE
HARMED AND IF WE DO OBTAIN ADDITIONAL FINANCING OUR THEN EXISTING SHAREHOLDERS
MAY SUFFER SUBSTANTIAL DILUTION.
We will require additional funds to sustain and expand our research and
development activities. We anticipate that we will require up to approximately
$500,000 to fund our anticipated research and development operations for the
next twelve months, depending on revenue from operations. Additional capital
will be required to effectively support the operations and to otherwise
implement our overall business strategy. Even if we do receive additional
financing, it may not be sufficient to sustain or expand our research and
development operations or continue our business operations.
There can be no assurance that financing will be available in amounts or on
terms acceptable to us, if at all. The inability to obtain additional capital
will restrict our ability to grow and may reduce our ability to continue to
conduct business operations. If we are unable to obtain additional financing, we
will likely be required to curtail our research and development plans. Any
additional equity financing may involve substantial dilution to our then
existing shareholders.
26
OUR INDEPENDENT AUDITORS HAVE EXPRESSED SUBSTANTIAL DOUBT ABOUT OUR ABILITY TO
CONTINUE AS A GOING CONCERN, WHICH MAY HINDER OUR ABILITY TO OBTAIN FUTURE
FINANCING.
In their report dated October 21, 2005, our independent auditors stated
that our financial statements for the year ended September 30, 2005 were
prepared assuming that we would continue as a going concern. Our ability to
continue as a going concern is an issue raised due to our incurring net losses
of $75,425,414 during the period September 16, 2002 (date of inception) through
September 30, 2005. We continue to experience net operating losses. Our ability
to continue as a going concern is subject to our ability to generate a profit
and/or obtain necessary funding from outside sources, including obtaining
additional funding from the sale of our securities, generating sales or
obtaining loans and grants from various financial institutions where possible.
Our continued net operating losses increase the difficulty in meeting such goals
and there can be no assurances that such methods will prove successful.
OUR RESEARCH AND DEVELOPMENT EFFORTS FOR NEW PRODUCTS MAY BE UNSUCCESSFUL.
We will incur significant research and development expenses to develop new
products and technologies. There can be no assurance that any of these products
or technologies will be successfully developed or that if developed they will be
commercially successful. In the event that we are unable to develop
commercialized products from our research and development efforts or we are
unable or unwilling to allocate amounts beyond our currently anticipated
research and development investment, we could lose our entire investment in
these new products and this may materially and adversely affect our business
operations, which would result in loss of revenues and greater operating
expenses.
OUR ACQUIRED TECHNOLOGY HAS YET TO BE INDEPENDENTLY VALIDATED.
In July 2005, we acquired certain intellectual property. Such intellectual
property relating to the botanical DNA, encapsulation methods, integrity of the
technology and all other stated claims by the seller need to be independently
validated by a third party. Satisfactory completion of this independent
validation will be required prior to their being available for commercial sale.
In the event that some or all of the technology cannot be independently
validated, we will be unable to commercially develop products utilizing such
technology, which could have a materially adverse effect on our business and
results of operations.
FAILURE TO LICENSE NEW TECHNOLOGIES COULD IMPAIR OUR NEW PRODUCT DEVELOPMENT.
To generate broad product lines, it is advantageous to sometimes license
technologies from third parties rather than depend exclusively on our own
employees. As a result, we believe our ability to license new technologies from
third parties is and will continue to be important to our ability to offer new
products.
In addition, from time to time we are notified or become aware of patents
held by third parties that are related to technologies we are selling or may
sell in the future. After a review of these patents, we may decide to seek a
license for these technologies from these third parties or discontinue our
products. There can be no assurance that we will be able to continue to
successfully identify new technologies developed by others. Even if we are able
to identify new technologies of interest, we may not be able to negotiate a
license on favorable terms, or at all. If we lose the rights to patented
technology, we may need to discontinue selling certain products or redesign our
products, and we may lose a competitive advantage. Potential competitors could
license technologies that we fail to license and potentially erode our market
share for certain products. Our licenses typically subject us to various
commercializations, sublicensing, minimum payment, and other obligations. If we
fail to comply with these requirements, we could lose important rights under a
license. In addition, certain rights granted under the license could be lost for
reasons beyond our control. We may not receive significant indemnification from
a licensor against third party claims of intellectual property infringement.
27
WE CURRENTLY HAVE NO OR LIMITED MANUFACTURING, SALES, MARKETING OR DISTRIBUTION
CAPABILITIES.
We currently have no in-house manufacturing capability. We rely on
third-party vendors for this service. We do not currently have any arrangements
with any distributors and we may not be able to enter into arrangements with
qualified distributors on acceptable terms or at all. We currently have a
limited sales and marketing team. If we are not able to develop greater sales,
marketing or distribution capacity, we may not be able to generate revenue or
sufficient revenue to support our operations.
IF WE FAIL TO INTRODUCE NEW PRODUCTS, OR OUR EXISTING PRODUCTS ARE NOT ACCEPTED
BY POTENTIAL CUSTOMERS, WE MAY NOT GAIN OR MAY LOSE MARKET SHARE.
Rapid technological changes and frequent new product introductions are
typical for the markets we serve. Our future success will depend in part on
continuous, timely development and introduction of new products that address
evolving market requirements. We believe successful new product introductions
provide a significant competitive advantage because customers invest their time
in selecting and learning to use new products, and are often reluctant to switch
products. To the extent we fail to introduce new and innovative products, we may
lose market share to our competitors, which will be difficult or impossible to
regain. Any inability, for technological or other reasons, to successfully
develop and introduce new products could reduce our growth rate or damage our
business.
We may experience delays in the development and introduction of products.
We cannot assure that we will keep pace with the rapid rate of change in life
sciences research or that our new products will adequately meet the requirements
of the marketplace or achieve market acceptance. Some of the factors affecting
market acceptance of new products include:
o Availability, quality and price relative to competitive products;
o The timing of introduction of the product relative to competitive
products;
o Customers' opinions of the products' utility;
o Ease of use;
o Consistency with prior practices;
o Scientists' opinions of the products' usefulness;
o Citation of the product in published research; and
o General trends in life sciences research.
We have not experienced any difficulties with the preceding factors,
however, there can be no assurance that we will not experience difficulties in
the future. The expenses or losses associated with unsuccessful product
development or lack of market acceptance of our new products could materially
adversely affect our business, operating results and financial condition.
A MANUFACTURER'S INABILITY TO PRODUCE OUR GOODS ON TIME AND TO OUR
SPECIFICATIONS COULD RESULT IN LOST REVENUE AND NET LOSSES.
We do not own or operate any manufacturing facilities and therefore depend
upon independent third parties for the manufacture of all of our products. Our
products are manufactured to our specifications. The inability of a manufacturer
to ship orders of our products in a timely manner or to meet our quality
standards could cause us to miss the delivery date requirements of our customers
for those items, which could result in cancellation of orders, refusal to accept
deliveries or a reduction in purchase prices, any of which could have a material
adverse effect as our revenues would decrease and we would incur net losses as a
result of sales of the product, if any sales could be made. Because of our
business, the dates on which customers need and require shipments of our
security products from us are critical.
28
IF WE NEED TO REPLACE MANUFACTURERS, OUR EXPENSES COULD INCREASE RESULTING IN
SMALLER PROFIT MARGINS.
We compete with other companies for the production capacity of our
manufacturers and import quota capacity. Some of these competitors have greater
financial and other resources than we have, and thus may have an advantage in
the competition for production and import quota capacity. If we experience a
significant increase in demand, or if an existing manufacturer of ours must be
replaced, we may have to expand our third-party manufacturing capacity. We
cannot assure you that this additional capacity will be available when required
on terms that are acceptable to us or similar to existing terms which we have
with our manufacturers, either from a production standpoint or a financial
standpoint. We do not have long-term contracts with any manufacturer. None of
the manufacturers we use produces our products exclusively.
Should we be forced to replace one or more of our manufacturers, we may
experience an adverse financial impact, or an adverse operational impact, such
as being forced to pay increased costs for such replacement manufacturing or
delays upon distribution and delivery of our products to our customers, which
could cause us to lose customers or lose revenues because of late shipments.
IF A MANUFACTURER OF OURS FAILS TO USE ACCEPTABLE LABOR PRACTICES, WE MIGHT HAVE
DELAYS IN SHIPMENTS OR FACE JOINT LIABILITY FOR VIOLATIONS, RESULTING IN
DECREASED REVENUE AND INCREASED EXPENSES.
While we require our independent manufacturers to operate in compliance
with applicable laws and regulations, we have no control over the ultimate
actions of our independent manufacturers. While our internal and vendor
operating guidelines promote ethical business practices and our staff and buying
agents periodically visit and monitor the operations of our independent
manufacturers, we do not control these manufacturers or their labor practices.
The violation of labor or other laws by an independent manufacturer of ours, or
by one of our licensing partners, or the divergence of an independent
manufacturer's or licensing partner's labor practices from those generally
accepted as ethical in the United States, could interrupt, or otherwise disrupt
the shipment of finished products to us or damage our reputation. Any of these,
in turn, could have a material adverse effect on our financial condition and
results of operations, such as the loss of potential revenue and incurring
additional expenses.
THE FAILURE TO MANAGE OUR GROWTH IN OPERATIONS AND ACQUISITIONS OF NEW PRODUCT
LINES AND NEW BUSINESSES COULD HAVE A MATERIAL ADVERSE EFFECT ON US.
The expected growth of our operations (as to which no representation can be
made) will place a significant strain on our current management resources. To
manage this expected growth, we will need to improve our:
o operations and financial systems;
o procedures and controls; and
o training and management of our employees.
Our future growth may be attributable to acquisitions of and new product
lines and new businesses. We expect that future acquisitions, if successfully
consummated, will create increased working capital requirements, which will
likely precede by several months any material contribution of an acquisition to
our net income.
Our failure to manage growth or future acquisitions successfully could
seriously harm our operating results. Also, acquisition costs could cause our
quarterly operating results to vary significantly. Furthermore, our stockholders
would be diluted if we financed the acquisitions by incurring convertible debt
or issuing securities.
29
Although we currently only have operations within the United States, if we
were to acquire an international operation; we will face additional risks,
including:
o difficulties in staffing, managing and integrating international
operations due to language, cultural or other differences;
o Different or conflicting regulatory or legal requirements;
o foreign currency fluctuations; and
o diversion of significant time and attention of our management.
IF WE ARE UNABLE TO RETAIN THE SERVICES OF MESSRS. SHEU, HAYWARD OR LIANG, OR IF
WE ARE UNABLE TO SUCCESSFULLY RECRUIT QUALIFIED MANAGERIAL AND SALES PERSONNEL
HAVING EXPERIENCE IN BUSINESS, WE MAY NOT BE ABLE TO CONTINUE OUR OPERATIONS.
Our success depends to a significant extent upon the continued service of
Dr. Jun-Jei Sheu, our Chairman of the Board of Directors, Dr. James Hayward, our
Chief Executive Officer and Dr. Bejamin Liang, our Secretary and Strategic
Technology Development Officer. We do not have employment agreements with Drs.
Sheu, Hayward or Liang. Loss of the services of Drs. Sheu, Hayward or Liang
could have a material adverse effect on our growth, revenues, and prospective
business. We do not maintain key-man insurance on the life of Drs. Sheu, Hayward
or Liang. We are not aware of any named executive officer or director who has
plans to leave us or retire. In addition, in order to successfully implement and
manage our business plan, we will be dependent upon, among other things,
successfully recruiting qualified managerial and sales personnel having
experience in business. Competition for qualified individuals is intense. There
can be no assurance that we will be able to find, attract and retain existing
employees or that we will be able to find, attract and retain qualified
personnel on acceptable terms.
FAILURE TO ATTRACT AND RETAIN QUALIFIED SCIENTIFIC OR PRODUCTION PERSONNEL COULD
HAVE A MATERIAL ADVERSE EFFECT ON US.
Recruiting and retaining qualified scientific and production personnel to
perform research and development work and product manufacturing is critical to
our success. Because the industry in which we compete is very competitive, we
face significant challenges attracting and retaining a qualified personnel base.
Although we believe we have been and will be able to attract and retain these
personnel, there is no assurance that we will be able to continue to
successfully attract qualified personnel. In addition, our anticipated growth
and expansion into areas and activities requiring additional expertise, such as
clinical testing, government approvals, production, and marketing will require
the addition of new management personnel and the development of additional
expertise by existing management personnel. The failure to attract and retain
these personnel or, alternatively, to develop this expertise internally would
adversely affect our business as our ability to conduct research and development
will be reduced or eliminated, resulting in fewer or no products for sale and
lower revenues. We generally do not enter into employment agreements requiring
these employees to continue in our employment for any period of time.
WE NEED TO EXPAND OUR SALES AND SUPPORT ORGANIZATIONS TO INCREASE MARKET
ACCEPTANCE OF OUR PRODUCTS.
We currently have a small customer service and support organization and
will need to increase our staff to support new customers and the expanding needs
of existing customers. The employment market for sales personnel, and customer
service and support personnel in this industry is very competitive, and we may
not be able to hire the kind and number of sales personnel, customer service and
support personnel we are targeting. Our inability to hire qualified sales,
customer service and support personnel may materially adversely affect our
business, operating results and financial condition.
30
THE BIOMEDICAL RESEARCH PRODUCTS INDUSTRY IS VERY COMPETITIVE, AND WE MAY BE
UNABLE TO CONTINUE TO COMPETE EFFECTIVELY IN THIS INDUSTRY IN THE FUTURE.
We are engaged in a segment of the biomedical research products industry
that is highly competitive. We compete with many other suppliers and new
competitors continue to enter the market. Many of our competitors, both in the
United States and elsewhere, are major pharmaceutical, chemical and
biotechnology companies, and many of them have substantially greater capital
resources, marketing experience, research and development staff, and facilities
than we do. Any of these companies could succeed in developing products that are
more effective than the products that we have or may develop and may be more
successful than us in producing and marketing their products. It is impossible
to quantify the number of competitors since they include both the companies we
attempt to sell our products and services to through their use of internal
security and various other security product companies. Some of the
anti-counterfeiting and fraud protection competitors that we are aware of
include: Authentix, InkSure, DNA Technologies, Inc., Art Guard International,
Theft Protection Systems, Tracetag and November AG. Although it is impossible to
determine the total market size and market data information because companies
are secretive about what security methods they utilize and how much they spend
on such measures, we have determined that annual sales by some of our
competitors have been as follows:
Inksure - $1.0 million
DNA Technologies, Inc. - $22.6 million
November AG - $5.8 million
We expect this competition to continue and intensify in the future.
Competition in our markets is primarily driven by:
o Product performance, features and liability;
o Price;
o Timing of product introductions;
o Ability to develop, maintain and protect proprietary products and
technologies;
o Sales and distribution capabilities;
o Technical support and service;
o Brand loyalty;
o Applications support; and
o Breadth of product line.
If a competitor develops superior technology or cost-effective alternatives
to our products, our business, financial condition and results of operations
could be materially adversely affected.
OUR TRADEMARK AND OTHER INTELLECTUAL PROPERTY RIGHTS MAY NOT BE ADEQUATELY
PROTECTED OUTSIDE THE UNITED STATES, RESULTING IN LOSS OF REVENUE.
We believe that our trademarks, whether licensed or owned by us, and other
proprietary rights are important to our success and our competitive position. In
the course of our international expansion, we may, however, experience conflict
with various third parties who acquire or claim ownership rights in certain
trademarks. We cannot assure that the actions we have taken to establish and
protect these trademarks and other proprietary rights will be adequate to
prevent imitation of our products by others or to prevent others from seeking to
block sales of our products as a violation of the trademarks and proprietary
rights of others. Also, we cannot assure you that others will not assert rights
in, or ownership of, trademarks and other proprietary rights of ours or that we
will be able to successfully resolve these types of conflicts to our
satisfaction. In addition, the laws of certain foreign countries may not protect
proprietary rights to the same extent, as do the laws of the United States.
31
INTELLECTUAL PROPERTY LITIGATION COULD HARM OUR BUSINESS.
Litigation regarding patents and other intellectual property rights is
extensive in the biotechnology industry. In the event of an intellectual
property dispute, we may be forced to litigate. This litigation could involve
proceedings instituted by the U.S. Patent and Trademark Office or the
International Trade Commission, as well as proceedings brought directly by
affected third parties. Intellectual property litigation can be extremely
expensive, and these expenses, as well as the consequences should we not
prevail, could seriously harm our business.
If a third party claims an intellectual property right to technology we
use, we might need to discontinue an important product or product line, alter
our products and processes, pay license fees or cease our affected business
activities. Although we might under these circumstances attempt to obtain a
license to this intellectual property, we may not be able to do so on favorable
terms, or at all. We are currently not aware of any intellectual property rights
that are being infringed nor have we received notice from a third party that we
may be infringing on any of their patents.
Furthermore, a third party may claim that we are using inventions covered
by the third party's patent rights and may go to court to stop us from engaging
in our normal operations and activities, including making or selling our product
candidates. These lawsuits are costly and could affect our results of operations
and divert the attention of managerial and technical personnel. There is a risk
that a court would decide that we are infringing the third party's patents and
would order us to stop the activities covered by the patents. In addition, there
is a risk that a court will order us to pay the other party damages for having
violated the other party's patents. The biotechnology industry has produced a
proliferation of patents, and it is not always clear to industry participants,
including us, which patents cover various types of products or methods of use.
The coverage of patents is subject to interpretation by the courts, and the
interpretation is not always uniform. If we are sued for patent infringement, we
would need to demonstrate that our products or methods of use either do not
infringe the patent claims of the relevant patent and/or that the patent claims
are invalid, and we may not be able to do this. Proving invalidity, in
particular, is difficult since it requires a showing of clear and convincing
evidence to overcome the presumption of validity enjoyed by issued patents.
Because some patent applications in the United States may be maintained in
secrecy until the patents are issued, because patent applications in the United
States and many foreign jurisdictions are typically not published until eighteen
months after filing, and because publications in the scientific literature often
lag behind actual discoveries, we cannot be certain that others have not filed
patent applications for technology covered by our licensors' issued patents or
our pending applications or our licensors' pending applications or that we or
our licensors were the first to invent the technology. Our competitors may have
filed, and may in the future file, patent applications covering technology
similar to ours. Any such patent application may have priority over our or our
licensors' patent applications and could further require us to obtain rights to
issued patents covering such technologies. If another party has filed a United
States patent application on inventions similar to ours, we may have to
participate in an interference proceeding declared by the United States Patent
and Trademark Office to determine priority of invention in the United States.
The costs of these proceedings could be substantial, and it is possible that
such efforts would be unsuccessful, resulting in a loss of our United States
patent position with respect to such inventions.
Some of our competitors may be able to sustain the costs of complex patent
litigation more effectively than we can because they have substantially greater
resources. In addition, any uncertainties resulting from the initiation and
continuation of any litigation could have a material adverse effect on our
ability to raise the funds necessary to continue our operations.
32
ACCIDENTS RELATED TO HAZARDOUS MATERIALS COULD ADVERSELY AFFECT OUR BUSINESS.
Some of our operations require the controlled use of hazardous materials.
Although we believe our safety procedures comply with the standards prescribed
by federal, state, local and foreign regulations, the risk of accidental
contamination of property or injury to individuals from these materials cannot
be completely eliminated. In the event of an accident, we could be liable for
any damages that result, which could seriously damage our business and results
of operations.
POTENTIAL PRODUCT LIABILITY CLAIMS COULD AFFECT OUR EARNINGS AND FINANCIAL
CONDITION.
We face a potential risk of liability claims based on our products and
services, and we have faced such claims in the past. We currently do not have
any product liability coverage but are attempting to obtain coverage which we
will believe to be adequate. We cannot assure, however, that we will be able to
obtain or maintain this insurance at reasonable cost and on reasonable terms. We
also cannot assure that this insurance, if obtained, will be adequate to protect
us against a product liability claim, should one arise. In the event that a
product liability claim is successfully brought against us, it could result in a
significant decrease in our liquidity or assets, which could result in the
reduction or termination of our business.
WE ARE OBLIGATED TO PAY LIQUIDATED DAMAGES AS A RESULT OF OUR FAILURE TO HAVE
THIS REGISTRATION STATEMENT DECLARED EFFECTIVE PRIOR TO JULY 15, 2005, AND THE
PAYMENT OF LIQUIDATED DAMAGES WILL EITHER RESULT IN DEPLETING OUR WORKING
CAPITAL OR ISSUANCE OF SHARES OF COMMON STOCK WHICH WOULD CAUSE DILUTION TO OUR
EXISTING SHAREHOLDERS.
Pursuant to the terms of our private placement that closed in January and
February 2005, if we did not have a registration statement registering the
shares underlying the convertible notes and warrants declared effective on or
before July 15, 2005, we are obligated to pay liquidated damages in the amount
of 3.5% per month of the face amount of the notes, which equals $257,985, until
the registration statement is declared effective. At our option, these
liquidated damages can be paid in cash or restricted shares of our common stock.
We have currently decided to pay the liquidated damages due at this point in
common stock, although any future payments of liquidated damages could be made
in cash. If we decide to pay the liquidated damages in cash, we would be
required to use our limited working capital and potentially raise additional
funds. If we decide to pay the liquidated damages in shares of common stock, the
number of shares issued would depend on our stock price at the time that payment
is due. Based on closing market prices of $0.66, $0.58, $0.70, $0.49, $0.32 and
$0.20 for our common stock on July 15, 2005, August 15, 2005, September 15,
2005, October 17, 2005, November 15, 2005 and December 15, 2005, respectively,
we issued approximately 390,887, 444,802, 368,550, 526,500, 806,204 and
1,289,927 shares of common stock per month, respectively, in liquidated damages.
The issuance of shares upon payment of liquidated damages will have the effect
of further diluting the proportionate equity interest and voting power of
holders of our common stock, including investors in this offering.
Risks Relating to Our Common Stock:
----------------------------------
THERE ARE A LARGE NUMBER OF SHARES UNDERLYING OUR WARRANTS THAT MAY BE AVAILABLE
FOR FUTURE SALE AND THE SALE OF THESE SHARES MAY DEPRESS THE MARKET PRICE OF OUR
COMMON STOCK AND WILL CAUSE IMMEDIATE AND SUBSTANTIAL DILUTION TO OUR EXISTING
STOCKHOLDERS.
As of December 5, 2005, we had 112,380,392 shares of common stock issued
and outstanding and outstanding warrants to purchase 37,081,967 shares of common
stock. All of the shares issuable upon exercise of our warrants may be sold
without restriction. The sale of these shares may adversely affect the market
price of our common stock. The issuance of shares upon exercise of warrants will
cause immediate and substantial dilution to the interests of other stockholders
since the selling stockholders may convert and sell the full amount issuable on
exercise.
33
IF WE FAIL TO REMAIN CURRENT ON OUR REPORTING REQUIREMENTS, WE COULD BE REMOVED
FROM THE OTC BULLETIN BOARD WHICH WOULD LIMIT THE ABILITY OF BROKER-DEALERS TO
SELL OUR SECURITIES AND THE ABILITY OF STOCKHOLDERS TO SELL THEIR SECURITIES IN
THE SECONDARY MARKET.
Companies trading on the OTC Bulletin Board, such as us, must be reporting
issuers under Section 12 of the Securities Exchange Act of 1934, as amended, and
must be current in their reports under Section 13, in order to maintain price
quotation privileges on the OTC Bulletin Board. If we fail to remain current on
our reporting requirements, we could be removed from the OTC Bulletin Board. As
a result, the market liquidity for our securities could be severely adversely
affected by limiting the ability of broker-dealers to sell our securities and
the ability of stockholders to sell their securities in the secondary market.
Prior to May 2001 and new management, we were delinquent in our reporting
requirements, having failed to file our quarterly and annual reports for the
years ended 1998 - 2000 (except the quarterly reports for the first two quarters
of 1999). We have been current in our reporting requirements for the last three
years, however, there can be no assurance that in the future we will always be
current in our reporting requirements.
OUR COMMON STOCK IS SUBJECT TO THE "PENNY STOCK" RULES OF THE SEC AND THE
TRADING MARKET IN OUR SECURITIES IS LIMITED, WHICH MAKES TRANSACTIONS IN OUR
STOCK CUMBERSOME AND MAY REDUCE THE VALUE OF AN INVESTMENT IN OUR STOCK.
The Securities and Exchange Commission has adopted Rule 15g-9 which
establishes the definition of a "penny stock," for the purposes relevant to us,
as any equity security that has a market price of less than $5.00 per share or
with an exercise price of less than $5.00 per share, subject to certain
exceptions. For any transaction involving a penny stock, unless exempt, the
rules require:
o that a broker or dealer approve a person's account for transactions in
penny stocks; and
o the broker or dealer receive from the investor a written agreement to
the transaction, setting forth the identity and quantity of the penny
stock to be purchased.
In order to approve a person's account for transactions in penny stocks,
the broker or dealer must:
o obtain financial information and investment experience objectives of
the person; and
o make a reasonable determination that the transactions in penny stocks
are suitable for that person and the person has sufficient knowledge
and experience in financial matters to be capable of evaluating the
risks of transactions in penny stocks.
The broker or dealer must also deliver, prior to any transaction in a penny
stock, a disclosure schedule prescribed by the Commission relating to the penny
stock market, which, in highlight form:
o sets forth the basis on which the broker or dealer made the
suitability determination; and
o that the broker or dealer received a signed, written agreement from
the investor prior to the transaction.
Generally, brokers may be less willing to execute transactions in
securities subject to the "penny stock" rules. This may make it more difficult
for investors to dispose of our common stock and cause a decline in the market
value of our stock.
Disclosure also has to be made about the risks of investing in penny stocks
in both public offerings and in secondary trading and about the commissions
payable to both the broker-dealer and the registered representative, current
quotations for the securities and the rights and remedies available to an
investor in cases of fraud in penny stock transactions. Finally, monthly
statements have to be sent disclosing recent price information for the penny
stock held in the account and information on the limited market in penny stocks.
34
ITEM 7. FINANCIAL STATEMENTS.
APPLIED DNA SCIENCES, INC.
INDEX TO FINANCIAL STATEMENTS
Page
Report of Independent Registered Public Accounting Firm F-1
Consolidated Balance Sheet as of September 30, 2005 F-2
Consolidated Statements of Losses for the years ended September 30, 2005 and 2004
and the period September 16, 2002 (date of inception) to September 30, 2005 F-3
Consolidated Statement of Stockholders' Equity (Deficiency) for the period
September 16, 2002 (date of inception) to September 30, 2005 F-4
Consolidated Statements of Cash Flows for the years ended September 30, 2005 and
2004 and the period September 16, 2002 (date of inception) to September 30, 2005 F-16
Notes to Consolidated Financial Statements F-17
35
RUSSELL BEDFORD STEFANOU MIRCHANDANI LLP
CERTIFIED PUBLIC ACCOUNTANTS
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Board of Directors
Applied DNA Sciences, Inc.
Los Angeles, California
We have audited the accompanying consolidated balance sheets of Applied DNA
Sciences, Inc. (a development stage company) as of September 30, 2005 and the
related consolidated statements of losses, deficiency in stockholders' equity,
and cash flows for the years ended September 30, 2005 AND 2004 and the period
September 16, 2002 (date of inception) through September 30, 2005. These
financial statements are the responsibility of the company's management. Our
responsibility is to express an opinion on the financial statements based upon
our audits.
We have conducted our audits in accordance with auditing standards of the
Public Company Accounting Oversight Board (PCAOB) (United States of America).
Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. An audit includes examining on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Applied DNA Sciences, Inc.
(a development stage company) at September 30, 2005 and the results of its
operations and its cash flows for the years ended September 30, 2005 and 2004,
and the period September 16, 2002 (date of inception) through September 30, 2005
in conformity with accounting principles generally accepted in the United States
of America.
The accompanying financial statements have been prepared assuming the
Company will continue as a going concern. As discussed in the Note K to the
accompanying financial statements, the Company is in the development stage and
has not established a source of revenues. This raises substantial doubt about
the company's ability to continue as a going concern. The financial statements
do not include any adjustments that might result from the outcome of this
uncertainty.
/s/ RUSSELL BEDFORD STEFANOU MIRCHANDANI LLP
--------------------------------------------
Russell Bedford Stefanou Mirchandani LLP
McLean, Virginia
October 21, 2005, except for Note J, as to which the date is November 30, 2005
F-1
APPLIED DNA SCIENCES, INC
(A development stage company)
CONSOLIDATED BALANCE SHEET
September 30, 2005
ASSETS
Current Assets:
Cash $ 31,190
Other Current Receivables 12,429
------------
Total Current Assets 43,619
Property, Plant and Equipment (Note A) 12,750
Less: accumulated depreciation (4,686)
------------
Total Property, Plant and Equipment 8,064
Other Assets:
Deposits 14,262
Intangible assets:
Patents (net of accumulated amortization of $11,764) (Note B) 22,493
Intellectual Property (net of accumulated amortization of $336,818) (Note B) 9,094,082
------------
Total Other Assets 9,130,837
------------
$ 9,182,520
============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable and accrued liabilities $ 2,185,468
Note payable (Note C) 410,429
------------
Total Current Liabilities 2,595,897
Commitments and contingencies (Note I)
STOCKHOLDERS' EQUITY: (Note E)
Convertible Preferred Stock, par value $0.001 per share; 10,000,000 shares
authorized; 60,000 shares issued and outstanding at September 30, 2005 6
Common Stock, par value $0.001 per share; 250,000,000 authorized;
112,230,392 shares issued and outstanding at September 30, 2005 112,230
Additional paid in capital 81,879,801
Common stock subscribed 20,000
Deficit accumulated during development stage (75,425,414)
------------
Total stockholders' equity 6,586,623
Total liabilities and stockholders' equity $ 9,182,520
============
See accompanying notes to consolidated financial statements
F-2
APPLIED DNA SCIENCES , INC.
( A development stage company)
CONSOLIDATED STATEMENTS OF LOSSES
For the Period
September 16, 2002
For the Year Ended For the Year Ended (Date Of Inception)
September 30, September 30, through September 30,
2005 2004 2005
--------------- -------------- ----------------------
Operating expenses:
General and administrative $ 42,662,152 $ 17,341,563 $ 63,483,689
Research and Development 638,873 238,535 877,408
Depreciation and Amortization 356,266 3,161 359,427
--------------- -------------- ----------------------
Total expenses 43,657,291 17,583,259 64,720,524
--------------- -------------- ----------------------
Loss from operations (43,657,291) (17,583,259) (64,720,524)
--------------- -------------- ----------------------
Other income(expense) 4,957 1,385 31,342
Interest (expense) (8,958,046) (1,776,385) (10,736,232)
Income (taxes) benefit - - -
--------------- -------------- ----------------------
Net loss $ (52,610,380) $ (19,358,259) $ (75,425,414)
=============== ============== ======================
Basic and diluted loss per common share (Note H) $ (0.82) $ (0.93) (2.12)
=============== ============== ======================
Weighted average common shares outstanding 63,905,259 20,819,700 35,570,559
=============== ============== ======================
See accompanying notes to consolidated financial statements
F-3
APPLIED DNA SCIENCES, INC
(A development stage company)
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY, (DEFICIENCY)
FOR THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
SEPTEMBER 30, 2005
Deficit
Additional Accumulated
Preferred Paid in Common Stock During
Preferred Shares Common Common Stock Capital Stock Subscription Development
Shares Amount Shares Amount Amount Subscribed Receivable Stage Total
--------- ----------- ----------- ----------- ----------- ---------- ----------- ----------- -----------
Issuance of common stock
to Founders in exchange
for services on September
16, 2002 at $.01 per share - $ - 100,000 $ 10 $ 990 - $ - $ - $ 1,000
Net Loss - - - - - - - (11,612) (11,612)
--------- ----------- ----------- ----------- ----------- ---------- ----------- ----------- -----------
Balance at September 30,
2002 - - 100,000 10 990 - - (11,612) (10,612)
Issuance of common stock
in connection with merger
with Prohealth Medical
Technologies , Inc on
October 1, 2002 - - 10,178,352 1,015 - - - - 1,015
Cancellation of Common
stock in connection with
merger with Prohealth
Medical Technologies ,
Inc on October
21, 2002 - - (100,000) (10) (1,000) - - - (1,010)
Issuance of common stock
in exchange for services
in October 2002 at $ 0.65
per share - - 602,000 60 39,070 - - - 39,130
Issuance of common stock in
exchange for subscription
in November and December
2002 at $ 0.065 per share - - 876,000 88 56,852 - (56,940) - -
Cancellation of common
stock in January 2003
previously issued in
exchange for consulting
services - - (836,000) (84) (54,264) - 54,340 - (8)
Issuance of common stock
in exchange for licensing
services valued
at $ 0.065 per share in
January 2003 - - 1,500,000 150 97,350 - - - 97,500
Issuance of common stock
in exchange
for consulting services
valued at $ 0.13 per share
in January 2003 - - 586,250 58 76,155 - - - 76,213
Issuance of common stock
in exchange
for consulting services
at $ 0.065 per
share in February 2003 - - 9,000 1 584 - - - 585
Issuance of common stock
to Founders in exchange
for services valued at
$0.0001 per share in
March 2003 - - 10,140,000 1,014 - - - - 1,014
Issuance of common stock
in exchange for consulting
services valued at
$2.50 per share in March 2003 - - 91,060 10 230,624 - - - 230,634
See accompanying notes to consolidated financial statements
F-4
APPLIED DNA SCIENCES, INC
(A development stage company)
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY, (DEFICIENCY)
FOR THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
SEPTEMBER 30, 2005
(Continued)
Deficit
Additional Accumulated
Preferred Paid in Common Stock During
Preferred Shares Common Common Stock Capital Stock Subscription Development
Shares Amount Shares Amount Amount Subscribed Receivable Stage Total
--------- ----------- ----------- ----------- ----------- ---------- ----------- ----------- -----------
Issuance of common stock in
exchange for consulting
services valued at $
0.065 per share in March 2003 - - 6,000 1 389 - - - 390
Common stock subscribed in
exchange for cash at $1 per
share in March 2003 - - - - 18,000 - - - 18,000
Common stock issued in
exchange for consulting
services at $ 0.065 per
share on April 1, 2003 - - 860,000 86 55,814 - - - 55,900
Common stock issued in
exchange for
cash at $ 1.00 per share
on April 9, 2003 - - 18,000 2 - - - - 2
Common stock issued in
exchange for
consulting services at $
0.065 per
share on April 9, 2003 - - 9,000 1 584 - - - 585
Common stock issued in
exchange for
consulting services at
$ 2.50 per
share on April 23, 2003 - - 5,000 1 12,499 - - - 12,500
Common stock issued in
exchange for
consulting services at
$ 2.50 per
share, on June 12, 2003 - - 10,000 1 24,999 - - - 25,000
Common stock issued in
exchange for
cash at $ 1.00 per share
on June 17, 2003 - - 50,000 5 49,995 - - - 50,000
Common stock subscribed
in exchange
for cash at $ 2.50 per
share pursuant
to private placement
on June 27, 2003 - - - - 24,000 - 24,000
Common stock retired in
exchange for note payable
at $0.0118 per share,
on June 30, 2003 - - (7,500,000) (750) 750 - - - -
Common stock issued in
exchange for
consulting services at
$0.065 per
share, on June 30, 2003 - - 270,000 27 17,523 - - - 17,550
Common stock subscribed
in exchange for cash at
$ 1.00 per share pursuant
to private placement on
June 30, 2003 - - - - - 10,000 - - 10,000
Common stock subscribed
in exchange for cash at
$ 2.50 per share pursuant
to private placement on
June 30, 2003 - - - - - 24,000 - - 24,000
Common stock issued in
exchange for consulting
services at approximately
$2.01 per share, July 2003 - - 213,060 21 428,798 - - - 428,819
See accompanying notes to consolidated financial statements
F-5
APPLIED DNA SCIENCES, INC
(A development stage company)
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY, (DEFICIENCY)
FOR THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
SEPTEMBER 30, 2005
(Continued)
Deficit
Additional Accumulated
Preferred Common Paid in Common Stock During
Preferred Shares Common Stock Capital Stock Subscription Development
Shares Amount Shares Amount Amount Subscribed Receivable Stage Total
--------- ----------- ----------- ----------- ----------- ---------- ----------- ----------- -----------
Common stock canceled
in July 2003,
previously issued for
services rendered at
$2.50 per share - - (24,000) (2) (59,998) - - - (60,000)
Common stock issued
in exchange for
options exercised at
$1.00 in July 2003 - - 20,000 2 19,998 - - - 20,000
Common stock issued
in exchange for
exercised of options
previously
subscribed at $1.00 in
July 2003 - - 10,000 1 9,999 (10,000) - - -
Common stock issued in
exchange for
consulting services at
approximately
$2.38 per share,
August 2003 - - 172,500 17 410,915 - - - 410,932
Common stock issued in
exchange for
options exercised at
$1.00 in August 2003 - - 29,000 3 28,997 - - - 29,000
Common stock issued
in exchange for
consulting services
at approximately
$2.42 per share,
September 2003 - - 395,260 40 952,957 - - - 952,997
Common stock issued
in exchange for
cash at $2.50 per
share-subscription
payable-September 2003 - - 19,200 2 47,998 (48,000) - - -
Common stock issued in
exchange for
cash at $2.50 per
share pursuant to
private placement
September 2003 - - 6,400 1 15,999 - - - 16,000
Common stock issued in
exchange for
options exercised at
$1.00 in September 2003 - - 95,000 10 94,991 - - - 95,001
Common stock subscription
receivable reclassification
adjustment - - - - - - 2,600 - 2,600
Common Stock subscribed to
at $2.50 per share in
September 2003 - - - - - 300,000 - - 300,000
Net Loss for the year
ended September 30, 2003 - - - - - - - (3,445,164) (3,445,164)
--------- ----------- ----------- ----------- ----------- ---------- ----------- ----------- -----------
Balance at September 30,
2003 - $ - 17,811,082 $ 1,781 $2,577,568 $ 300,000 $ - $(3,456,776) $ (577,427)
========= =========== =========== =========== =========== ========== =========== =========== ===========
See accompanying notes to consolidated financial statements
F-6
APPLIED DNA SCIENCES, INC
(A development stage company)
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY, (DEFICIENCY)
FOR THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
SEPTEMBER 30, 2005
(Continued)
Deficit
Additional Accumulated
Preferred Paid in Common Stock During
Preferred Shares Common Common Stock Capital Stock Subscription Development
Shares Amount Shares Amount Amount Subscribed Receivable Stage Total
--------- ----------- ----------- ----------- ----------- ---------- ----------- ----------- -----------
Preferred shares issues
in exchange for services
at $25.00 per share,
October 2003 15,000 15 15
Common stock issued in
exchange for consulting
services at
approximately $2.85 per
share, October 2003 287,439 29 820,389 - - - 820,418
Common stock issued in
exchange for cash at
$2.50 per
share-subscription
payable-October 2003 120,000 12 299,988 (300,000) - - -
Common stock canceled
in October 2003,
previously issued for
services rendered at
$2.50 per share (100,000) (10) (249,990) - - - (250,000)
Common stock issued in
exchange for consulting
services at approximately
$3 per share,
November 2003 100,000 10 299,990 - - - 300,000
Common stock subscribed
in exchange for cash at
$2.50 per share pursuant
to private placement,
November, 2003 100,000 10 249,990 - - - 250,000
Common stock subscribed
in exchange for cash at
$2.50 per share pursuant
to private placement,
December, 2003 6,400 1 15,999 - - - 16,000
Common stock issued in
exchange for consulting
services at approximately
$2.59 per share,
December 2003 2,125,500 213 5,504,737 - - - 5,504,950
Common Stock subscribed to
at $2.50 per share in
December 2003 - - - 104,000 - - 104,000
Beneficial conversion
feature relating
to notes payable - - 1,168,474 - - - 1,168,474
Beneficial conversion
feature relating
to warrants - - 206,526 - - - 206,526
Adjust common stock par
value from $0.0001 to
$0.50 per share, per
amendment of articles
dated Dec 2003 - 10,223,166 (10,223,166) - - - -
Common Stock issued
pursuant to subscription
at $2.50 share in Jan 2004 41,600 20,800 83,200 (104,000) - - -
Common stock issued in
exchange for consulting
services at $2.95 per
share, Jan 2004 13,040 6,520 31,948 - - - 38,468
Common stock issued in
exchange for consulting
services at $2.60 per
share, Jan 2004 123,000 61,500 258,300 - - - 319,800
Common stock issued in
exchange for consulting
services at $3.05 per
share, Jan 2004 1,000 500 2,550 - - - 3,050
Common stock issued in
exchange for employee
services at $3.07 per
share, Feb 2004 6,283 3,142 16,147 - - - 19,289
Common stock issued in
exchange for consulting
services at $3.04 per
share, Mar 2004 44,740 22,370 113,640 - - - 136,010
Common Stock issued for
options exercised at
$1.00 per share in Mar
2004 55,000 27,500 27,500 - - - 55,000
Common stock issued in
exchange for employee
services at $3.00 per
share, Mar 2004 5,443 2,722 13,623 - - - 16,345
See accompanying notes to consolidated financial statements
F-7
APPLIED DNA SCIENCES, INC
(A development stage company)
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY, (DEFICIENCY)
FOR THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
SEPTEMBER 30, 2005
(Continued)
Deficit
Additional Accumulated
Preferred Paid in Common Stock During
Preferred Shares Common Common Stock Capital Stock Subscription Development
Shares Amount Shares Amount Amount Subscribed Receivable Stage Total
--------- ----------- ----------- ----------- ----------- ---------- ----------- ----------- -----------
Common stock issued in
exchange for employee
services at $3.15 per
share, Mar 2004 5,769 2,885 15,292 - - - 18,177
Preferred shared
converted to common
shares for consulting
services at $3.00 per
share, Mar 2004 (5000) (5) 125,000 62,500 312,500 - - - 374,995
Common stock issued in
exchange for employee
services at $3.03 per
share, Mar 2004 8,806 4,400 22,238 - - - 26,639
Common Stock issued
pursuant to
subscription at $2.50
per share in Mar. 2004 22,500 11,250 (9,000) - - - 2,250
Beneficial Conversion
Feature relating
to Notes Payable - - 122,362 - - - 122,362
Beneficial Conversion
Feature relating
to Warrants - - 177,638 - - - 177,638
Common stock issued in
exchange for consulting
services at $2.58 per
share, Apr 2004 9,860 4,930 20,511 - - - 25,441
Common stock issued in
exchange for consulting
services at $2.35 per
share, Apr 2004 11,712 5,856 21,667 - - - 27,523
Common stock issued in
exchange for consulting
services at $1.50 per
share, Apr 2004 367,500 183,750 367,500 - - - 551,250
Common stock returned
to treasury at
$0.065 per share,
Apr 2004 (50,000) (25,000) 21,750 - - - (3,250)
Preferred stock
converted to common
stock for consulting
services at $1.01
per share in May 2004 (4000) (4) 100,000 50,000 51,250 - - - 101,246
Common stock issued per
subscription May 2004 10,000 5,000 (4,000) - (1,000) - -
Common stock issued in
exchange for consulting
services at $0.86 per
share in May 2004 137,000 68,500 50,730 - - - 119,230
Common stock issued in
exchange for consulting
services at $1.15 per
share in May 2004 26,380 13,190 17,147 - - - 30,337
Common stock returned to
treasury at $0.065 per
share, Jun 2004 (5,000) (2,500) 2,175 - - - (325)
See accompanying notes to consolidated financial statements
F-8
APPLIED DNA SCIENCES, INC
(A development stage company)
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY, (DEFICIENCY)
FOR THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
SEPTEMBER 30, 2005
(Continued)
Deficit
Additional Accumulated
Preferred Paid in Common Stock During
Preferred Shares Common Common Stock Capital Stock Subscription Development
Shares Amount Shares Amount Amount Subscribed Receivable Stage Total
--------- ----------- ----------- ----------- ----------- ---------- ----------- ----------- -----------
Common stock issued in
exchange for consulting
services at $0.67 per
share in June 2004 270,500 135,250 45,310 - - - 180,560
Common stock issued in
exchange for consulting
services at $0.89 per
share in June 2004 8,000 4,000 3,120 - - - 7,120
Common stock issued in
exchange for consulting
services at $0.65 per
share in June 2004 50,000 25,000 7,250 - - - 32,250
Common stock issued
pursuant to private
placement at $1.00
per share in June 2004 250,000 125,000 125,000 - - - 250,000
Common stock issued in
exchange for consulting
services at $0.54 per
share in July 2004 100,000 50,000 4,000 - - - 54,000
Common stock issued in
exchange for consulting
services at $0.72 per
share in July 2004 5,000 2,500 1,100 - - - 3,600
Common stock issued in
exchange for consulting
services at $0.47 per
share in July 2004 100,000 50,000 (2,749) - - - 47,251
Common stock issued in
exchange for consulting
services at $0.39 per
share in August 2004 100,000 50,000 (11,000) - - - 39,000
Preferred stock converted
to common stock for
consulting services at
$0.39 per share in
August 2004 (2000) (2) 50,000 25,000 (5,500) - - - 19,498
See accompanying notes to consolidated financial statements
F-9
APPLIED DNA SCIENCES, INC
(A development stage company)
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY, (DEFICIENCY)
FOR THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
SEPTEMBER 30, 2005
(Continued)
Deficit
Additional Accumulated
Preferred Paid in Common Stock During
Preferred Shares Common Common Stock Capital Stock Subscription Development
Shares Amount Shares Amount Amount Subscribed Receivable Stage Total
--------- ----------- ----------- ----------- ----------- ---------- ----------- ----------- -----------
Common stock issued in
exchange for consulting
services at $0.50 per
share in August 2004 100,000 50,000 250 50,250
Common stock issued in
exchange for consulting
services at $0.56 per
share in August 2004 200,000 100,000 12,500 - - - 112,500
Common stock issued in
exchange for consulting
services at $0.41 per
share in August 2004 92,500 46,250 (8,605) - - - 37,645
Common stock issued in
exchange for consulting
services at $0.52 per
share in September 2004 1,000,000 500,000 17,500 - - - 517,500
Common stock issued in
exchange for consulting
services at $0.46 per
share in September 2004 5,000 2,500 (212) - - - 2,288
Common stock issued
pursuant to subscription
at $0.50 per share in
September 2004 40,000 20,000 - - - - 20,000
Preferred shares
converted to common
stock for consulting
services at $0.41
per share in September
2004 (4000) (4) 100,000 50,000 4,000 - - - 53,996
Preferred shares issued
in exchange for service
at $25 per share in
September 2004 60,000 6 1,499,994 1,500,000
Warrants issued to
consultants in the
fourth quarter 2004 2,019,862 2,019,862
Net Loss - - - - - (19,358,259)(19,358,259)
--------- ----------- ----------- ----------- ----------- ---------- ----------- ----------- -----------
September 30, 2004 60,000 6 23,981,054 11,990,527 6,118,993 - (1,000)(22,815,034) (4,706,508)
========= =========== =========== =========== =========== ========== =========== =========== ===========
See accompanying notes to consolidated financial statements
F-10
APPLIED DNA SCIENCES, INC
(A development stage company)
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY, (DEFICIENCY)
FOR THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
SEPTEMBER 30, 2005
(Continued)
Deficit
Additional Accumulated
Preferred Paid in Common Stock During
Preferred Shares Common Common Stock Capital Stock Subscription Development
Shares Amount Shares Amount Amount Subscribed Receivable Stage Total
--------- ----------- ----------- ----------- ----------- ---------- ----------- ----------- -----------
Common stock issued
in exchange for
consulting services
at $0.68 per share
in October 2004 - - 200,000 100,000 36,000 - - - 136,000
Common stock returned
for shares previously
issued for services
rendered at $0.60
per share, October 2004 - - (1,069,600) (534,800) (107,298) - - - (642,098)
Common stock issued
in exchange for
consulting services at
$0.60 per share in
October 2004 - - 82,500 41,250 8,250 - - - 49,500
Common Stock issued
pursuant to subscription
at $0.60 share in
October 2004 - - 500,000 250,000 50,000 (300,000) - - -
Common stock issued in
exchange for consulting
services by noteholders
at $0.50 per share
in October 2004 - - 532,500 266,250 - - - - 266,250
Common Stock issued
pursuant to subscription
at $0.50 share in
October 2004 - - 500,000 250,000 - - - - 250,000
Common Stock issued pursuant
to subscription at $0.45
share in October 2004 - - 1,000,000 500,000 (50,000) (450,000) - - -
Common stock issued in
exchange for consulting
services by noteholders
at $0.45 per share
in October 2004 - - 315,000 157,500 (15,750) - - - 141,750
Common Stock issued in
exchange for consulting
services at $0.47 share
in November 2004 - - 100,000 50,000 (3,000) - - - 47,000
Common Stock issued in
exchange for consulting
services at $0.80 share
in November 2004 - - 300,000 150,000 90,000 - - - 240,000
Common Stock issued in
exchange for consulting
services at $1.44 share
in November 2004 - - 115,000 57,500 108,100 - - - 165,600
Common Stock issued in
exchange for employee
services at $1.44 share
in November 2004 - - 5,000 2,500 4,700 - - - 7,200
See accompanying notes to consolidated financial statements.
F-11
APPLIED DNA
SCIENCES, INC
(A development stage company)
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY, (DEFICIENCY)
FOR THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
SEPTEMBER 30, 2005
(Continued)
Deficit
Additional Accumulated
Preferred Paid in Common Stock During
Preferred Shares Common Common Stock Capital Stock Subscription Development
Shares Amount Shares Amount Amount Subscribed Receivable Stage Total
--------- ----------- ----------- ----------- ----------- ---------- ----------- ----------- -----------
Common Stock issued in
exchange for employee
services at $0.60 share
in November 2004 - - 60,000 30,000 6,000 (4,000) - - 32,000
Beneficial Conversion
discount relating to
Notes Payable - - - - 936,541 - - - 936,541
Beneficial Conversion
Feature relating to
Warrants - - - - 528,459 - - - 528,459
Common stock issued at
$0.016 in exchange for
note payable in December
2004 5,500,000 2,750,000 (2,661,500) 88,500
Common Stock issued in
exchange for consulting
services at $1.44 share
in December 2004 - - 5,796,785 2,898,393 5,418,814 - - - 8,317,207
Common stock issued
pursuant to subscription
at $0.50 per share in
December 2004 - - 2,930,000 1,465,000 - (125,000) - - 1,340,000
Warrants issued to
consultants in
Dec. 2004 - - 394,698 394,698
See accompanying notes to consolidated financial statements
F-12
APPLIED DNA SCIENCES, INC
(A development stage company)
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY, (DEFICIENCY)
FOR THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
SEPTEMBER 30, 2005
(Continued)
Deficit
Additional Accumulated
Preferred Paid in Common Stock During
Preferred Shares Common Common Stock Capital Stock Subscription Development
Shares Amount Shares Amount Amount Subscribed Receivable Stage Total
--------- ----------- ----------- ----------- ----------- ---------- ----------- ----------- -----------
Warrants exercised at
$0.10 per share in January
2005 - - 25,000 12,500 (10,000) - - - 2,500
Common Stock issued in
settlement of debt at
$0.33 per share in January
2005 - - 1,628,789 814,395 (276,895) - - - 537,500
Warrants exercised at
$0.10 per share in January
2005 - - 17,500 8,750 (7,000) - - - 1,750
Common Stock issued in
settlement of debt at
$0.33 per share in January
2005 - - 2,399,012 1,199,503 (407,830) - - - 791,673
Common Stock issued in
exchange for consulting
services at $1.30 per share
in January 2005 - - 315,636 157,818 252,509 - - 410,327
Common Stock issued in
settlement of debt at
$0.33 per share in February
2005 - - 75,757 37,879 (12,879) - - - 25,000
Warrants exercised at
$0.10 per share in February
2005 - - 20,000 10,000 (8,000) - - - 2,000
Common Stock issued in
settlement of debt at
$0.33 per share in February
2005 - - 606,060 303,030 (103,030) - - - 200,000
Warrants exercised at
$0.10 per share in February
2005 - - 45,000 22,500 (18,000) - - - 4,500
Common Stock issued in
settlement of debt at
$0.40 per share in February
2005 - - 1,500,000 750,000 (150,000) - - - 600,000
Common Stock issued in
settlement of debt at
$0.33 per share in February
2005 - - 278,433 139,217 (47,334) - - - 91,883
Common Stock issued in
exchange for consulting
services at $1.17 per share
in February 2005 - - 17,236 8,618 11,548 - - 20,166
Common stock issued
pursuant to subscription
at $0.50 per share
in February 2005 - - 300,000 150,000 - - - - 150,000
Common Stock issued in
exchange for consulting
services at $0.95 per share
in February 2005 - - 716,500 358,250 322,425 - - 680,675
Common Stock issued in
exchange for consulting
services at $0.95 per share
in February 2005 - - 10,500 5,250 4,725 - - 9,975
Common stock issued
pursuant to subscription
at $0.50 per share
in March 2005 - - 13,202,000 6,601,000 - - - - 6,601,000
Common Stock issued in
exchange for consulting
services at $1.19 per share
in March 2005 - - 185,000 92,500 127,650 - - 220,150
Options exercised at
$0.60 per share in March
2005 - - 100,000 50,000 10,000 - - - 60,000
Common Stock issued in
exchange for consulting
services at $0.98 per share
in March 2005 - - 1,675,272 837,636 804,131 - - 1,641,767
Common Stock issued in
exchange for consulting
services at $0.92 per share
in March 2005 - - 24,333 12,167 10,219 - - 22,386
Common Stock issued in
exchange for consulting
services at $0.99 per share
in March 2005 - - 15,000 7,500 7,350 - - 14,850
Common stock issued
pursuant to subscription
at $0.50 per share
in March 2005 - - 1,240,000 620,000 - - - - 620,000
Common stock canceled
For shares issued in
exchange of debt
in March 2005 - - (500,000) (250,000) - - - - (250,000)
Common stock subscribed
Canceled in March 2005 - - - - - 750,000 - - 750,000
Common Stock issued in
exchange for consulting
services at $0.89 per share
in March 2005 - - 10,000 5,000 3,900 - - - 8,900
Adjust common stock par
value from $0.50 to
$0.001 per share, per
amendment of articles
dated March 2005 - - - (32,312,879) 32,312,879 - - - -
Beneficial Conversion
discount relating to
Notes Payable in March
2005 - - - - 4,179,554 - - - 4,179,554
Beneficial Conversion
Feature relating to
Warrants in March 2005 - - - - 3,191,446 - - - 3,191,446
Stock options granted to
employees in exchange
for services rendered, at
exercise price below
fair value of common stock
in March 2005 - - - - 180,000 - - - 180,000
See accompanying notes to consolidated financial statements
F-13
APPLIED DNA SCIENCES, INC
(A development stage company)
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY, (DEFICIENCY)
FOR THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
SEPTEMBER 30, 2005
(Continued)
Deficit
Additional Accumulated
Preferred Paid in Common Stock During
Preferred Shares Common Common Stock Capital Stock Subscription Development
Shares Amount Shares Amount Amount Subscribed Receivable Stage Total
--------- ----------- ----------- ----------- ----------- ---------- ----------- ----------- -----------
Common Stock issued in
exchange for consulting
services at $0.80 per share
in April 2005 - - 160,000 160 127,840 - - - 128,000
Common Stock issued in
exchange for consulting
services at $0.80 per share
in April 2005 - - 40,000 40 31,960 - - - 32,000
Common Stock issued in
exchange for consulting
services at $0.75 per share
in April 2005 - - 850,000 850 636,650 - - - 637,500
Common Stock issued in
settlement of debt at
$0.33 per share in April
2005 - - 500,000 500 164,500 - - - 165,000
Common Stock canceled during
April 2005, previously
issued for services
rendered at $3.42 per share - - (10,000) (10) (34,190) - - - (34,200)
Common Stock issued in
settlement of debt at
$0.33 per share in April
2005 - - 75,758 77 24,923 (25,000) - - -
Common Stock issued in
exchange for consulting
services at $0.68 per share
in April 2005 - - 50,000 50 33,950 - - - 34,000
Proceeds received against
subscription Payable in
June 2005 - - - - - 118,000 - - 118,000
Common Stock canceled in
June 2005, previously
issued for services
rendered at $0.50 per share - - (10,000) (10) (4,990) - - - (5,000)
Cancellation of previously
granted stock options granted
to employees for services
rendered, at exercise price
below fair value of common stock - - - - (180,000) - - - (180,000)
Warrants issued to consultants
and Employees during the quarter
ended June 30, 2005 - - - - 849,046 - - - 849,046
Common Stock issued in
exchange for consulting
services at $0.60 per share
in July 2005 - - 157,000 157 94,043 - - - 94,200
Common Stock issued in
exchange for intellectual
property at $0.67 per share
in July 2005 - - 36,000,000 36,000 24,084,000 - - - 24,120,000
Common Stock issued in
exchange for consulting
services at $0.60 per share
in July 2005 - - 640,000 640 383,360 - - - 384,000
Options exercised at
$0.48 per share in July
2005 - - 8,000,000 8,000 3,832,000 - - - 3,840,000
Common Stock issued in
exchange for consulting
services at $0.94 per share
in September 2005 - - 121,985 122 168,217 - - - 168,339
Options exercised at
$0.48 per share in August
2005 - - 250,000 250 119,750 - - - 120,000
Common Stock penalty shares
issued pursuant to pending
SB-2 registration
at $0.62 per share in
September 2005 - - 814,158 814 501,858 - - - 502,672
Common Stock penalty shares
issued pursuant to pending
SB-2 registration
at $0.70 per share in
September 2005 - - 391,224 391 273,466 - - - 273,857
Common Stock issued in
exchange for consulting
services at $0.94 per share
in September 2005 - - 185,000 185 173,715 - - - 173,900
Common Stock returned in
September 2005, previously
issued for services
rendered at $0.40 per share - - (740,000) (740) (353,232) 56,000 1,000 - (296,972)
Un-issued warrants cancelled
during the quarter
ended Sept 30, 2005 - - - - (287,440) - - - (287,440)
Net Loss - - - - - - - (52,610,380)(52,610,380)
--------- ----------- ----------- ----------- ----------- ---------- ----------- ----------- -----------
Balance as of September
30, 2005 60,000 $ 6 112,230,392 $ 112,230 $81,879,801 $ 20,000 $ - $(75,425,414)$ 6,586,623
========= =========== =========== =========== =========== ========== =========== =========== ===========
See accompanying notes to consolidated financial statements
F-14
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Period
September 16, 2002
For the Year Ended For the Year Ended (Date of Inception)
September 30, September 30, through September
2005 2004 30, 2005
------------- ------------- -------------
Cash Flows from operating activities:
Net loss from operating activities $ (52,610,380) $(19,358,259) $(75,425,414)
Adjustments to reconcile net loss to net
cash (used in) operating
activities:
Depreciation and amortization 350,107 3,161 353,268
Organizational expenses - - 88,500
Preferred shares issued in exchange for
service at $25 per share in September 2004 - 1,500,000 1,500,000
Warrants issued to consultants 956,304 2,019,862 2,976,166
Amortization of beneficial conversion
feature 8,836,000 1,625,000 10,461,000
Common stock issued:
in exchange for
consultant services rendered 14,805,128 10,105,382 27,202,860
in exchange for intellectual property 14,689,100 - 14,689,100
ESOP shares 3,960,000 - 3,960,000
Penalty shares pursuant to pending SB-2
Registration 776,529 - 776,529
Common stock canceled-previously issued for
services rendered (1,078,270) (285,575) (1,363,845)
Changes in assets and liabilities:
Other Current Assets (12,429) - (12,429)
Security Deposits 9,297 (23,559) (14,262)
Capital expenditures 16,757 (29,507) (12,750)
Increase in-Other Assets - - (13,890)
Increase (decrease) in: -
Increase in due related parties (111,943) 20,000 40,753
Accounts payable and accrued liabilities 297,755 1,301,710 2,053,464
------------- ------------- -------------
Net cash (used in) operating activities (9,116,045) (3,121,785) (12,740,950)
Cash flows from investing activities:
Payments for Patent Filing (4,347) (21,351) (25,698)
------------- ------------- -------------
Net cash (used in) investing activities (4,347) (21,351) (25,698)
Cash flows from financing activities:
Proceeds from sale of common stock, net of
cost - - 432,000
Proceeds from subscription of common stock 9,079,000 124,000 9,204,000
Proceeds from sale of options 70,750 87,000 311,750
Net advances from shareholders - (9,504) 100,088
Proceeds from loans - 2,750,000 2,750,000
------------- ------------- -------------
Net cash provided by financing activities 9,149,750 2,951,496 12,797,838
------------- ------------- -------------
Increase (decrease) in cash and cash
equivalents 29,358 (191,640) 31,190
Cash and cash equivalents, beginning of year 1,832 193,471 -
------------- ------------- -------------
Cash and cash equivalents, end of year
$ 31,190 $ 1,832 $ 31,190
============== ============ =============
Supplemental Information:
Cash paid during the period for interest $ - $ - $ -
Cash paid during the year for taxes - - -
Non-cash disclosures:
Common stock issued for services
$ 14,805,128 $10,105,382 $ 27,202,860
============== ============ =============
Common stock issued in exchange for intellectual
property $ 9,430,900 $ - $ 9,430,900
============== ============ =============
Common stock issued in exchange for
previously incurred debt $ 3,109,533 $ - $ 3,109,533
============== ============ =============
Common stock issued for ESOP shares $ 3,960,000 $ - $ 3,960,000
============== ============ =============
Common stock penalty shares issued pursuant to
Pending SB-2 registration $ 776,529 $ - $ 776,529
============== ============ =============
Amortization of beneficial conversion
feature $ 8,836,000 $ 1,625,000 $ 10,461,000
============== ============ =============
Common stock canceled-previously issued for
services rendered $ (1,078,270) $ (285,575) $ (1,363,845)
============== ============ =============
Preferred shares issued in exchange for
service at $25 per share in September 2004 $ - $ 1,500,000 $ 1,500,000
============== ============ =============
Warrants issued to consultants $ 956,304 $ 2,019,862 $ 2,976,166
============== ============ =============
Acquisition:
Common stock retained $ - $ 1,015
Assets acquired - (135)
------------- -------------
Total consideration paid $ - $ 880
============ =============
Organization expenses- note issued in
exchange of shares retired $ - $ 88,500
============ =============
See accompanying notes to consolidated financial statements
F-16
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE A - SUMMARY OF ACCOUNTING POLICIES
A summary of the significant accounting policies applied in the preparation of
the accompanying financial statements follows.
BUSINESS AND BASIS OF PRESENTATION
On September 16, 2002, Applied DNA Sciences, Inc. (the "Company") was
incorporated under the laws of the State of Nevada. The Company is in the
development stage , as defined by Statement of Financial Accounting Standards
No. 7 ("SFAS No. 7") and its efforts have been principally devoted to developing
DNA embedded biotechnology security solutions in the United States. To date, the
Company has generated nominal sales revenues, has incurred expenses and has
sustained losses. Consequently, its operations are subject to all the risks
inherent in the establishment of a new business enterprise. For the period from
inception through September 30, 2005, the Company has accumulated losses of
$75,425,414.
ESTIMATES
The preparation of the financial statement in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect certain reported amounts and disclosures. Accordingly, actual results
could differ from those estimates.
REVENUE RECOGNITION
The Company recognizes revenue in accordance with SEC Staff Accounting Bulletin
No. 101, "Revenue Recognition in Financial Statements" ("SAB 101"). SAB 101
requires that four basic criteria must be met before revenue can be recognized
:(1) persuasive evidence of an arrangement exists; (2) delivery has occurred;
(3) the selling price is fixed and determinable; and (4) collectibility is
reasonably assured. Determination of criteria (3) and (4) are based on
management's judgments regarding the fixed nature of the selling prices of the
products delivered and the collectibility of those amounts. Provisions for
discounts and rebates to customers, estimated returns and allowances, and other
adjustments are provided for in the same period the related sales are recorded.
On December 17, 2003, the SEC staff released Staff Accounting Bulletin (SAB) No.
104, Revenue Recognition. The staff updated and revised the existing revenue
recognition in Topic 13, Revenue Recognition, to make its interpretive guidance
consistent with current accounting guidance, principally EITF Issue No. 00-21,
"Revenue Arrangements with Multiple Deliverables." Also, SAB 104 incorporates
portions of the Revenue Recognition in Financial Statements - Frequently Asked
Questions and Answers document that the SEC staff considered relevant and
rescinds the remainder. The company's revenue recognition policies are
consistent with this guidance; therefore, this guidance will not have an
immediate impact on the company's consolidated financial statements.
CASH EQUIVALENTS
For the purpose of the accompanying financial statements, all highly liquid
investments with a maturity of three months or less are considered to be cash
equivalents.
F-17
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE A - SUMMARY OF ACCOUNTING POLICIES (continued)
INCOME TAXES
The Company has adopted Financial Accounting Standard No. 109 (SFAS 109) which
requires the recognition of deferred tax liabilities and assets for the expected
future tax consequences of events that have been included in the financial
statement or tax returns. Under this method, deferred tax liabilities and assets
are determined based on the difference between financial statements and tax
basis of assets and liabilities using enacted tax rates in effect for the year
in which the differences are expected to reverse. Temporary differences between
taxable income reported for financial reporting purposes and income tax purposes
are insignificant.
PROPERTY AND EQUIPMENT
Property and equipment are stated at cost and depreciated over their estimated
useful lives of 3 to 5 years using the straight line method. At September 30,
2005 property and equipment consist of:
September
30, 2005
------------
Furniture $ 12,750
Accumulated depreciation 4,686
------------
Net $ 8,064
Impairment of Long-Lived Assets
The Company has adopted Statement of Financial Accounting Standards No. 144
(SFAS 144). The Statement requires that long-lived assets and certain
identifiable intangibles held and used by the Company be reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be recoverable. Events relating to recoverability may include
significant unfavorable changes in business conditions, recurring losses, or a
forecasted inability to achieve break-even operating results over an extended
period. The Company evaluates the recoverability of long-lived assets based upon
forecasted undercounted cash flows. Should an impairment in value be indicated,
the carrying value of intangible assets will be adjusted, based on estimates of
future discounted cash flows resulting from the use and ultimate disposition of
the asset. SFAS No. 144 also requires assets to be disposed of be reported at
the lower of the carrying amount or the fair value less costs to sell.
COMPREHENSIVE INCOME
The Company does not have any items of comprehensive income in any of the
periods presented.
F-18
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE A - SUMMARY OF ACCOUNTING POLICIES (continued)
SEGMENT INFORMATION
The Company adopted Statement of Financial Accounting Standards No. 131,
Disclosures about Segments of an Enterprise and Related Information ("SFAS
131"). SFAS establishes standards for reporting information regarding operating
segments in annual financial statements and requires selected information for
those segments to be presented in interim financial reports issued to
stockholders. SFAS 131 also establishes standards for related disclosures about
products and services and geographic areas. Operating segments are identified as
components of an enterprise about which separate discrete financial information
is available for evaluation by the chief operating decision maker, or decision
making group, in making decisions how to allocate resources and assess
performance. The information disclosed herein, materially represents all of the
financial information related to the Company's principal operating segment.
NET LOSS PER SHARE
The Company has adopted Statement of Financial Accounting Standard No. 128,
"Earnings Per Share," specifying the computation, presentation and disclosure
requirements of earnings per share information. Basic earnings per share has
been calculated based upon the weighted average number of common shares
outstanding. Stock options and warrants have been excluded as common stock
equivalents in the diluted earnings per share because they are either
antidilutive, or their effect is not material. Fully diluted shares outstanding
were 112,230,392 and 23,981,054 for the years ended September 30, 2005 and 2004,
respectively.
STOCK BASED COMPENSATION
In December 2002, the FASB issued SFAS No. 148, "Accounting for Stock-Based
Compensation-Transition and Disclosure-an amendment of SFAS 123." This statement
amends SFAS No. 123, "Accounting for Stock-Based Compensation," to provide
alternative methods of transition for a voluntary change to the fair value based
method of accounting for stock-based employee compensation. In addition, this
statement amends the disclosure requirements of SFAS No. 123 to require
prominent disclosures in both annual and interim financial statements about the
method of accounting for stock-based employee compensation and the effect of the
method used on reported results. The Company has chosen to continue to account
for stock-based compensation using the intrinsic value method prescribed in APB
Opinion No. 25 and related interpretations. Accordingly, compensation expense
for stock options is measured as the excess, if any, of the fair market value of
the Company's stock at the date of the grant over the exercise price of the
related option. The Company has adopted the annual disclosure provisions of SFAS
No. 148 in its financial reports for the year ended September 30, 2005 and for
the subsequent periods.
Had compensation costs for the Company's stock options been determined based on
the fair value at the grant dates for the awards, the Company's net loss and
losses per share would have been as follows (transactions involving stock
options issued to employees and Black-Scholes model assumptions are presented in
Note E):
F-19
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE A - SUMMARY OF ACCOUNTING POLICIES (continued)
For the Period
September, 16
2002 (Date of
For The Year For The Year Inception
ended Sept 30 ended Sept 30 through
2005 2004 Sept 30,2005
-------------- ---------------- ----------------
Net loss - as reported $ (52,610,380) $ (19,358,259) $ (75,425,414)
Add: Total stock based employee
compensation expense as reported under
intrinsic value method ( APB No. 25) - - -
Deduct: Total stock based employee
compensation expense as reported under
fair value method ( APB No. 123) (1,406,350) - (1,406,350)
---------------- ---------------- ----------------
Net loss - Pro Forma $ (54,016,730) $ (19,358,259) $ (76,831,764)
================ ================ ================
Net loss attributable to common
stockholders - Pro Forma $ (54,016,730) $ (19,258,259) $ (76,831,764)
================ ================ ================
Basic (and assuming dilution) loss
per share - as reported $ (0.82) $ (0.93) $ (2.12)
================ ================ ================
Basic (and assuming dilution) loss
per share - Pro Forma $ (0.85) $ (0.93) $ (2.16)
================ ================ ================
LIQUIDITY
As shown in the accompanying financial statements, the Company incurred a net
loss of $75,425,414 during the period September 16, 2002 (date of inception)
through September 30, 2005. The Company's current liabilities exceeded its
current assets by $2,552,278 as of September 30, 2005.
CONCENTRATIONS OF CREDIT RISK
Financial instruments and related items, which potentially subject the Company
to concentrations of credit risk, consist primarily of cash, cash equivalents
and trade receivables. The Company places its cash and temporary cash
investments with high credit quality institutions. At times, such investments
may be in excess of the FDIC insurance limit.
F-20
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE A - SUMMARY OF ACCOUNTING POLICIES (continued)
RESEARCH AND DEVELOPMENT
The Company accounts for research and development costs in accordance with the
Financial Accounting Standards Board's Statement of Financial Accounting
Standards No. 2 ("SFAS 2"), "Accounting for Research and Development Costs.
Under SFAS 2, all research and development costs must be charged to expense as
incurred. Accordingly, internal research and development costs are expensed as
incurred. Third-party research and developments costs are expensed when the
contracted work has been performed or as milestone results have been achieved.
Company-sponsored research and development costs related to both present and
future products are expensed in the period incurred. The Company incurred
research and development expenses of $638,873, $238,535 and $877,408 for the
years ended September 30, 2005, September 30, 2004 and from September 16, 2002
(date of inception) through September 30, 2005, respectively. On July 12, 2005,
the Company exchanged 36 million shares of stock with a value of $24,120,000 for
intellectual property acquired from Biowell Technology, Inc.(see Note B). The
Company capitalized $9,430,900 as an intangible asset and expensed $14,689,100
to acquisition costs in the year ended September 30, 2005
RECLASSIFICATIONS
Certain reclassifications have been made in prior year's financial statements to
conform to classifications used in the current year.
INTANGIBLE ASSETS
The Company amortized its intangible assets using the straight-line method over
their estimated period of benefit. The estimated useful for patents is five
years while intellectual property uses a seven year useful life. We periodically
evaluate the recoverability of intangible assets and take into account events or
circumstances that warrant revised estimates of useful lives or that indicate
that an impairment exists. All of our intangible assets are subject to
amortization.
NEW ACCOUNTING PRONOUNCEMENTS
SFAS 123R. On March 31, 2004 the Financial Accounting Standards Board ("FASB")
issued its exposure draft, "Share-Based Payments", which is a proposed amendment
to SFAS 123. The exposure draft would require all share-based payments to
employees, including grants of employee stock options and purchases under
employee stock purchase plans, to be recognized in the statement of operations
based on their fair value. The FASB issued the final standard in December 2004
that is effective for small business issuers for annual periods beginning after
December 15, 2005. The Company has not yet assessed the impact of adopting this
new standard.
F-21
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE A - SUMMARY OF ACCOUNTING POLICIES (continued)
SFAS 151. In November 2004, the Financial Accounting Standards Board (FASB)
issued SFAS 151, Inventory Costs-- an amendment of ARB No. 43, Chapter 4. This
Statement amends the guidance in ARB No. 43, Chapter 4, "Inventory Pricing," to
clarify the accounting for abnormal amounts of idle facility expense, freight,
handling costs, and wasted material (spoilage). Paragraph 5 of ARB 43, Chapter
4, previously stated that ". . . under some circumstances, items such as idle
facility expense, excessive spoilage, double freight, and rehandling costs may
be so abnormal as to require treatment as current period charges. . . ." This
Statement requires that those items be recognized as current-period charges
regardless of whether they meet the criterion of "so abnormal." In addition,
this Statement requires that allocation of fixed production overheads to the
costs of conversion be based on the normal capacity of the production
facilities. This Statement is effective for inventory costs incurred during
fiscal years beginning after June 15, 2005. The Company does not anticipate that
the implementation of this standard will have a material impact on its financial
position, results of operations or cash flows.
SFAS 152. In December 2004, the FASB issued SFAS No.152, "Accounting for Real
Estate Time-Sharing Transactions--an amendment of FASB Statements No. 66 and 67"
("SFAS 152) The amendments made by Statement 152 This Statement amends FASB
Statement No. 66, Accounting for Sales of Real Estate, to reference the
financial accounting and reporting guidance for real estate time-sharing
transactions that is provided in AICPA Statement of Position (SOP) 04-2,
Accounting for Real Estate Time-Sharing Transactions. This Statement also amends
FASB Statement No. 67, Accounting for Costs and Initial Rental Operations of
Real Estate Projects, to state that the guidance for (a) incidental operations
and (b) costs incurred to sell real estate projects does not apply to real
estate time-sharing transactions. The accounting for those operations and costs
is subject to the guidance in SOP 04-2. This Statement is effective for
financial statements for fiscal years beginning after June 15, 2005. with
earlier application encouraged. The Company does not anticipate that the
implementation of this standard will have a material impact on its financial
position, results of operations or cash flows.
SFAS 153. On December 16, 2004, FASB issued Statement of Financial Accounting
Standards No. 153, Exchanges of Nonmonetary Assets, an amendment of APB Opinion
No. 29, Accounting for Nonmonetary Transactions (" SFAS 153"). This statement
amends APB Opinion 29 to eliminate the exception for nonmonetary exchanges of
similar productive assets and replaces it with a general exception for exchanges
of nonmonetary assets that do not have commercial substance. Under SFAS 153, if
a nonmonetary exchange of similar productive assets meets a commercial-substance
criterion and fair value is determinable, the transaction must be accounted for
at fair value resulting in recognition of any gain or loss. SFAS 153 is
effective for nonmonetary transactions in fiscal periods that begin after June
15, 2005. The Company does not anticipate that the implementation of this
standard will have a material impact on its financial position, results of
operations or cash flows.
NOTE B - ACQUISITION OF INTANGIBLE ASSETS
The Company has adopted SFAS No. 142, Goodwill and Other Intangible Assets,
whereby the Company periodically test its intangible assets for impairment. On
an annual basis, and when there is reason to suspect that their values have been
diminished or impaired, these assets are tested for impairment, and write-downs
will be included in results from operations.
On July 12, 2005, the Company acquired certain intellectual properties from
Biowell Technology, Inc. ("Biowell") through an Asset Purchase Agreement
("Agreement") in exchange for 36 million shares of the Company's restricted
common stock having an aggregate fair value at the date of issuance of $
24,120,000. The value of the acquired intangible assets was $9,430,900, with the
balance of the purchase price, or $14,689,100, charged to operations as a cost
of the transaction.
The identifiable intangible assets acquired and their carrying value at
September 30, 2005 are:
F-22
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE B - ACQUISITION OF INTANGIBLE ASSETS (continued)
Weighted
Average
Gross Amortization
Carrying Accumulated Residual Period
Amount Amortization Net Value (Years)
------------- --------------- ------------ ---------- ----------
Amortizable
Intangible
Assets:
Intellectual
Property $9,430,900 $336,818 $9,094,082 - 7
Patents 34,237 11,764 22,493 - 5
---------- ---------- ----------
Total
Amortized
Identifiable
Intangible $9,465,137 $348,582 $9,116,575 - 6.99
========== ======== ========== -
Assets
Total amortization expense charged to operations for the year ended September
30, 2005 and 2004 were $ 346,825 and $1,756 respectively.
Estimated amortization expense as of September 30, 2005 is as follows:
2006 $ 1,357,279
2007 1,357,279
2008 1,349,748
2009 1,349,271
2010 and after 3,704,998
Total $ 9,116,575
============
NOTE C - NOTE PAYABLE
At September 30, 2005, notes payable are as follows:
Note payable, unsecured, related party, payable from August 1, 2005, 410,429
right to convert to restricted stock in lieu of cash, rate of interest
2%, 160,000 shares prior to October 31, 2005 or 180,000 shares after ---------
that date. Since September 2005, the Company has made no payments and
is now in default.
410,429
Less: current portion ---------
410,429
Note payable - long-term ---------
$-
NOTE D - RELATED PARTY TRANSACTIONS
On October 18, 2005, Maureen Huppe, a Company shareholder obtained a judgment in
Los Angeles County, California against Lawrence Lee, director of the Company,
for short swing profits as a result of trading Company shares. Per the judgment,
Mr. Lee is obligated to reimburse the Company $245,911 in damages plus legal
fees. In addition, the company owes Mr. Lee $35,162 in outstanding accrued
liabilities. In offsetting the outstanding liability against the pending
reimbursement, the company anticipates proceeds of approximately $211,000 from
Mr. Lee.
F-23
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE E - CAPITAL STOCK
The Company is authorized to issue 10,000,000 shares of preferred stock with a
$.001 par value per share. The Company is authorized to issue 250,000,000 shares
of common stock, with a $0.001 par value per share as the result of a
shareholder meeting conducted on February 14, 2005. Prior to the February 14,
2005 share increase and par value change, the Company had 100,000,000 authorized
shares with a par value of $0.50. In February 2005, the Company passed a
resolution authorizing change in the par value per common shares from $0.50 per
share to $0.001 per share.
During the period September 16, 2002 through September 30, 2003, the Company
issued 100,000 shares of common stock in exchange for reimbursement of services
provided by the founders of the Company. The Company valued the shares issued at
approximately $1,000, which represents the fair value of the services received
which did not differ materially from the value of the stock issued.
In October, 2002, the Company issued 10,178,352 shares of common stock in
exchange for the previously issued 100,000 shares to the Company's founders in
connection with the merger with Prohealth Medical Technologies, Inc.
In October, 2002 the Company canceled 100,000 shares of common stock issued to
the Company's founders.
In October 2002 the Company issued 602,000 shares of common stock in exchange
for services valued at $ 0.065 per share. In accordance with EITF 96-18 the
measurement date to determine fair value was in October 2002. This was the date
at which a commitment for performance by the counter party to earn the equity
instrument was reached. The Company valued the shares issued at approximately
$0.065 per share, which presents the fair value of the services received which
did not differ materially from the value of the stock issued.
In November and December 2002, the Company issued 876,000 shares of common stock
in exchange for subscription at $ 0.065 per share. In accordance with EITF 96-18
the measurement date to determine fair value was in October 2002. This was the
date at which a commitment for performance by the counter party to earn the
equity instrument was reached. The Company valued the shares issued at
approximately $0.065 per share, which presents the fair value of the services
received which did not differ materially from the value of the stock issued.
In January 2003, the Company canceled 836,000 shares of common stock previously
issued in exchange for consulting services.
In January 2003, the Company issued 1,500,000 shares of common stock in exchange
for a licensing agreement (see Note I). The Company valued the shares issued at
approximately $ .065 per share, which represents the fair value of the license
received which did not differ materially from the value of the stock issued. The
Company charged the cost of the license to operations.
In January 2003, the Company issued 586,250 shares of common stock in exchange
for consulting services. In accordance with EITF 96-18 the measurement date to
determine fair value was in October 2002. This was the date at which a
commitment for performance by the counter party to earn the equity instrument
was reached. The Company valued the shares issued at approximately $0.13 per
share, which presents the fair value of the services received which did not
differ materially from the value of the stock issued.
F-24
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE E - CAPITAL STOCK (continued)
In February 2003, the Company issued 9,000 shares of common stock in exchange
for consulting services. In accordance with EITF 96-18 the measurement date to
determine fair value was in October 2002. This was the date at which a
commitment for performance by the counter party to earn the equity instrument
was reached. The Company valued the shares issued at approximately $0.065 per
share, which presents the fair value of the services received which did not
differ materially from the value of the stock issued.
In March 2003, the Company issued 10,140,000 shares of common stock to Company's
founders in exchange for services. In accordance with EITF 96-18 the measurement
date to determine fair value was in September 2002. This was the date at which a
commitment for performance by the counter party to earn the equity instrument
was reached. The Company valued the shares issued at approximately $0.0001 per
share, which presents the fair value of the services received which did not
differ materially from the value of the stock issued.
In March 2003, the Company issued 91,060 shares of common stock in exchange for
consulting services. The Company valued the shares issued at approximately $2.53
per share, which represents the fair value of the services received which did
not differ materially from the value of the stock issued.
In March 2003, the Company issued 6,000 shares of common stock in exchange for
consulting services. The Company valued the shares issued at approximately $
0.065 per share, which represents the fair value of the services received which
did not differ materially from the value of the stock issued.
In March 2003, the Company received subscription for 18,000 shares of common
stock in exchange for cash at $1 per share.
On April 1, 2003, the Company issued 860,000 shares of common stock in exchange
for consulting services provided to the Company. In accordance with EITF 96-18
the measurement date to determine fair value was in October 2002. This was the
date at which a commitment for performance by the counter party to earn the
equity instrument was reached. The Company valued the shares issued at
approximately $0.065 per share, which presents the fair value of the services
received which did not differ materially from the value of the stock issued.
On April 9, 2003, the Company issued 18,000 shares of common stock in exchange
for previously issued options to purchase the Company's common stock at $1.00
per share.
On April 9, 2003, the Company issued 9,000 shares of common stock in exchange
for consulting services provided to the Company. In accordance with EITF 96-18
the measurement date to determine fair value was in October 2002. This was the
date at which a commitment for performance by the counter party to earn the
equity instrument was reached. The Company valued the shares issued at
approximately $0.065 per share, which presents the fair value of the services
received which did not differ materially from the value of the stock issued.
On April 23, 2003, the Company issued 5,000 shares of common stock in exchange
for consulting services provided to the Company. The Company valued the shares
issued at approximately $2.50 per share, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
F-25
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE E - CAPITAL STOCK (continued)
On June 12, 2003, the Company issued 10,000 shares common stock in exchange for
consulting services provided to the Company. The Company valued the shares
issued at approximately $ 2.50 per share, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
On June 17 2003, the Company issued 50,000 shares of common stock in exchange
for cash at $1.00 per share
On June 30, 2003, the Company issued 270,000 shares of common stock in exchange
for consulting services provided to the Company. In accordance with EITF 96-18
the measurement date to determine fair value was in October 2002. This was the
date at which a commitment for performance by the counter party to earn the
equity instrument was reached. The Company valued the shares issued at
approximately $0.065 per share, which presents the fair value of the services
received which did not differ materially from the value of the stock issued.
On June 30, 2003, the Company received $10,000 as subscription for options to
purchase the Company's common stock at $1.00 per share.
In June, 2003, the Company received $48,000 in connection with a subscription to
purchase the Company's common stock pursuant to a private placement.
In connection with the Company's acquisition of ProHealth, the controlling owner
of ProHealth granted the Company an option to acquire up to 8,500,000 shares of
the Company's common stock in exchange for $100,000 (see Note C). The option
expires on December 10, 2004. On June 30, 2003, the Company exercised its option
and acquired 7,500,000 common shares under this agreement in exchange for an
$88,500 convertible promissory note payable to the former controlling owner. The
Company has an option through December 10, 2004 to acquire the remaining
1,000,000 shares from the former controlling owner in exchange for $11,500. On
June 30, 2003, the Company retired the 7,500,000 shares common acquired pursuant
to the option agreement.
In July 2003 the Company issued 213,060 shares of common stock for consulting
services provided to the Company. The Company valued the shares issued at
approximately $ 2.01 per share, which represents the fair value of the services
received which did not differ materially from the value of the stock issued.
In July 2003, the Company canceled 24,000 shares of common stock, previously
issued for services valued at $2.50 per share.
In July 2003, the Company received $20,000 in exchange for previously issued
options to purchase the Company's common stock at $1.00 per share.
In July 2003, the Company issued 10,000 shares of common stock for cash
previously subscribed at $1.00 per share.
In August 2003, the Company issued 172,500 shares of common stock in exchange
for consulting services provided to the Company. The Company valued the shares
issued at approximately $ 2.38 per share, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued
F-26
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE E - CAPITAL STOCK (continued)
In August 2003, the Company received $29,000 in exchange for previously issued
options to purchase the Company's common stock at $1.00 per share.
In September 2003, the Company issued 395,260 shares of common stock in exchange
for consulting services provided to the Company. The Company valued the shares
issued at approximately $ 2.42 per share, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In September 2003, the Company issued 19,200 shares of common stock for cash
previously subscribed at $2.50 per share.
In September 2003, the Company issued 6,400 shares of common stock issued in
exchange for cash at $2.50 per share pursuant to private placement.
In September 2003, the Company received $95,000 in exchange for previously
issued options to purchase the Company's common stock at $1.00 per share.
In September 2003, the Company received $300,000 in connection with a
subscription to purchase the Company's common stock pursuant to a private
placement.
The Company valued the shares issued for consulting services at the rate which
represents the fair value of the services received which did not differ
materially from the value of the stock issued.
In October 2003, the Company issued 15,000 shares of convertible preferred stock
in exchange for services. The Company valued the shares issued at the $15 par
value and recorded the value for services when the shares were converted into
common shares as identified below.
In October 2003, the Company issued 287,439 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$2.85 per share for a total of $820,418, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In October 2003, the Company issued 120,000 shares of common stock for shares
previously subscribed at $2.50 per share in September 2003.
In October 2003, the Company canceled 100,000 shares of common stock previously
issued in exchange for services at $2.50 per share.
In November 2003, the Company issued 100,000 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$3.00 per share, which represents the fair value of the services received which
did not differ materially from the value of the stock issued.
In November 2003, the Company sold 100,000 shares of common stock subscribed for
cash at $2.50 per share pursuant to private placement.
F-27
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE E - CAPITAL STOCK (continued)
In December 2003, the Company sold 6,400 shares of common stock subscribed for
cash at $2.50 per share pursuant to private placement.
In December 2003, the Company issued 2,125,500 shares of common stock in
exchange for consulting services. The Company valued the shares issued at
approximately $2.59 per share, which represents the fair value of the services
received which did not differ materially from the value of the stock issued.
In December 2003, the Company received $104,000 in exchange for a common stock
subscription at $2.50 per share pursuant to private placement.
In January 2004, the Company issued 41,600 shares of common stock at $2.50 share
pursuant to a subscription made on December 2003.
In January 2004, the Company issued 13,040 shares of common stock at $2.95 per
share in exchange for consulting services valued at $38,468.
In January 2004, the Company issued 123,000 shares of common stock at $2.60 per
share in exchange for consulting services valued at $319,800.
In January 2004, the Company issued 1,000 shares of common stock at $3.05 per
share in exchange for consulting services valued at $3,050.
In February 2004, the Company issued 6,283 shares of common stock at $3.07 per
share in exchange for employee services valued at $19,288.
In March 2004, the Company issued 44,740 shares of common stock at $3.04 per
share in exchange for consulting services valued at $136,010.
In March 2004, the Company issued 55,000 of common stock for options exercised
at $1.00 per share.
In March 2004, the Company issued 5,443 shares of common stock at $3.00 per
share in exchange for employee services valued at $16,344.
In March 2004, the Company issued 5,769 shares of common stock at $3.15 per
share in exchange for employee services valued at $18,177.
In March 2004, the Company converted 5,000 preferred shares into 125,000 shares
of common stock at $3.00 per share in exchange for employee services valued at
$375,000.
In March 2004, the Company issued 8,806 shares of common stock at $3.03 per
share in exchange for employee services valued at $26,639.
F-28
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE E - CAPITAL STOCK (continued)
In April 2004, the Company issued 22,500 shares of common stock at $0.10 for
subscription of warrants to be exercised.
In April 2004, the Company issued 9,860 shares of common stock at $2.58 per
share in exchange for employee services valued at $25,441.
In April 2004, the Company issued 11,712 shares of common stock at $2.35 per
share in exchange for consulting services valued at $27,523.
In April 2004, the Company issued 367,500 shares of common stock at $1.50 per
share in exchange for consulting services valued at $551,250.
In April 2004, the Company retired 50,000 shares of common stock previously
issued for consulting services at $0.065 per share or $3,250.
In May 2004, the Company converted 4,000 preferred shares into 100,000 shares of
common stock at $1.01 per share in exchange for consulting services valued at
$101,250.
In May 2004, the Company issued 10,000 shares of common stock at $0.10 per share
in a stock subscription for $1,000.
In May 2004, the Company issued 137,000 shares of common stock at $0.86 per
share in exchange for consulting services valued at $119,233.
In May 2004, the Company issued 26,380 shares of common stock at $1.15 per share
in exchange for consulting services valued at $30,337.
In June 2004, the Company retired 5,000 shares of common stock previously issued
for consulting services at $0.065 per share or $325.
In June 2004, the Company issued 270,500 shares of common stock at $0.67 per
share in exchange for consulting services valued at $180,560.
In June 2004, the Company issued 8,000 shares of common stock at $0.89 per share
in exchange for consulting services valued at $7,120.
In June 2004, the Company issued 50,000 shares of common stock at $0.645 per
share in exchange for consulting services valued at $32,250.
In June 2004, the Company sold 250,000 shares of common stock at $1.00 per share
for total proceeds of $250,000 pursuant to private placement.
In July 2004, the Company issued 100,000 shares of common stock at $0.54 per
share in exchange for consulting services valued at $54,000.
F-29
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE E - CAPITAL STOCK (continued)
In July 2004, the Company issued 5,000 shares of common stock at $0.72 per share
in exchange for consulting services valued at $3,600.
In July 2004, the Company issued 100,000 shares of common stock at $0.47 per
share in exchange for consulting services valued at $47,250.
In August 2004, the Company converted 2,000 preferred shares into 50,000 shares
of common stock at $0.39 in exchange for consulting services valued at $19,500.
In August 2004, the Company issued 100,000 shares of common stock at $0.39 in
exchange for consulting services valued at $39,000.
In August 2004, the Company issued 100,000 shares of common stock at $0.50 in
exchange for consulting services valued at $50,250.
In August 2004, the Company issued 200,000 shares of common stock at $0.56 in
exchange for consulting services valued at $112,500.
In September 2004, the Company issued 1,000,000 shares of common stock at $0.52
in exchange for consulting services valued at $517,500.
In September 2004, the Company issued 45,000 shares of common stock at $0.50 in
exchange for consulting services valued at $22,288.
In September 2004, the Company converted 4,000 preferred shares into 100,000
shares of common stock at $0.41 in exchange for consulting services valued at
$54,000.
In September 2004, the Company issued 60,000 convertible preferred shares at
$25.00, in exchange for consulting services valued at $1,500,000.
In accordance with EITF 96-18 the measurement date to determine fair value was
the date at which a commitment for performance by the counter party to earn the
equity instrument was reached. The Company valued the shares issued for
consulting services at the rate which represents the fair value of the services
received which did not differ materially from the value of the stock issued.
In October 2004, the Company issued 200,000 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$0.68 per share for a total of $136,000, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In October 2004, shareholders returned 1,069,600 shares to treasury issued
earlier in exchange for services valued at $642,098.
F-30
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE E - CAPITAL STOCK (continued)
In October 2004, the Company issued 82,500 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$0.60 per share for a total of $49,500, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In October 2004, the Company sold 500,000 shares of common stock subscribed for
cash at $0.60 per share pursuant to private placement.
In October 2004, the Company issued 532,500 shares of common stock to existing
noteholders. The Company valued the shares issued at approximately $0.50 per
share for a total of $266,250.
In October 2004, the Company sold 500,000 shares of common stock subscribed for
cash at $0.50 per share pursuant to private placement.
In October 2004, the Company sold 1,000,000 shares of common stock subscribed
for cash at $0.45 per share pursuant to private placement.
In October 2004, the Company issued 315,000 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$0.45 per share for a total of $141,750, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In November 2004, the Company issued 100,000 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$0.47 per share for a total of $47,000, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In November 2004, the Company issued 300,000 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$0.80 per share for a total of $240,000, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In November 2004, the Company issued 115,000 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$1.44 per share for a total of $165,600, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In November 2004, the Company issued 5,000 shares of common stock in exchange
for employee services. The Company valued the shares issued at approximately
$1.44 per share for a total of $7,200, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In November 2004, the Company issued 60,000 shares of common stock in exchange
for employee services. The Company valued the shares issued at approximately
$0.60 per share for a total of $36,000, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In December 2004, the Company issued net 5,500,000 shares of common stock for
default as per terms of notes payable for $88,500. Out of total, 3,500,000
shares were retained in escrow on behalf of another party for future deferred
compensation.
F-31
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE E - CAPITAL STOCK (continued)
In December 2004, the Company issued 5,796,785 shares of common stock in
exchange for consulting services. The Company valued the shares issued at
approximately $1.44 per share for a total of $8,317,207, which represents the
fair value of the services received which did not differ materially from the
value of the stock issued.
In December 2004, the Company issued 2,930,000 shares of common stock subscribed
for cash at $0.50 per share pursuant to the exercise terms of a promissory note
payable.
In January 2005, we issued 25,000 shares of common stock for warrants exercised
at $0.10 share. This issuance is considered exempt under Regulation D of the
Securities Act of 1933 and Rule 506 promulgated thereunder.
In January 2005, we retired $537,500 of convertible notes payable for 1,628,789
shares of common stock. The Notes are convertible into shares of our common
stock at a price of $0.33 per share.
In January 2005, we issued 17,500 shares of common stock for warrants exercised
at $0.10 share. This issuance is considered exempt under Regulation D of the
Securities Act of 1933 and Rule 506 promulgated thereunder.
In January 2005, we retired $791,673 of convertible notes payable for 2,399,012
shares of common stock. The Notes are convertible into shares of our common
stock at a price of $0.33 per share.
In January, 2005, the Company issued 315,636 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$1.30 per share for a total of $410,327, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In February 2005, we retired $25,000 of convertible notes payable for 75,757
shares of common stock. The Notes are convertible into shares of our common
stock at a price of $0.33 per share.
In February 2005, we issued 20,000 shares of common stock for warrants exercised
at $0.10 share. This issuance is considered exempt under Regulation D of the
Securities Act of 1933 and Rule 506 promulgated thereunder.
In February 2005, we retired $200,000 of convertible notes payable for 606,060
shares of common stock. The Notes are convertible into shares of our common
stock at a price of $0.33 per share.
In February 2005, we issued 45,000 shares of common stock for warrants exercised
at $0.10 share. This issuance is considered exempt under Regulation D of the
Securities Act of 1933 and Rule 506 promulgated thereunder.
In February 2005, we retired $600,000 of convertible notes payable for 1,500,000
shares of common stock. The Notes are convertible into shares of our common
stock at a price of $0.40 per share.
In February 2005, we retired $91,883 of convertible notes payable for 278,433
shares of common stock. The Notes are convertible into shares of our common
stock at a price of $0.33 per share.
In February, 2005, the Company issued 17,236 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$1.17 per share for a total of $20,166, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In February, 2005, the Company issued 300,000 shares of common stock subscribed
for cash at $0.50 per share for a total of $150,000 pursuant to the exercise
terms of a promissory note payable. This issuance is considered exempt under
Regulation D of the Securities Act of 1933 and Rule 506 promulgated thereunder.
In February, 2005, the Company issued 716,500 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$0.95 per share for a total of $680,675, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In February, 2005, the Company issued 10,500 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$0.95 per share for a total of $9,975, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In March, 2005, the Company issued 13,202,000 shares of common stock subscribed
for cash at $0.50 per share for a total of $6,601,000 pursuant to the exercise
terms of a promissory note payable. This issuance is considered exempt under
Regulation D of the Securities Act of 1933 and Rule 506 promulgated thereunder.
In March, 2005, the Company issued 185,000 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$1.19 per share for a total of $220,150, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In March 2005, we issued 100,000 shares of common stock for options exercised at
$0.60 share. This issuance is considered exempt under Regulation D of the
Securities Act of 1933 and Rule 506 promulgated thereunder.
In March, 2005, the Company issued 1,675,272 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$0.98 per share for a total of $1,641,767, which represents the fair value of
the services received which did not differ materially from the value of the
stock issued.
In March, 2005, the Company issued 24,333 shares of common stock in exchange for
consulting services. The Company valued the shares issued at approximately $0.92
per share for a total of $22,386, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In March, 2005, the Company issued 15,000 shares of common stock in exchange for
consulting services. The Company valued the shares issued at approximately $0.99
per share for a total of $14,850, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In March, 2005, the Company issued 1,240,000 shares of common stock subscribed
for cash at $0.50 per share for a total of $620,000 pursuant to the exercise
terms of a promissory note payable. This issuance is considered exempt under
Regulation D of the Securities Act of 1933 and Rule 506 promulgated thereunder.
In March, 2005, the Company canceled shares previously issued within the quarter
for exchange of debt valued at $250,000.
F-32
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE E - CAPITAL STOCK (continued)
In March, 2005, the Company issued 10,000 shares of common stock in exchange for
consulting services. The Company valued the shares issued at approximately $0.89
per share for a total of $8,900, which represents the fair value of the services
received which did not differ materially from the value of the stock issued.
The Company recognized an imbedded beneficial conversion feature present in the
January/February Offering note ("January/February PPM"). The Company allocated a
portion of the proceeds equal to the intrinsic value of that feature to
additional paid in capital. The Company recognized and measured an aggregate of
4,179,554 of the proceeds, which is equal to the intrinsic value of the imbedded
beneficial conversion feature, to additional paid in capital and a discount
against the Bridge Offering. The debt discount attributed to the beneficial
conversion feature was fully amortized over the fiscal first quarter period as
interest expense.
The Company recognized the value attributable to the warrants in the amount of
$3,191,446 to additional paid in capital and a discount against the
January/February 2005 PPM.
In March, 2005, the Company granted an aggregate of 300,000 stock options to
employees that vested immediately. The exercise prices of the stock options
granted were below the fair value of the Company's common stock at the grant
date. Compensation expense of $180,000 and $0 was charged to operations during
the period ended March 31, 2005 and 2004, respectively.
In April, 2005, the Company issued 160,000 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$0.80 per share for a total of $128,000, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In April, 2005, the Company issued 40,000 shares of common stock in exchange for
consulting services. The Company valued the shares issued at approximately $0.80
per share for a total of $32,000, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In April, 2005, the Company issued 850,000 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$0.75 per share for a total of $637,500, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In April 2005, we retired $165,000 of convertible notes payable for 500,000
shares of common stock. The Notes are convertible into shares of our common
stock at a price of $0.33 per share.
In April, 2005, a shareholder returned 10,000 shares previously issued for
services valued at $34,200 in exchange for a cash settlement.
In April 2005, we retired convertible notes payable for 75,758 shares of common
stock. The Notes are convertible into shares of our common stock at a price of
$0.33 per share.
In April 2005, the Company issued 50,000 shares of common stock in exchange for
consulting services. The Company valued the shares issued at approximately $0.68
per share for a total of $34,000, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
F-33
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE E - CAPITAL STOCK (continued)
In June 2005, a shareholder returned 10,000 shares previously issued for
services valued at $5,000.
In June 2005, the Company cancelled 300,000 stock options previously granted
valued at $180,000. In accordance with EITF 96-18 the measurement date to
determine fair value was the date at which a commitment for performance by the
counter party to earn the equity instrument was reached. The Company valued the
shares issued for consulting services at the rate which represents the fair
value of the services received which did not differ materially from the value of
the stock issued.
In July 2005, the Company issued 157,000 shares of common stock in exchange for
consulting services. The Company valued the shares issued at approximately $0.60
per share for a total of $94,200, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In July 2005, the Company issued 36 million shares in exchange for intellectual
property at approximately $0.67 per share for a total of $24,120,000.
In July 2005, the Company issued 640,000 shares of common stock in exchange for
consulting services. The Company valued the shares issued at approximately $0.60
per share for a total of $384,000, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In July 2005, the Company issued 8,000,000 S-8 shares to employees as part of
the Employee Stock Ownership Plan (see note F). The Company valued the shares
issued at approximately $0.48 per share for a total of $3,840,000, which
represents the fair value of the services received which did not differ
materially from the value of the stock issued.
In July 2005, the Company issued 121,985 shares of common stock in exchange for
consulting services. The Company valued the shares issued at approximately $0.94
per share for a total of $168,339, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In July 2005, the Company issued 250,000 S-8 shares to consultants as part of
the Employee Stock Ownership Plan (see note F). The Company valued the shares
issued at approximately $0.48 per share for a total of $120,000, which
represents the fair value of the services received which did not differ
materially from the value of the stock issued.
In September 2005, the Company issued 814,158 penalty shares pursuant to the
pending SB-2 registration terms. In connection with the 7,371,000 million
convertible debt financing in the quarter ended March 30, 2005, the Company was
obligated to complete a stock registration by July 2005. Since the registration
was not effective by July 2005, the Company paid the required $257,985 of
liquidated damages in shares of Company stock accruing at the rate of 3.5% per
month on the face value of the Notes for the month of July and August 2005. The
Company valued the shares issued at approximately $0.62 per share for a total of
$502,672.
In September 2005, the Company issued 391,224 penalty shares pursuant to the
pending SB-2 registration terms. In connection with the 7,371,000 million
convertible debt financing in the quarter ended March 30, 2005, the Company was
obligated to complete a stock registration by July 2005. Since the registration
was not effective by July 2005, the Company paid the required $257,985 of
liquidated damages in shares of Company stock accruing at the rate of 3.5% per
month on the face value of the Notes for the month of September 2005. The
Company valued the shares issued at approximately $0.70 per share for a total of
$273,857.
F-34
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE E - CAPITAL STOCK (continued)
In September 2005, the Company issued 185,000 shares of common stock in exchange
for consulting services. The Company valued the shares issued at approximately
$0.94 per share for a total of $173,900, which represents the fair value of the
services received which did not differ materially from the value of the stock
issued.
In September, 2005, the Company cancelled 740,000 shares previously issued for
services valued at $296,972.
In September, 2005, the Company cancelled un-issued warrants valued at $287,440.
NOTE F - STOCK OPTIONS AND WARRANTS
Warrants
The Company issued options and warrants during the years ended September 30,
2005 and 2004 for consulting and employee services, fees in connection with
obtaining financing and various other services. The following table summarizes
the changes in options and warrants outstanding and the related prices for the
shares of the Company's common stock issued to shareholders of the Company.
These warrants were granted in lieu of cash compensation for services performed
or financing expenses in connection with the sale of the Company's common stock.
Warrants Outstanding Warrants Exercisable
Weighted Average Weighed Weighted
Number Remaining Contractual Average Number Average
Exercise Prices Outstanding Life (Years) Exercise Price Exercisable Exercise Price
--------------- ----------- --------------------- -------------- -------------- ---------------------
$0.10 105,464 3.79 $ 0.10 105,464 $ 0.10
$0.20 5,000 3.13 $ 0.20 5,000 $ 0.20
$0.50 50,000 4.02 $ 0.50 50,000 $ 0.50
$0.55 9,000,000 2.72 $ 0.55 9,000,000 $ 0.55
$0.60 9,282,000 3.63 $ 0.60 9,282,000 $ 0.60
$0.68 3,660,000 4.00 $ 0.68 3,660,000 $ 0.68
$0.70 750.000 1.84 $ 0.70 750.000 $ 0.70
$0.75 17,727,000 4.00 $ 0.75 17,727,000 $ 0.75
$1.00 100,000 1.04 $ 1.00 100,000 $ 1.00
$3.00 62,503 0.25 $ 3.00 62,503 $ 3.00
----------- --------------
40,741,967 40,741,967
F-35
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE F - STOCK OPTIONS AND WARRANTS (continued)
Transactions involving warrants are summarized as follows:
Weighted Average Price
Number of Shares Per Share
Balance, September 30, 2003 383,500 $ 1.38
------------ ------------
Granted 4,574,753 0.58
Exercised (88,000) 1.00
Canceled or expired - -
------------ ------------
Balance, September 30, 2004 4,870,253 $ 0.63
------------ ------------
Granted 37,113,000 0.67
Exercised (207,500) 0.34
Canceled or expired (1,033,786) 0.65
------------ ------------
Balance, September 30, 2005 40,741,967 $ 0.67
------------ ------------
In July 2005, the Company entered into an agreement with Trilogy Capital
Partners, Inc. and Joff Pollon ("Trilogy" and "Pollon") to provide marketing
services to the Company for a term of one year, and terminable thereafter by
either party upon 30 days prior written notice. In connection with the
agreement, we agreed to pay Trilogy a monthly fee of $12,500. The Company also
issued to Trilogy a warrant to purchase 7.5 million shares of common stock at
$0.55 per share and Pollon a warrant to purchase 1.5 million shares of common
stock at $0.55 per share, exercisable for a period of three years from issuance.
The warrant contains a "cashless" exercise provision. The shares underlying the
warrants contain registration rights. The holder has contractually agreed to
restrict its ability to convert or exercise the warrants and receive shares of
our common stock such that the number of shares of common stock held by it after
such conversion or exercise does not exceed 5% of the then issued and
outstanding shares of common stock. In the quarter ended September 30, 2005, the
Company charged $180,000 to operations for compensatory warrants granted in
exchange for services per EITF 00-19. The difference between the exercise price
and the in-the-money value at September 30, 2005 was recorded as an expense with
the difference booked as a current liability.
In the quarter ended December 31, 2004, the Company charged $394,698 to
operations for compensatory warrants granted in exchange for services. The
estimated value of the compensatory warrants granted to non-employees in
exchange for services and financing expenses was determined using the
Black-Scholes pricing model and the following assumptions: contractual term of 2
to 5 years, a risk free interest rate of 4.25%, a dividend yield of 0% and
volatility of 22.9%.
In the quarter ended June 30, 2005, the Company charged $849,046 to operations
for compensatory warrants granted in exchange for services. The estimated value
of the compensatory warrants granted to non-employees in exchange for services
and financing expenses was determined using the Black-Scholes pricing model and
the following assumptions: contractual term of 2 to 5 years, a risk free
interest rate of 3.89%, a dividend yield of 0% and volatility of 55.9%. In the
quarter ended September 30, 2005, the Company reversed $765,460 of compensatory
warrants due to the cashless exercise provisions. Both the stock price and
exercise price were $0.60 as of June 30, 2005 resulting in no charge to
operations per EITF 00-19. As of September 30, 2005, the stock price was lower
than the exercise price with no charge to expense. In the quarter ended
September 30, 2005, the Company reclassified 3 million warrants due to their
"cashless" exercise provision. The Company issued warrants to directors and
advisors to purchase 3 million shares of common stock at $0.60 per share,
exercisable for a period of four years from issuance. The shares underlying the
warrants contain registration rights. In the quarter ended September 30, 2005,
the Company charged zero to operations for compensatory warrants granted in
exchange for services per EITF 00-19 since the $0.60 exercise price exceeded the
market price at September 30, 2005. As a result of this reclassification, in the
quarter ended September 30, 2005 the Company reversed $794,642 in intrinsic
value expense previously recorded in the quarter ended June 30, 2005.
F-35
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE F - STOCK OPTIONS AND WARRANTS (continued)
During the three months ended March 31, 2005, the Company granted an aggregate
of 300,000 stock options to directors that vested immediately. The exercise
prices of the stock options granted were below the fair value of the Company's
common stock at the grant date. Compensation expense of $180,000 was charged to
operations during the period ended March 30, 2005. In the quarter ended June 30,
2005, the Company canceled the unexercised 300,000 stock options and credited
expense for the previously recorded $180,000 in compensation. In exchange for
the canceled options, the Company issued 50,000 warrants with a $0.50 exercise
price and a five year life during the quarter ended June 30, 2005.
During the quarter ended September 30, 2005, the Company charged $327,202 to
operations for compensatory warrants granted in exchange for services for
warrants issued in December 2004. The estimated value of the compensatory
warrants granted to employees in exchange for services was determined using the
Black-Scholes pricing model and the following assumptions: contractual term of 3
years, a risk free interest rate of 4.38%, a dividend yield of 0% and volatility
of 100.1%.
The amount of the expense charged to operations for compensatory warrants
granted in exchange for services was $956,304 and $2,019,862, respectively, for
the years ended September 30, 2005 and 2004.
On February 14, 2005, the Company established an Employee Stock Ownership Plan
(ESOP), authorizing 16 million shares for the future issuance of incentive stock
options, non-statutory options and S-8 shares. Incentive options and S-8 shares
are issued at fair market value while non-statutory options are issued at 110%
of fair market value. 3.660 million shares were granted as incentive stock
options and vested as follows; 50% or 1.830 million shares vesting on April 1,
2005, 25% vesting on July 1, 2005 and the remaining 25% vesting on October 1,
2005. No ESOP shares were exercised as of June 30, 2005. ESOP grants must be
exercised within five (5) years. Had the Company charged these warrants to
operations, the resulting expense would have totaled $1,406,350.
On July 28, 2005, the Company issued 8,250,000 S-8 shares to nine employees
under the ESOP resulting in a $3,960,000 charge to expense. Net remaining
available ESOP shares total 4,090,000.
NOTE G- INCOME TAXES
The Company has adopted Financial Accounting Standard No. 109 which requires the
recognition of deferred tax liabilities and assets for the expected future tax
consequences of events that have been included in the financial statement or tax
returns. Under this method, deferred tax liabilities and assets are determined
based on the difference between financial statements and tax bases of assets and
liabilities using enacted tax rates in effect for the year in which the
differences are expected to reverse. Temporary differences between taxable
income reported for financial reporting purposes and income tax purposes are
insignificant.
At September 30, 2005, the Company has available for federal income tax purposes
a net operating loss carryforward of approximately $50,275,314, expiring in the
year 2023, that may be used to offset future taxable income. The Company has
provided a valuation reserve against the full amount of the net operating loss
benefit, since in the opinion of management based upon the earnings history of
the Company, it is more likely than not that the benefits will not be realized.
Due to significant changes in the Company's ownership, the future use of its
existing net operating losses may be limited. Components of deferred tax assets
as of September 30, 2005 are as follows:
F-36
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE G- INCOME TAXES (continued)
Non current:
Net operating loss carryforward $17,596,000
Valuation allowance (17,596,000)
------------
Net deferred tax asset $ -
------------
NOTE H-LOSSES PER SHARE
The following table presents the computation of basic and diluted losses per
share:
For the Year Ended For the Year Ended
September 30, 2005 September 30, 2004
------------------ ------------------
Loss available for common shareholders $ (52,610,380) $ (19,358,259)
================== ==================
Basic and fully diluted loss per share $ (0.82) $ (0.93)
================== ==================
Weighted average common shares outstanding 63,905,259 20,819,700
Net loss per share is based upon the weighted average of shares of common stock
outstanding
NOTE I- COMMITMENTS AND CONTINGENCIES
F-37
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE I- COMMITMENTS AND CONTINGENCIES (continued)
CONSULTING AGREEMENTS
On August 6, 2004 the Company retained Giuliani Partners, on a non-exclusive
basis, to provide advice and assistance to the Company regarding issues
associated with Applied DNA's proprietary DNA embedded security. On April 8,
2005 the Company terminated the agreement with Giuliani Partners, whereby both
parties agreed to discharge, waive and release one another from all obligations
under the consulting agreement. Total compensation paid to Giuliani Partners
through June 30, 2005 was $1,250,000.
On March 24, 2005, the Company amended its existing Cooperative Research and
Development Agreement ("CRADA") with Battelle Energy Alliance, LLC, the
Department of Energy's National Laboratory in Idaho Falls, Idaho (the
"Amendment"). The Amendment adds additional joint research projects, including
development of marker applications for textiles, inks, gasoline, and explosive
materials. Per the Amendment and at the Company's discretion, the Company can
spend up to $1,701,216 to further develop and refine selected DNA and related
applications. In November 2005, the agreement was terminated.
LITIGATION
STERN & Co. v. Applied DNA Sciences, Inc., Case No.: 05 CV 00202
Plaintiff Stern & Co. commenced this action against us in the United States
District Court for the Southern District of New York on or about January 10,
2005. In this action, Stern & Co. alleges that it entered into a contract with
us to perform media and investor relations for a monthly fee of $5,000 and stock
options. Stern & Co. claims that we failed to make certain payments pursuant to
the contract and seeks damages in the amount of $96,042.00. We answered the
complaint on May 12, 2005, denying Stern & Co.'s allegations and we asserted a
number of defenses. This action is in the early stages of discovery and we
intend to vigorously defend this matter. Management believes the ultimate
outcome of this matter will not have a material adverse effect on the Conpany's
consolidated financial position or results of operations.
OCEANIC CONSULTING, S.A. V. APPLIED DNA SCIENCES, INC., INDEX NO.: 603974/04
Plaintiff Oceanic Consulting, S.A. commenced this action on or about November
24, 2004 against us in the Supreme Court of the State of New York, County of New
York. Oceanic Consulting, S.A. asserts a cause of action for breach of contract
based upon the allegation that we failed to make payments pursuant to a
consulting agreement. Oceanic Consulting, S.A.also asserts a causes of action in
which it seeks reimbursement of its expenses and attorneys' fees. Oceanic
Consulting, S.A. seeks damages in the amount of $137,500.00. Oceanic Consulting,
S.A. moved for a default judgment, which we have opposed based upon Oceanic
Consulting, S.A.'s failure to properly serve the complaint as well as our
meritorious defenses. Thereafter, Oceanic Consulting, S.A. agreed to withdraw
its motion for a default judgment and accepted service of our answer on May 23,
2005. We dispute the allegations of the complaint. This action is in the early
stages of discovery and we intend to vigorously defend this matter. Management
believes the ultimate outcome of this matter will not have a material adverse
effect on the Conpany's consolidated financial position or results of
operations.
CRYSTAL RESEARCH ASSOCIATES, LLC V. APPLIED DNA SCIENCES, INC., DOCKET NO.:
L-7947-04
On April 29, 2005, Crystal Research Associates, LLC obtained a default judgment
against us for $13,000 in the Superior Court of New Jersey, Middlesex County. We
intend to move to vacate the default judgment on various grounds. We dispute the
allegations of the complaint and we intend to vigorously defend this matter.
F-38
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE I- COMMITMENTS AND CONTINGENCIES (continued)
FRANCHISING AND DISTRIBUTION AGREEMENTS
On July 15, 2005, Applied DNA Sciences, Inc. (the "Company") closed upon the
stock purchase agreement (the "Agreement") with Biowell Technology Inc., a
Taiwan corporation ("Biowell") that was executed on January 28, 2005. Pursuant
to the Agreement, the Company, through its wholly-owned subsidiary, APDN
(B.V.I.) Inc., a British Virgin Islands company, acquired all of the issued and
outstanding shares of Rixflex Holdings Limited, a British Virgin Islands company
("Rixflex"). Pursuant to an asset purchase agreement, Biowell transferred all of
its intellectual property (the "Biowell Technology") to Rixflex prior to the
Company's acquisition of Rixflex. In exchange for all of the issued and
outstanding shares of Rixflex, we issued to the shareholders of Rixflex 36
million shares of our common stock.
In connection with the closing, the Company terminated the October 2002 license
agreement with Biowell, replacing it with a new Biowell license agreement
granting an exclusive license in selected Asian countries for an initial period
through December 31, 2010. If Biowell meets its performance goals, the license
agreement extends for an additional five year term. Sub-license payments due to
the Company are 50% for all fees, payments and consideration received. Biowell
is required to pay a royalty of 10% on all net sales made and is required to
meet certain minimum annual net sales in its various territories. Under this
agreements, the Company recognized $3,129 in revenues in this year ended
September 30, 2005.
The Company has entered into a Distribution and Franchising Agreement
("Franchise Agreement") in July 2003. Under the terms of the Franchise
Agreement, the franchisee is obligated to pay the Company $3,000,000 payable
$25,000 upon execution of the Franchise Agreement and the balance of $2,975,000
payable over five (5) years with interest accruing at 8% per annum. Payments
under the Franchise Agreement are subject to franchisee's net profits, as
defined, under the Franchise Agreement. During the year ended September 30, 2005
and 2004 the Company has received the initial $0 and $25,000, as installment and
has recognized the receipt as other income in the accompanying financial
statements.
OPERATING LEASE COMMITMENTS
The Company leases office space under operating lease in Los Angeles, California
for its corporate use from an entity controlled by significant former
shareholder, expiring in November 2006. In November 2005, the Company vacated
the Los Angeles facility to relocate to the new Stony Brook New York address.
Lease termination costs are included in the Subsequent Event disclosure (see
Note J). Total lease rental expenses for the years ended on September 30, 2005
and 2004, was $120,804 and $120,804, respectively.
F-39
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE I- COMMITMENTS AND CONTINGENCIES (continued)
Commitments for minimum rentals under non-cancelable lease at September 30, 2005
are as follows:
Year ended September 30, $ 51,562
2006 4,687
2007
-------------
$ 56,249
EMPLOYMENT AND CONSULTING AGREEMENTS
The Company has employment agreements with some of the Company's officers and
certain employees. These employment agreements provide for salaries and
benefits, including stock options. In June of 2005, an Addendum was made to
several employment agreements providing defined commitments should the Company
terminate the employee with or without cause. It is the Company's position that
the form of Addendum was not approved by the Board of Directors, and is
therefore null and void, ab initio, as of the date that each one was executed by
an officer of the Company.
The Company has consulting agreements with two outside contractors to provide
marketing and financial advisory services. The Agreements are generally for a
term of 12 months from inception and renewable automatically from year to year
unless either the Company or consultant terminates such engagement by written
notice.
As part of the Biowell acquisition, the Company entered into a consulting
agreement with Timpix International Limited for the consulting services of three
former Biowell employees, Jun-Jei Sheu, Ben Liang and Johnson Chen. The
consulting agreement is for the shorter of two years, or until all of the
consultants have obtained a visa to work in the United States and execute
employment agreements with the Company. Such consulting agreement shall
automatically renew for one year periods until terminated. Pursuant to the
consulting agreement, the Company shall pay $47,000 per month, which is
apportioned at $20,000 per month for Mr. Sheu, $15,000 per month for Mr. Liang
and $12,000 per month for Mr. Chen. In the event that either of Messrs. Sheu,
Liang or Chen becomes employed by the Company, the monthly consulting fee shall
be reduced accordingly.
F-40
APPLIED DNA SCIENCES, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2005 AND 2004
NOTE J- SUBSEQUENT EVENTS
In November 2005, the Company closed its Los Angeles facility and relocated to
Stony Brook, New York. As part of the relocation, the Company terminated many of
its Los Angeles based employees, sold excess office furnishings and terminated
its facility lease. In anticipation of future expenses related to the
relocation, the Company established a reserve for severed employees, lease
termination and new office relocation expenses in the amount of $451,000.
In October 2005, the Company received a Notice of Termination from the Idaho
National Laboratory. The Notice gives APDN 90-day advance notice of termination.
The effective Termination date is January 23, 2006. We are exploring a
settlement and mutual release with the Idaho National Laboratory.
NOTE K - GOING CONCERN
The accompanying financial statements have been prepared on a going concern
basis, which contemplates the realization of assets and the satisfaction of
liabilities in the normal course of business. As shown in the accompanying
financial statements during the period September 16, 2002 through September 30,
2005, the Company incurred a loss of $75,425,414. These factors among others may
indicate that the Company will be unable to continue as a going concern for a
reasonable period of time.
The Company's existence is dependent upon management's ability to develop
profitable operations. Management is devoting substantially all of its efforts
to developing DNA embedded biotechnology security solutions in the United States
and there can be no assurance that the Company's efforts will be successful.
However, the planned principal operations have not commenced and no assurance
can be given that management's actions will result in profitable operations or
the resolution of its liquidity problems. The accompanying statements do not
include any adjustments that might result should the Company be unable to
continue as a going concern.
In order to improve the Company's liquidity, the Company's management is
actively pursing additional equity financing through discussions with investment
bankers and private investors. There can be no assurance the Company will be
successful in its effort to secure additional equity financing.
F-41
ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
There have been no disagreements between the Company and its accountants as to
matters which require disclosure.
ITEM 8A - CONTROLS AND PROCEDURES
a) Evaluation of Disclosure Controls and Procedures. As of September 30,
2005, the Company's management carried out an evaluation, under the
supervision of the Company's Chief Executive Officer and Chief
Financial Officer of the effectiveness of the design and operation of
the Company's system of disclosure controls and procedures pursuant to
the Securities and Exchange Act, Rule 13a-15(e) and 15d-15(e) under
the Exchange Act). Based upon that evaluation, the Chief Executive
Officer and Chief Financial Officer concluded that the Company's
disclosure controls and procedures were not effective, as of the date
of their evaluation, for the purposes of recording, processing,
summarizing and timely reporting material information required to be
disclosed in reports filed by the Company under the Securities
Exchange Act of 1934. Please see the subsection "Significant
Deficiencies In Disclosure Controls And Procedures Or Internal
Controls" below.
b) Changes in internal controls. Except as described below, there were no
changes in internal controls over financial reporting that occurred
during the period covered by this report that have materially
affected, or are reasonably likely to materially effect, our internal
control over financial reporting.
SIGNIFICANT DEFICIENCIES IN DISCLOSURE CONTROLS AND PROCEDURES OR INTERNAL
CONTROLS
On July 11, 2005, the Company determined there were errors in accounting
for the valuation of equity consulting service transactions during the January
through March 2005 time period. The valuation resulted in the overstatement of
approximately $2.9 million in services provided. The errors were discovered in
connection with a comment raised by the Securities and Exchange Commission
("SEC") in their review and comment on our registration statement on Form SB-2.
The SEC requested that we provided additional disclosure regarding issuances of
common stock to non-employees in exchange for services. Upon reviewing and
updating our disclosure, we discovered our errors. Upon this determination,
management and the board of directors were alerted to the facts and
circumstances regarding the errors in valuation. Authorized officers of the
Company discussed this matter with the Company's independent public accounting
firm who agreed that the Company's quarterly financials could not be relied upon
and needed to be restated. On August 3, 2005, the Company filed an amended
10-QSB for the quarter ended March 31, 2005 with the SEC which included the
amended financials.
The Company is looking to take corrective action to resolve these
weaknesses and deficiencies. The Company has recently reduced personnel in order
to control costs and expenses and has recently moved from California to New
York, which resulted in the resignation of the Company's Chief Financial
Officer. The Company is currently searching for a qualified, full-time Chief
Financial Officer as well as a full-time bookkeeper. The Company believes that
these actions will correct the material deficiencies and significant weaknesses
in its controls and procedures and it anticipates that the appropriate personnel
will be hired and the material deficiencies and weaknesses will be fully
corrected before the end of the March 31, 2006 quarter.
ITEM 8B - OTHER INFORMATION
NONE.
36
ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS.
DIRECTORS AND EXECUTIVE OFFICERS
Names: Ages Titles: Board of Directors
------------------------- ---- ---------------------- ------------------
Jun-Jei Sheu 39 Chairman Director
James Hayward 52 Chief Executive Officer
Peter Brocklesby 52 President Director
Lawrence Lee 44 Director
Ming-Hwa Benjamin Liang 42 Secretary
Directors are elected to serve until the next annual meeting of
stockholders and until their successors are elected and qualified. Currently
there are three seats on our board of directors.
Currently, our Directors are not compensated for their services. Officers
are elected by the Board of Directors and serve until their successors are
appointed by the Board of Directors. Biographical resumes of each officer and
director are set forth below.
CHAIRMAN OF THE BOARD - JUN-JEI SHEU
On July 15, 2005, Dr. Jun-Jei Sheu was appointed as a director and elected
Chairman by the board of directors. Since November 2000, Dr. Sheu has been the
Chairman of Biowell Technology Inc. Between November 2000 and August 2005, Dr.
Sheu was the CEO of Biowell Technology Inc. Dr. Sheu received his Bachelors
degree in Biology from Fu-Jen Catholic University in 1988, his Masters degree in
Biology from Fu-Jen Catholic University in 1990, his Ph.D in Life Sciences from
Intermural of Academia Sinica & National Defense Medical Center in 1996 and his
MBA from South Australia University in 2000. Dr. Sheu is also a director of
Biowell Technology (S) Pte Ltd., a Singapore company, Biotechcard International
Pte (S) Ltd. a Singapore company, Yan Zhan Life Technology & Marketing Inc., a
Taiwanese company and Biowell Technology (Suzhou) Co. Ltd., a Chinese company,
all of which are biotechnology companies.
CHIEF EXECUTIVE OFFICER - JAMES HAYWARD
On October 5, 2005, the board of directors appointed Dr. James Hayward as
our Acting Chief Executive Officer. Since June 2004, Dr. Hayward has been the
Chairman of Evotope Biosciences, Inc., a drug development company based in Stony
Brook, New York. Since 2001, Dr. Hayward has been a director of Q-RNA, Inc., a
biotech company based in New York, New York. Since 2000, Dr. Hayward has been a
General Partner of Double D Venture Fund, a venture capital firm based in New
York, New York. Between 1990 and July 2004, Dr. Hayward was the Chairman,
President and CEO of The Collaborative Group, Ltd., a biotech and consumer
product company based in Stony Brook, New York. Dr. Hayward received his
Bachelors degree in Biology and Chemistry from the State University of New York
at Oneonta in 1976 and his Ph.D. in Molecular Biology from the State University
of New York at Stony Brook in 1983.
PRESIDENT AND DIRECTOR - PETER BROCKLESBY
Mr. Brocklesby became our President and a Director in May 2004. Between
2000 and January 2003, Mr. Brocklesby was the Vice President for Business
Development at Boss Industrial Design Company, a communications and electronic
product design company based in Newport Beach, California. Between January 2003
and May 2004, Mr. Brocklesby served as a Project Development Consultant to
Professor Alfred Wong, A.W. Technologies at the University of California at Los
Angeles. In March 2003, Mr. Brocklesby co-founded Cool Grip, Inc., a golf
accessory company, based in Newport Beach, California, and served as the Vice
President of Business Development through May 2004.
37
Mr. Brocklesby graduated from Leeds University, UK with a BA Honors degree
in History in 1970. He attended the Royal Air Force College, UK and was
commissioned in the RAF. In 1977, after 7 years service in the UK Armed Forces,
Mr. Brocklesby left to become Director of Logistics for Air Asia (Air America),
a US defense contractor providing support for the US military and for other
governments in Asia.
Following acquisition of Air Asia by E-Systems, Inc., a multi-billion
dollar defense contractor, and now part of Raytheon, Mr. Brocklesby was
appointed VP Marketing. E-Systems specialized in the development and integration
of advanced airborne and land-based military and government communications
systems, electronic warfare equipment, electronic surveillance and airborne
intelligence gathering systems.
DIRECTOR - LARRY LEE
Larry Lee has served as a Director since September 2002. Between 1994 and
2001, Mr. Lee was a senior scientist and manager for GM Hughes Electronics, a
Los Angeles, California based electronics, space and defense company. Between
January 2000 and September 2002, Mr. Lee was a manager and senior staff
scientist for Boeing, a space and defense company, in their Los Angeles,
California location. Between September 2002 and March 2004, Mr. Lee served as
our President and Chief Executive Officer. Since August 2004, Mr. Lee has been a
senior staff scientist with Boeing.
Mr. Lee currently serves on the board of advisors and/or partners for
several U.S. and international companies including: Dery Resources Inc.; IMC,
and VO Management, LLC.
Mr. Lee has a Master of Science in Computer/Electronic Engineering from
California State University and a Bachelor of Science in Mechanical/Biomedical
Engineering from Virginia Tech. He has also received advanced training in
Business Executive Management and Finance from University of California, Los
Angeles and the Hughes Education Center.
SECRETARY AND STRATEGIC TECHNOLOGY DEVELOPMENT OFFICER - MING-HWA BENJAMIN LIANG
Ming-Hwa Bejamin Liang has been our Secretary and Strategic Technology
Development Officer since October 2005. Between May 1999 and September 2005, Mr.
Liang has been the director of research and development for Biowell Technology
Inc. Mr. Liang received his bachelors degree in Bio-Agriculture from Colorado
State University in 1989, his Masters in Horticulture from the University of
Missouri at Columbia in 1991, his Ph.D. in Plant Science from the University of
Missouri at Columbia in 1991 and his LL. M. in Intellectual Property Law from
Shih Hsin University, Taiwan in 2004.
COMPLIANCE WITH SECTION 16(A) OF THE SECURITIES EXCHANGE ACT OF 1934
Since we are governed under Section 15(d) of the Exchange Act, we are not
required to file reports of executive officers and directors and persons who own
more than 10% of a registered class of the Company's equity securities pursuant
to Section 16(a) of the Exchange Act.
38
ITEM 10. EXECUTIVE COMPENSATION.
We may elect to award a cash bonus to key employees, directors, officers
and consultants based on meeting individual and corporate planned objectives. We
currently have no written employment agreements with any of our officers,
however, the following shows the annual salaries, bonuses and stock options for
our executive officers:
------------------------------------------------------------------------------------------------------------------------------------
SUMMARY COMPENSATION TABLE
----------------------------------------------------------------------- -------------------------------------------- ---------------
Long-Term Compensation
---------------------------- ------------------------------------------ --------------------------------- ---------- ---------------
Annual Compensation Awards Payouts
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
Name and Fiscal Annual Annual Other Restricted Securities LTIP All Other
Annual Underlying
Salary Bonus Compensation Stock Awards Options/SARs Payouts Compensation
Principal Position Year ($) ($) ($) ($) (#) ($) ($)
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
Peter Brocklesby, 2005 162,750 0 83,719 480,000 0 0 0
President
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2004 0 0 0 31,903 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2003 0 0 0 0 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
Rob Hutchison, CEO 2005 0 0 138,453 0 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2004 159,400 0 0 39,000 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2003 0 0 0 0 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
Lawrence C. Lee, 2005 0 0 202,000 0 0 0 0
CEO
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2004 150,000 0 0 2,017,500 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2003 300,000 0 0 0 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
John Barnett, 2005 152,000 100,000 0 599,000 0 0 0
Vice President of
Sales
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2004 87,908 0 6,478 18,899 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2003 0 0 0 328,180 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
Jaime Cardona, 2005 101,750 100,000 0 675,900 0 0 0
Employee
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2004 78,608 0 7,258 139,849 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2003 0 0 0 31,250 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
Adrian Butash, 2005 131,250 0 108,808 480,000 0 0 0
Executive Vice
President of
Marketing
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2004 0 0 21,200 0 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2003 0 0 0 0 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
Karin Klemm, COO 2005 0 0 187,884 480,000 0 0 0
& CFO
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2004 0 0 112,500 0 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2003 0 0 0 0 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
Paul Reep, Chief 2005 165,750 0 4,000 480,000 0 0 0
Technology Officer
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2004 71,753 0 17,736 95,011 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2003 0 0 0 39,900 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
Michael Hill, 2005 0 0 230,000 0 0 0 0
Director
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2004 0 0 0 112,200 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
2003 0 0 0 0 0 0 0
------------------- -------- ------------- ---------- ----------------- --------------- ----------------- ---------- ---------------
40
ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS.
The following table sets forth certain information regarding beneficial
ownership of our common stock as of December 5, 2005:
o by each person who is known by us to beneficially own more than 5% of
our common stock;
o by each of our officers and directors; and
o by all of our officers and directors as a group.
----------------------------------------------- ------------------------ -------------------------- --------------------
NAME AND ADDRESS OF BENEFICIAL OWNER TITLE OF CLASS NUMBER OF SHARES OWNED(1) PERCENTAGE OF
CLASS (2)
----------------------------------------------- ------------------------ -------------------------- --------------------
----------------------------------------------- ------------------------ -------------------------- --------------------
Jun-Jei Sheu Common Stock 8,616,747 (3) 7.67%
25 Health Sciences Drive, Suite 113
Stony Brook, New York 11790
----------------------------------------------- ------------------------ -------------------------- --------------------
----------------------------------------------- ------------------------ -------------------------- --------------------
James Hayward Common Stock 0 0%
25 Health Sciences Drive, Suite 113
Stony Brook, New York 11790
----------------------------------------------- ------------------------ -------------------------- --------------------
----------------------------------------------- ------------------------ -------------------------- --------------------
Peter Brocklesby Common Stock 2,000,000 (4) 1.28%
25 Health Sciences Drive, Suite 113
Stony Brook, New York 11790
----------------------------------------------- ------------------------ -------------------------- --------------------
----------------------------------------------- ------------------------ -------------------------- --------------------
Lawrence Lee Common Stock 4,260,000 (5) 3.79%
25 Health Sciences Drive, Suite 113
Stony Brook, New York 11790
----------------------------------------------- ------------------------ -------------------------- --------------------
----------------------------------------------- ------------------------ -------------------------- --------------------
Bejamin Liang Common Stock 230,000 (6) *
25 Health Sciences Drive, Suite 113
Stony Brook, New York 11790
----------------------------------------------- ------------------------ -------------------------- --------------------
----------------------------------------------- ------------------------ -------------------------- --------------------
All Officers and Directors Common Stock 15,106,747 (7) 13.44%
As a Group (5 persons)
----------------------------------------------- ------------------------ -------------------------- --------------------
(1) Beneficial Ownership is determined in accordance with the rules of the
Securities and Exchange Commission and generally includes voting or investment
power with respect to securities. Shares of common stock subject to options or
warrants currently exercisable or convertible, or exercisable or convertible
within 60 days of December 5, 2005 are deemed outstanding for computing the
percentage of the person holding such option or warrant but are not deemed
outstanding for computing the percentage of any other person.
(2) Based upon 112,380,392 shares issued and outstanding on December 5, 2005.
(3) Includes 315,859 shares owned by his wife and 254,354 shares owned by his
minor children. Also includes 7,003,052 shares owned by Biowell Technology,
Inc., of which Dr. Sheu is deemed a beneficial owner.
(4) Includes 1,000,000 shares underlying currently exercisable options.
(5) Includes 600,000 shares underlying currently exercisable options.
41
(6) Includes 120,000 shares owned by his wife.
(7) Includes 1,600,000 shares underlying currently exercisable options.
SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS
In November of 2002, we created a special compensation plan to pay the
founders, consultants and professionals that had been contributing valuable
services to us during the previous nine months. The plan is called the
Professional/Employee/Consultant Compensation Plan. Share and option issuances
from the Compensation Plan were to be staggered over the following six to eight
months, and consultants that were to continue providing services thereafter
either became employees or received renewed contracts from us in July of 2003,
which contracts contained a more traditional cash compensation component. The
Compensation Plan was designed by the Board to meet our important team building
objectives in our early stages, and to be temporary. As of December 31, 2005, a
total of 1,440,003 shares have been issued from the Compensation Plan and
560,000 options, 264,000 of which were exercised as of as of December 31, 2005.
Each qualified and eligible recipient of shares and/or options under the
Compensation Plan received securities in lieu of cash payment for services. Each
recipient agreed, in his or her respective consulting contract with us, to sell
a limited number of shares monthly. We feel that this carefully designed
Compensation Plan was successful in attracting and retaining a strong team at a
time when we had no established revenue stream and limited or no outside
financing.
In our financial statements, shares that were issued from November 2002
through June 30, 2003 that were valued at $0.065 per share were shares issued
from this Compensation Plan created in November of 2002 on the basis of
contracts executed at that time for previously rendered services. Common Stock
disclosed as being issued in exchange for cash at $1.00 per share represents
options that were exercised under this Plan. In December of 2004, we adjusted
the exercise price to $0.60 per share.
Any other unrestricted shares that were issued either before or after July
1, 2003 were valued at the fair market value.
------------------ ------------------- ------------------------- ------------------
Plan Category Number of Securities to be Weighted Average Exercise Number of Securities
Issued Upon Exercise of Price of Outstanding Options, Remaining Available
Outstanding Options, Warrants and Rights for Future Issuance
Warrants and Rights
------------------- ------------------- --------------------------- -------------------
(a) (b) (c)
------------------- ------------------- --------------------------- -------------------
Professional/Consultant/
Employee Stock and Stock
Option Compensation Plan 2,000,000 $177,600 -0-
------------------- ------------------- ---------------------------- -------------------
Total 2,000,000 $177,600 -0-
------------------- ------------------- ---------------------------- -------------------
As of December 31, 2005, a total of 1,440,000 shares have been issued from
the Compensation Plan and 560,000 options have been issued, 264,000 of which
were exercised as of that date.
On January 26, 2005, the majority stockholders approved the 2005 Stock
Incentive Plan and authorized 16,000,000 shares of Common Stock for issuance of
stock awards and stock options thereunder. As of December 31, 2005, a total of
9.000.000 shares have been issued from the Compensation Plan.
42
DESCRIPTION OF SECURITIES
COMMON STOCK
We are authorized to issue up to 250,000,000 shares of common stock, par
value $.001. As of December 5, 2005, there were 112,380,392 shares of common
stock outstanding. Holders of the common stock are entitled to one vote per
share on all matters to be voted upon by the stockholders. Holders of common
stock are entitled to receive ratably such dividends, if any, as may be declared
by the Board of Directors out of funds legally available therefor. Upon the
liquidation, dissolution, or winding up of our company, the holders of common
stock are entitled to share ratably in all of our assets which are legally
available for distribution after payment of all debts and other liabilities and
liquidation preference of any outstanding common stock. Holders of common stock
have no preemptive, subscription, redemption or conversion rights. The
outstanding shares of common stock are validly issued, fully paid and
nonassessable.
We have engaged American Stock Transfer & Trust Company, located in
Brooklyn, New York, as independent transfer agent or registrar.
PREFERRED STOCK
We are authorized to issue up to 10,000,000 shares of Preferred Stock, par
value $.001. The 10,000,000 shares of Preferred Stock authorized are
undesignated as to preferences, privileges and restrictions. As the shares are
issued, the Board of Directors must establish a "series" of the shares to be
issued and designate the preferences, privileges and restrictions applicable to
that series. To date, the Board has designated a Founders' Series of Convertible
Preferred Stock, which, in six months from the date of issuance, shall be
convertible at the option of the holder and upon our reaching certain financial
objectives, into shares of our restricted Common Stock. Each share, when
eligible, is convertible into 25 fully paid and non-assessable shares of our
Common Stock, subject to a leak out agreement that extends the Rule 144 period
to two years. Holders will be permitted to sell, after a one year holding period
through a three year holding period, 1% of the issued and outstanding shares of
our common stock every 90 days. This series has been authorized by the Board of
Directors. On or about February 1, 2005, the Founders' Series of Preferred Stock
was converted into 1,500,000 shares of our common stock. As of December 5, 2005,
there were no shares of preferred stock issued and outstanding.
OPTIONS
There are currently options outstanding that have been issued to our
officers, directors and employees to purchase 3,660,000 shares of our common
stock pursuant to our Professional/Employee/Consultant Compensation Plan and
employment agreements.
WARRANTS
In connection with the sale of convertible promissory notes in December
2004, we issued 2,930,000 warrants to purchase shares of common stock. The
warrants are exercisable until three years from the date of issuance at a
purchase price of $0.75 per share.
In addition, in connection with a private placement offering in January and
February of 2005, we have issued 14,742,000 warrants. The warrants are
exercisable until five years from the date of issuance at a purchase price of
$0.75 per share.
We also have outstanding 105,464 warrants exercisable at $0.10 per share,
5,000 warrants exercisable at $0.20 per share, 50,000 warrants exercisable at
$0.50 per share, 9,000,000 warrants at $0.55 per share, 9,282,000 warrants
exercisable at $0.60 per share, 750,000 warrants exercisable at $0.70 per share,
55,000 warrants exercisable at $0.75 per share, 100,000 warrants exercisable at
$1.00 per share and 62,503 warrants exercisable at $3.00 per share.
43
CONVERTIBLE SECURITIES
To obtain funding for our ongoing operations, we sold $1,465,000 in
convertible promissory notes to 13 investors in December 2004. Each promissory
note was automatically convertible into shares of our common stock, at a price
of $0.50 per share, upon the closing of a private placement for $1 million or
more. On January 28, 2005, we closed upon a private placement transaction in
excess of $1 million, and on February 2, 2005, the promissory notes were
converted into an aggregate of 2,930,000 shares of common stock.
To obtain funding for our ongoing operations, we conducted a private
placement offering in January and February 2005, in which we sold $7,371,000 of
10% Secured Convertible Promissory Notes to 61 investors. The 10% Secured
Convertible Promissory Notes automatically convert into shares of our common
stock, at a price of $0.50 per share, upon the filing of this registration
statement.
In connection with the private placement, we granted the investors
registration rights. Pursuant to the registration rights agreement, if we did
not file the registration statement by February 15, 2005, or if we did not have
the registration statement declared effective on or before July 15, 2005, we are
obligated to pay liquidated damages in the amount of 3.5% per month of the face
amount of the notes, which equals $257,985, until the registration statement is
declared effective. At our option, these liquidated damages can be paid in cash
or restricted shares of our common stock. We have currently decided to pay the
liquidated damages due at this point in common stock, although any future
payments of liquidated damages could be made in cash. If we decide to pay the
liquidated damages in cash, we would be required to use our limited working
capital and potentially raise additional funds. If we decide to pay the
liquidated damages in shares of common stock, the number of shares issued would
depend on our stock price at the time that payment is due. Based on closing
market prices of $0.66, $0.58, $0.70, $0.49 and $0.32 for our common stock on
July 15, 2005, August 15, 2005, September 15, 2005, October 17, 2005 and
November 15, 2005, respectively, we issued approximately 390,887, 444,802,
368,550, 526,500 and 806,204 shares of common stock per month, respectively, in
liquidated damages.
ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
In September of 2004, Larry Lee entered into a private transaction with Mr.
Chaim Stern, selling a total of 2,500,000 shares to him, after which he loaned
all proceeds of $600,000 to us. On November 3, 2004, we issued a promissory note
to Larry Lee for the loan of the $600,000. The note bore interest at 6% per
annum, and was payable upon demand any time following 120 days after we complete
a financing of at least $5 million. We had the right to repay the note, plus all
accrued interest, at any time, in whole or in part, without premium or penalty.
Upon the repayment of $125,000, we had the right to repay the remainder due
under the note by the issuance of shares of common stock and founders' preferred
stock. We repaid the note in full by paying Mr. Lee $125,000 and issued him
500,000 shares of common stock and 60,000 shares of founders' preferred stock.
On July 15, 2005, we entered into a licensing agreement with Biowell
Technology for the license of our intellectual property. Dr. Sheu, our Chairman
of the Board of Directors, is the CEO of Biowell Technology.
On July 15, 2005, we entered into a consulting agreement with Timpix
International Limited for the consulting services of three employees, including
Dr. Sheu, our Chairman of the Board of Directors. The consulting agreement is
for the shorter of two years, or until all of the consultants have obtained a
visa to work in the United States and execute employment agreements with us.
Such consulting agreement shall automatically renew for one year periods until
terminated. Pursuant to the consulting agreement, we shall pay $47,000 per
month, of which $20,000 is apportioned per month for Dr. Sheu.
44
On October 18, 2005, Maureen Huppe, a shareholder, obtained a judgment in
United States District Court, Los Angeles, California, against Lawrence Lee, one
of our directors, for short swing profits as a result of trading shares of our
stock. Per the judgment, Mr. Lee is obligated to reimburse us $245,911 in
damages plus legal fees. In addition, we owe Mr. Lee $35,162 in outstanding
accrued liabilities. In offsetting the outstanding liability against the pending
reimbursement, we anticipate proceeds of approximately $211,000 from Mr. Lee.
We have no policy regarding entering into transactions with affiliated
parties.
ITEM 13. EXHIBITS.
Exhibit Description
------- ----------------------------------------------------------------------
2.1 Articles of Merger of Foreign and Domestic Corporations, filed
December 19, 1998 with the Nevada Secretary of State, filed as an
exhibit to the annual report on Form 10-KSB filed with the Commission
on December 29, 2003 and incorporated herein by reference.
3.1 Articles of Incorporation of DCC Acquisition Corporation, filed April
20, 1998 with the Nevada Secretary of State, filed as an exhibit to
the annual report on Form 10-KSB filed with the Commission on December
29, 2003 and incorporated herein by reference.
3.2 Articles of Amendment of Articles of Incorporation of DCC Acquisition
Corp. changing corporation name to ProHealth Medical Technologies,
Inc.
3.3 Certificate of Designations, Powers, preferences and Rights of the
Founders' Series of Convertible Preferred Stock, filed as an exhibit
to the annual report on Form 10-KSB filed with the Commission on
December 29, 2003 and incorporated herein by reference.
3.4 Articles of Amendment of Articles of Incorporation of Applied DNA
Sciences, Inc. increasing the par value of the company's common stock,
filed on December 3, 2003 with the Nevada Secretary of State, filed as
an exhibit to the annual report on Form 10-KSB filed with the
Commission on December 29, 2003 and incorporated herein by reference.
3.5 By-Laws of Applied DNA Sciences, Inc., filed as an exhibit to the
annual report on Form 10-KSB filed with the Commission on December 29,
2003 and incorporated herein by reference.
4.1 Form of Subscription Agreement, filed as an exhibit to the current
report on Form 8-K filed with the Commission on January 28, 2005 and
incorporated herein by reference.
4.2 Form of 10% Secured Convertible Promissory Note, filed as an exhibit
to the current report on Form 8-K filed with the Commission on January
28, 2005 and incorporated herein by reference.
4.3 Form of Warrant Agreement, filed as an exhibit to the current report
on Form 8-K filed with the Commission on January 28, 2005 and
incorporated herein by reference.
4.4 Registration Rights Agreement, dated January 28, 2005, between the
Company and Vertical Capital Partners, Inc., on behalf of the
investors, filed as an exhibit to the current report on Form 8-K filed
with the Commission on January 28, 2005 and incorporated herein by
reference.
4.5 Security Agreement, dated January 28, 2005, between the Company and
Vertical Capital Partners, Inc., on behalf of the investors, filed as
an exhibit to the current report on Form 8-K filed with the Commission
on January 28, 2005 and incorporated herein by reference.
45
10.1 Exclusive License Agreement between Biowell Technology Corp. and
Applied DNA Sciences, Inc. executed on October 8, 2002, filed as an
exhibit to the registration statement on Form SB-2 filed with the
Commission on February 15, 2005 and incorporated herein by reference.
10.2 Sub-License Agreement with G. A. Corporate Finance Ltd. Applied DNA
Sciences, Inc., executed on July 29, 2003, as amended, filed as an
exhibit to the current report on Form 8-K filed with the Commission on
September 29, 2003 and incorporated herein by reference.
10.3 Indemnification Agreement with Larry Lee, filed as an exhibit to the
registration statement on Form SB-2 filed with the Commission on
February 15, 2005 and incorporated herein by reference.
10.4 Indemnification Agreement with Robin Hutchison, filed as an exhibit to
the registration statement on Form SB-2 filed with the Commission on
February 15, 2005 and incorporated herein by reference.
10.5 Indemnification Agreement with Peter Brocklesby, filed as an exhibit
to the registration statement on Form SB-2 filed with the Commission
on February 15, 2005 and incorporated herein by reference.
10.6 Indemnification Agreement with Adrian Botash, filed as an exhibit to
the registration statement on Form SB-2 filed with the Commission on
February 15, 2005 and incorporated herein by reference.
10.7 Stock Purchase Agreement, dated as of January 28, 2005, by and between
Applied DNA Sciences, Inc. and Biowell Technology, Inc., filed as an
exhibit to the current report on Form 8-K filed with the Commission on
February 2, 2005 and incorporated herein by reference.
10.8 Investment Advisory Agreement, dated as of February 14, 2005, by and
between Applied DNA Sciences, Inc. and First London Finance, Ltd.,
filed as an exhibit to the registration statement on Form SB-2 filed
with the Commission on February 15, 2005 and incorporated herein by
reference.
10.9 Amendment to the License Agreement, dated as of November 2, 2004, by
and between Applied DNA Sciences, Inc. and Biowell Technology Inc.,
filed as an exhibit to the registration statement on Form SB-2 filed
with the Commission on June 16, 2005 and incorporated herein by
reference.
10.10 Joint Product Development and Marketing Agreement, dated as of
November 10, 2004, by and between Applied DNA Sciences, Inc. and
Hologrammas S.A. de C.V., filed as an exhibit to the registration
statement on Form SB-2 filed with the Commission on October 28, 2005
and incorporated herein by reference.
10.11 Cooperative Research and Development Agreement, dated as of September
2, 2004, by and between Applied DNA Sciences, Inc. and Bechtel BWXT
Idaho, LLC, filed as an exhibit to the registration statement on Form
SB-2 filed with the Commission on October 28, 2005 and incorporated
herein by reference.
10.12 Amendment to the Cooperative Research and Development Agreement, dated
as of March 24, 2005, by and between Applied DNA Sciences, Inc. and
Battelle Energy Alliance, LLC, filed as an exhibit to the current
report on Form 8-K filed with the Commission on May 10, 2005 and
incorporated herein by reference.
46
10.13 Stock Purchase Amendment Agreement, dated as of July 12, 2005, by and
between Applied DNA Sciences, Inc. and Biowell Technology, Inc., filed
as an exhibit to the current report on Form 8-K filed with the
Commission on July 21, 2005 and incorporated herein by reference.
10.14 License Agreement, dated as of July 12, 2005, by and between Applied
DNA Sciences, Inc. and Biowell Technology, Inc., filed as an exhibit
to the current report on Form 8-K filed with the Commission on July
21, 2005 and incorporated herein by reference.
10.15 Amendment to the License Agreement, dated as of October 10, 2005, by
and between Applied DNA Sciences, Inc. and Biowell Technology, Inc.,
filed as an exhibit to the registration statement on Form SB-2 filed
with the Commission on October 28, 2005 and incorporated herein by
reference.
10.16 Consulting Agreement, dated as of July 12, 2005, by and between
Applied DNA Sciences, Inc. and Timpix International Limited, filed as
an exhibit to the current report on Form 8-K filed with the Commission
on July 21, 2005 and incorporated herein by reference.
10.17 Letter of Engagement, dated as of June 20, 2005, by and between
Applied DNA Sciences, Inc. and Trilogy Capital Partners, Inc., filed
as an exhibit to the current report on Form 8-K filed with the
Commission on July 21, 2005 and incorporated herein by reference.
31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14 and
Rule 15d-14(a), promulgated under the Securities and Exchange Act of
1934, as amended
31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14 and
Rule 15d 14(a), promulgated under the Securities and Exchange Act of
1934, as amended
32.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive
Officer)
32.2 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial
Officer)
47
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.
Audit Fees.
The aggregate fees billed by our auditors, for professional services
rendered for the audit of our annual financial statements for the years ended
September 30, 2005 and 2004, and for the reviews of the financial statements
included in our Quarterly Reports on Form 10-QSB during that fiscal year were
$134,341, and $120,433, respectively.
Tax Fees
Russell Bedford Stefanou Mirchandani LLP did not bill us for tax related
work during fiscal years 2005 or 2004.
All Other Fees
Russell Bedford Stefanou Mirchandani LLP did not bill us for any other
services during fiscal 2005 or 2004.
The Board of Directors has considered whether the provision of non-audit
services is compatible with maintaining the principal accountant's independence.
48
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
APPLIED DNA SCIENCES, INC.
Date: January 12, 2006 /s/ JAMES HAYWARD
-----------------
James Hayward
Chief Executive Officer
(Principal Executive Officer)
and Chief Financial Officer
(Principal Financial Officer
and Principal Accounting Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report
has been signed below by the following persons on behalf of the registrant and
in the capacities and on the dates indicated.
Name Position Date
----------------------------------- ------------------------------------------------------------------ ------------------------
/s/ JAMES HAYWARD Chief Executive Officer (Principal Executive Officer) and Chief January 12, 2006
----------------- Financial Officer (Principal Financial Officer and Principal
James Hayward Accounting Officer)
----------------------------------- ------------------------------------------------------------------ ------------------------
/s/ JUN-JEI SHEU Chairman of the Board of Directors January 12, 2006
----------------
Jun-Jei Sheu
----------------------------------- ------------------------------------------------------------------ ------------------------
/s/ PETER BROCKLESBY President and Director January 12, 2006
--------------------
Peter Brocklesby
----------------------------------- ------------------------------------------------------------------ ------------------------
/s/ LAWRENCE LEE Director January 12, 2006
----------------
Lawrence Lee
----------------------------------- ------------------------------------------------------------------ ------------------------
49